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Chapter 1 
General introduction 

General introduction 
Background 
In this century, a large body of research about the effectiveness of therapeutic measures 
has been performed and the results of this research have altered daily clinical practice to a 
great extent. In the eighteenth century, the adagium 'cure rarely, improve sometimes and 
comfort always' [1] expressed the lack of effective therapeutic measures available to the 
doctors of that time. The great killers of those times were infectious diseases. Due to 
improved hygiene and the discovery of vaccins and antibiotic drugs these diseases are 
seldom the primary cause of mortality nowadays. Although the availability of effective 
vaccins and drugs are not the only factors that contribute to the low mortality from 
infectious diseases, they are certainly effective. Penicillin has never been tested in a 
randomized trial, since its effectiveness was so spectacular, that a randomized trial would 
have been unnecessary. Its cost-effectiveness has never been questioned, not because in 
those times unlimited resources were available, but simply, because it was so effective 
that the price was accepted as reasonable without any discussion. 
Alas, not every new treatment has been so clearly effective, and in order to distinguish 
real treatment effects from placebo effects or biased observation, sophisticated research 
methods like double-blind, placebo controlled randomized trials have been invented. With 
these methods it is possible to detect a treatment effect or treatment improvement, if any, 
at a statistically significant level, provided that the number of randomized patients is 
sufficiently high. If the numbers of patients in individual trials are too low, a meta 
analysis of aggregated results of several trials can demonstrate very small differences in 
effectiveness of treatments at a statistically signifant level. However, once we know that 
treatment A is more effective than treatment B, we have to deal with the next problem: is 
the benefit worth the human and financial costs? In other words, is the statistically 
signifant benefit clinically relevant? 
This question is not always a difficult one. If treatment A is not only more effective, but 
also carries less side-effects and is cheaper, we obviously prefer treatment A to treatment 
B. In decision analytic terms we say that treatment A is dominant over treatment B: A is 
better on all relevant aspects. This was for example the case in a study about the question 
whether paracentesis, antibiotics, paracentesis and antibiotics or wait-and-see in children 
9 
with otitis media acuta was better; wait-and-see turned out to be equally effective as the 
other treatment alternatives, both in terms of probability of cure and in terms of 
symptom-relief [3]. Clearly, no side-effects are to be expected either. 
If however, a moderate or small gain in effectiveness is achieved at the cost of a 
substantial increase in toxicity or treatment-related mutilation, not to speak of a huge 
increase in financial costs, we are confronted with a dilemma: is the increase in 
effectiveness worth the increase in detrimental effects? In order to answer this question 
we have to tradeoff the benefits against the drawbacks of a treatment. 
In decision analytic terms, these decisions are decisions with multiple competing 
objectives, which require tradeoffs between different attributes. 
An additional feature of these decisions is the uncertainty that accompanies most 
decisions. The decision is made on the basis of formerly accumulated data, but it is never 
sure that the patient will exactly experience the expected gain or loss. It is rather the 
opposite: he will experience some gain or loss that is likely to be approximate to, but 
usually not equal to the expected gain or loss. We are confronted with decisions with 
multiple competing objectives under uncertainty. This feature adds an extra dimension to 
the choices to be made: the choices are risky. If risk is prominent in a decision problem, 
i.e. bad outcomes are possible and the probability of occurrence of bad outcomes is 
perceived as a real threat, attitude towards risk plays an important role in making 
tradeoffs. 
Treatment decisions in breast cancer 
Clinicians make such tradeoffs, implicitly and intuitively, everyday. Subjective values 
clearly play a role in doing so. That this can lead to major treatment differences has been 
demonstrated by studies on treatment variability [4, 5, 6, 7]. A woman with breast cancer 
who lives in Seattle is much more likely to be treated by lumpectomy and irradiation than 
a woman in Iowa, who will probably undergo mastectomy [5]. These regional differences 
in treatment cannot sufficiently be explained by patient or tumor characteristics. It is 
likely that the low utilization of breast conserving therapy in women with breast cancer is 
primarily due to physician rather than to patient preference [8, 9]. 
The choice of treatment, based on subjective tradeoffs, often directly affects the wellbeing 
of the patient. It is therefore more appropriate that these tradeoffs are made by the patient 
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than by the physician. The involvement of the patient into the decision process can avoid 
undesirable influence of subjective physician preferences. 
Decision analysis 
Decision analysis usually involves the development of a decision tree that models the 
possible events after each treatment option, and permits to distinguish between what 
might objectively happen and the subjective valuation of these events [10]. For example, 
in order to decide whether or not to undergo adjuvant chemotherapy for patients with 
node-negative breast cancer, Hillner et al developed a detailed model of all relevant 
events after either strategy, e.g. experiencing toxicity, developing a recurrence, dying 
from breast cancer or from other causes, in order to estimate the benefit in terms of life-
expectancy and the drawbacks in terms of toxicity [11]. Since it is impossible to simply 
subtract the loss in well-being from the gain in life-expectancy, both attributes must be 
expressed in a common magnitude. This common magnitude is utility. 
Utility is defined as "levels of subjective satisfaction, distress, or desirability that people 
associate with (an aspect of) a health state" [12]. The problem is to develop procedures 
of measurement that lead to cardinal measures of utility, i.e. measures that can 
meaningfully be added or subtracted. Then, if the gain in life-expectancy is expressed as 
a gain in expected utility and the loss of well-being as a loss of expected utility, it is 
easy to see whether the gain in one attribute compensates the loss in another attribute. 
Since the patient cannot easily overview the complete problem, the measurement of 
utilities might be particularly useful. Measuring the patients' utilities and integrating 
these utilities into the decision analysis does not require that the patient oversees the 
problem completely, whereas directly asking the patient which treatment she prefers, 
does require such an overview. 
Aims of this thesis 
The research reported in this thesis aims at the development of clinically feasible 
procedures that can be applied to involve the patient actively in the choice between 
treatment options. The reported research falls apart in two main components: 1. 
investigation of properties of utility assessment procedures and 2. the development of 
decision trees which model the possible events after each treatment option. 
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Chapter 2 
Trading off risks and benefits in medical treatment 
decisions: comparison of utility assessment methods 
Lia CG. Verhoef 
Lukas J. Α. Stalpers 
André L.M. Verbeek 
Willem A.J. van Daal 
Partly published in Ned Tijdschr Geneeskd 1990;134:2195-2200 

Abstract 
Many treatment choices involve a tradeoff between possible beneficial and detrimental 
effects of the treatment. At the individual level, the decision can be based on the 
patient's individual preferences and risk attitude, provided that these preferences can be 
measured reliably. Four methods (visual analog scaling, time tradeoff test, standard 
gamble and additive conjoint measurement) are reviewed. These methods are compared 
with respect to their feasibility, reliability, and validity and with respect to their ability 
to distinguish between valid and invalid responses of the individuals tested. Violations of 
basic assumptions underlying utility assessment are often encountered but only additive 
conjoint measurement is designed to recognize violations. We conclude that the time 
tradeoff test and additive conjoint measurement, both adjusted for risk attitude or 
standard gamble can be applied for the purpose of assessing risky utilities. Additive 
conjoint measurement is best suited for systematic investigation of the extent and nature 
of violations of basic assumptions of utility assessment. The need to further investigate 
the reasons why and the extent to which people violate these basic assumptions is 
emphasized. 
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Introduction 
Choosing between treatment alternatives requires a balance of their risks and costs 
against their possible benefits. In clinical situations where the benefit of treatment is not 
unequivocal and/or the treatment burden is heavy, the choice may largely depend on the 
individual patient's attitude towards risks and benefits. Examples of clinical problems 
that require individualized treatment choices are the choice between laryngectomy or 
irradiation in patients with laryngeal cancer [1], the decision whether or not to undergo 
adjuvant medical therapy in node-negative breast cancer [2], and the choice between 
mastectomy or breast conserving therapy in early breast cancer [3]. 
In clinical decision analysis, formalized procedures are applied to distinguish between 
patients who would and who would not benefit from the treatment options under 
consideration. Individual patient characteristics like age, comorbidity, and stage of 
disease can be taken into account, but also subjective health state preferences and 
attitudes towards risk. Both objective and subjective outcome measures are expressed in 
terms of a common magnitude. This common magnitude is called utility. The optimal 
choice is found by 'maximizing expected utility': the option that yields the highest 
expected utility is the best option according to expected utility theory [4]. 
Methods that most frequently have been used to assess utilities are the standard gamble 
(SG), the time tradeoff test (TTO), and visual analog scaling (VAS). The aim of this 
paper is to give a brief outline of these assessment methods and to introduce a relatively 
unknown assessment method, additive conjoint measurement (ACM). 
If important decisions are based on utility measurement, the quality of the assessment 
method is crucial. When is a test a good test? Criteria that should be met by an optimal 
quality of life test have been specified by Spitzer et al [5]. The most important ones are 
that the test should be simple, easy to understand, valid, and acceptable to the patient. 
Also, it should cover an adequate range of dimensions of quality of life. 
Torrance stated: "Utility values are valid if the subjects are appropriate, if the health 
state descriptions are adequate to properly describe the states and neutral in their 
influence on the measurement, the measurement questions are framed in a balanced or 
neutral way and if the measurement technique itself is reliable and valid" [6]. 
In this paper, the utility assessment methods are compared with each other with respect 
to their usefulness in individual utility assessment. We shall illustrate the methods with a 
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clinical example. 
We use "health state values", "values" or "utilities" for the numeric values that are 
assigned to health states. Analogous to Froberg & Kane we define health state values or 
utilities as "levels of subjective satisfaction, distress, or desirability that people associate 
with (an aspect of) a health state. Other synonyms for this level of subjective satisfaction 
are quality of life, weight, or rating of the health state." [7]. 
Clinical example 
A woman, age 50, presented with a palpable breast mass. At mammography, a lesion 
with a diameter of 4.5 cm, suspect for breast cancer is seen and a fine needle aspiration 
confirms the diagnosis. The axilla is clinically not involved and additional diagnostic 
studies do not reveal evidence for distant metastases. Standard treatment for such lesions 
is a modified radical mastectomy but the patient expresses a strong desire for breast 
conserving treatment (BCT, that is, lumpectomy and axillary dissection followed by 
irradiation). The surgeon explains to her that in order to reach an acceptable cosmetic 
result, a tumor of this size can only be treated by BCT if only a small rim of normal 
breast tissue is removed with the tumor. Therefore, she will have a considerable risk of 
local recurrence after BCT and she will probably run an enlarged risk to die from the 
disease [8, 9, 10]. If a local recurrence occurs, a salvage mastectomy will be necessary. 
The patient considers a very small increase in the probability to die from the disease 
acceptable but she is not able to make a definite tradeoff between life-expectancy and 
breast preservation. In order to quantify this tradeoff, the surgeon undertakes a clinical 
decision analysis. In this example, a very simple decision tree is used (figure 1). From 
this decision tree, it follows that the probability of cure is lower after BCT (0.54) than 
after mastectomy (0.60). The surgeon decides to measure the utilities of his patient in 
order to investigate whether the benefits of BCT outweigh the risks. This example 
illustrates two points: First, objective probabilities may not be the guiding principle to 
make a decision. Second, the patient now has to tradeoff a 0.06 lower probability of cure 
against a preserved breast. 
Utility assessment 
Utility assessment methods can be subdivided into single attribute and multiattribute 
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Figure 1 
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Figure 1. Decision tree. After BCT, there is a 60% probability of recurrence, but if this 
recurrence is local (60% of all recurrences) salvage mastectomy is possible with a 
success rate of 40 %. If salvage mastectomy is not successfull, the patient will develop a 
second recurrence and inevitably die from breast cancer. If salvage mastectomy is not 
possible, the patient will also die from breast cancer. After mastectomy, there is a 40% 
probability to develop a recurrence. Salvage mastectomy is not possible, and a 
recurrence will always lead to death due to breast cancer. 
utility measurement. Single attribute utility measurement can be applied if one 
dimension dominates the decision problem. For example, if two treatments result in the 
same life expectancies but differ in their prospects with respect to quality of life [11]. 
Estimating utility functions in the decomposed approach can be done by assessing 
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utilities for the separate attributes with single attribute measurement. Subsequently, the 
utility functions are combined into one utility function for the combined attributes. It is 
also possible to measure the utilities for the different attributes together and to analyze 
the results in order to estimate separate utility functions for the attributes. 
For example, it has been established that breast conserving therapy in stage I breast 
cancer is equally effective as a modified radical mastectomy, both in terms of local 
recurrence risk and in terms of survival, if the surgical procedure is a quadrantectomy 
(i.e. removing a whole quadrant of the breast) [8, 12]. However, the cosmetic result 
after quadrantectomy is usually worse than after lumpectomy. Only the subjective value 
of the preservation of the breast determines the choice. Some women will prefer a 
mastectomy to a deformed breast and others will not. 
If two or more dimensions are present and tradeoffs between these dimensions must be 
made in order to reach a decision, then multiattribute utility assessment is adequate [13]. 
In our clinical example both quality of life and life expectancy play a role in the 
tradeoff. Most difficult decisions in medicine can be viewed as decisions with multiple 
competing objectives requiring multiattribute utility assessment [14, 15]. 
Multiattribute utility assessment can be performed by holistic measurement. In holistic 
utility measurement, all dimensions of one outcome are assessed together. For instance, 
the outcome cure after salvage mastectomy for local recurrence after initial BCT could 
be assessed as such in a holistic measurement strategy (figure 1). In table 1, the 
outcomes to be assessed in order to solve the example decision problem are listed, both 
for a holistic and a decomposed approach. Λ decomposed approach could be 
operationalized in our example by assessing utility of life years and quality of life 
separately. Utility of life years and quality of life are then subsequently combined. 
An outcome measure that is often used for the combination of the attributes life 
expectancy and quality of life, are Quality Adjusted Life Years (QALYs) [1, 2, 3, 16, 
17]. QALYs are computed by multiplying the number of life years in a certain health 
state by an adjustment factor for quality of life. For example, if healthy after 
mastectomy is assigned a utility of 0.97, then 10 years in that health state are equal to 
9.7 QALYs. QALYs are a useful outcome measure to compare different treatment 
strategies in medicine, since the use of QALYs enables the decision analyst to estimate 
the effect of broadly varying outcomes in one simple measure. It is possible to comprise 
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Table 1 
Holistic 
(Life-long) cure after BCT 
(Life-long) cure after mastectomy 
(Life-long) cure after salvage mastectomy for local recurrence after initial BCT 
Initial BCT, death after unsuccessful salvage mastectomy after 4 years 
Initial BCT, death due to breast cancer after 3 years 
Decomposed 
Quality of life: Healthy after BCT 
Healthy after (salvage) mastectomy 
Distant metastases 
Death 
Life expectancy: Life years 
Table 1. Outcomes to be assessed in a holistic and decomposed approach. 
such different treatment effects as permanent disability, severe toxicity and permanent full 
recovery in one estimate of the average number of QALYs after the treatment. By 
comparing this number with the expected number of QALYs after another treatment, it is 
easily seen which treatment is best, without having to compare numerous possible 
outcomes with various probabilities of occurrence. 
A second distinction is generally made between risky and riskless utilities [11, 18]. This 
distinction requires an explanation of the notion of risk attitude. Suppose the following: 
you are confronted with a lottery with two possible outcomes: a 50 % probability to die 
immediately and a 50 % probability to live out 25 healthy years. How many certain 
healthy life years (the certainty equivalent) would make you indifferent between the 
lottery and the certainty equivalent? The expected value of the lottery is 12.5 years, but 
let us suppose that 7 years (for sure) are equally valuable to the respondent as the lottery. 
This indicates risk-aversion, since the subject is willing to accept a certainty equivalent 
that is less than the expected value of the lottery in order to avoid risk. Assigning the 
arbitrary value 1 to 25 years and the value 0 to 0 years of life, the expected value of the 
gamble is (0.5 * 0) + (0.5 * 1) = 0.5. Seven certain years are thus worth 0.5 utility units 
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(see figure 2, closed circle, indicated by arrows). If the answer is more than 12.5 years, 
the subject is risk-seeking, since he is only willing to give up the gamble (with a chance 
to survive 25 years) for more than its expected value. In figure 2, the open circles 
denote a risk-prone answer, in this example 18 years. Using now the answer to the first 
gamble as an anchor, a second gamble can be offered: 50 % probability to survive 7 
(18) years and a 50% probability to die immediately. The value of this gamble is (0.5 * 
0.5) + (0.5 * 0) = 0.25. If the certainty equivalent to this gamble is 3 (12) years, this 
means that 3 (12) years is worth 0.25. The risk-averse answers thus yield a concave 
utility function and the risk-seeking answers yield a convex utility function. Risk-
neutrality, in which the certainty equivalent is equal to the expected value of the gamble, 
is denoted by the straight line. 
In general, instruments in which questions are presented as riskless or certain options, 
yield riskless utilities, and instruments offering risky or uncertain options yield risky 
utilities. If utility functions are viewed as parametric families of convex or concave 
life years 
Figure 2. Utility fonctions for years of life. A risk-averse (closed circles), a risk-seeking 
(open circles) and a risk-neutral (straight line) utility function for life years is shown. 
For further explanation, see text. 
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functions, for example power functions, the exponent of the power function is an 
indicator of convexity or concavity of the function, and thus of risk attitude. This 
exponent may then be viewed as a risk parameter. Miyamoto [19] and Maas [20] have 
shown how riskless utilities can be converted into risky utilities by introducing a risk 
parameter into a utility model, which can be estimated separately. 
Some authors argue that the distinction between riskless and risky utilities is spurious 
since in some situations risk aversion can be explained by the diminishing marginal 
value of the attributes. For example, the value of distant years is typically lower than 
the value of years in the near future. Therefore, the riskless utility function of life years 
is typically concave downward (see the upper curve in figure 2), consistent with the 
assumption that the value of additional life years is diminishing when the number of 
additional life years increases. Since risk-aversion also yields a utility function that is 
concave downward, it has been argued that risk-aversion does not have an independent 
effect on the utility of an attribute, but that risk-aversion and diminishing marginal value 
are in fact indistinguishable. 
There is, however, ample reason to believe that a distinction between risky and riskless 
utilities does exist. Many choices in health care involve unique, non-repetitive decisions 
under uncertainty, often involving irreversible detrimental outcomes, although 
sometimes at a low probability. These outcomes can be viewed as so-called "ruin" 
prospects [21]. The essence of a ruin prospect is that it is unfavourable and irreversible. 
For example, imagine a gamble with a positive expected value but with a small 
probability of death. If death occurs, the subject is out of the game and will not be able 
to experience the benefit that can be expected on average. Such a situation requires a 
tradeoff of the expected average benefit against the individual risk. This tradeoff will 
depend on individual risk tolerance [21, 22]. 
It is remarkable that a risk-prone or risk-averse attitude has been viewed as a bias [23, 
24], rather than as an individual characteristic that should be taken into account along 
with health state values. The importance of risk attitude in treatment decisions has been 
demonstrated in the earliest applications of preference measurement in medicine. An 
example is the study by McNeil et al of the role of patient preferences in the choice 
between radiotherapy and surgery in laryngeal cancer [25]. 
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Whose utilities ? 
Utilities can be assessed with the aim to use the results at group level. In most published 
decision analyses, average group utilities, often measured in doctors, nurses, or students 
are applied [2, 17]. It is then implicitly assumed that the utilities measured in the 
research population are also valid for patients who face the decision. Furthermore, it is 
assumed that an average utility value is sufficient for a decision for the individual 
patient, even though his or her own utilities might differ widely from this average 
utility. It has been shown that most demographic characteristics do not systematically 
covary with health state preferences, and that variability of preference within groups is 
considerable [23, 26, 27]. It is therefore problematic to use average group results in 
making individual treatment choices. Apart from that, there are fundamental objections 
against averaging utilities across subjects. This requires the assumption that a common, 
quantitative value scale exists across subjects, which is questionable [7, 28]. 
It is preferred to make treatment decisions on the basis of individual utility assessment. 
Once a formal decision analysis model has been developed, individual patient utilities 
can be incorporated into the model in order to produce an individualized treatment 
advice. 
Description of assessment methods 
Visual analog scaling 
Visual analog scaling (VAS) measures values without introducing risk. A rating scale 
consists of a line of which one extreme represents the best, and the other extreme 
represents the worst outcome. For example, in order to rate the value of life after 
mastectomy, the patient is asked to position this health state on a line with endpoints 
healthy after BCT and death (figure 3). Subjects are asked to position intermediate 
outcomes on the scale according to their subjective valuation of that outcome. It is a 
simple method that can be applied in self-administered questionnaires [29]. 
Unfortunately, a number of biases has been described in using this method, of which 
anchoring and stimulus spacing bias are the most prominent [30]. An important feature 
of VAS is that different health states are valued relative to each other, without trading 
off another attribute. If the aim of the assessment is to determine which risk of disability 
or death is acceptable in order to experience a better health state, this assessment 
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Figure 3 
death τ τ healthy after ВСТ 
life with distant metastases healthy after mastectomy 
Figure 3. Visual analog scale. For explanation, see text. 
method does not grasp the essential tradeoff. Values measured with VAS are 
systematically lower than values measured with methods in which such a tradeoff is 
explicit, like the TTO and the SG (see below) [23, 31]. Some authors have proposed a 
power transformation of VAS-results in order to equalize them to TTO-results1 [26, 
31]. 
Standard gamble 
The standard gamble is the most classical measurement method, based on the axioms of 
utility theory of von Neumann and Morgenstern [4]. The subject is offered two 
alternatives A and B. Alternative A consists of a gamble with a good and a bad outcome 
with probabilities Ρ and 1-P, respectively. Alternative В represents a certain, 
intermediate outcome. For example, in the decision tree of figure 1 the best outcome is 
cure after BCT, and the worst outcome is initial mastectomy, death due to breast cancer 
after 3 years. For convenience, these two outcomes are assigned the values 1 and 0, 
respectively. If we want to assess the intermediate outcome cure after mastectomy, the 
probability Ρ is varied until the subject is indifferent between A and В [24] (figure 4). If 
1
 Torrance [26] found the following functional relationship between VAS- and TTO-values: 
VAS = l-(l-TTO)0, which can be rewritten as TTO = l-(l-VAS)16l.De Haes has used the transformation 
TTO=l-(l-VAS)' a, based on results of Bombardier et al [31]. 
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Figure 4 
CHOOSE 
alternative A 
alternative В 
cure after BCT 
death due to breast 
cancer after 3 years 
cure after mastectomy 
Figure 4. Standard gamble, variable probability. For explanation, see text. 
the subject is indifferent between the gamble and the certain outcome at P=0.97, then 
the utility of cure after mastectomy is taken to be 0.97 going by the expected utility rule 
(0.97*1 + 0.03*0 = 0.97) [32, 33]. For the other outcomes, utilities are obtained in an 
analogous way. In a decomposed approach, the numbers of life years should be kept 
constant in order to assess utilities of health states. For example, a gamble with 
probability Ρ that outcome 3 years, healthy after BCT will occur and probability 1-P that 
immediate death will occur is compared to a certain outcome 3 years, distant 
metastases. The resulting utility can be combined by multiplication with a utility 
function for life years that is found by varying the numbers of life years and keeping the 
health state constant under the assumption of utility independence (see section 
'Axiomatic validity')[34]. 
The described elicitation method is known as the "variable probability method" [11, 
24]. In the "variable certainty equivalent method" the probabilities are kept constant and 
the certainty equivalent is varied. This method is described on page 20 and 21. In this 
variant the certainty equivalent should be a continuous variable. Examples of the 
variable certainty equivalent method have been published by McNeil et al [25, 35] (see 
also chapter 5]. Certainty equivalents for life years are used to obtain risky utilities for 
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fe years, which can subsequently be combined with riskless utilities found with th 
TO [19, 25, 36, 37] or with ACM [20] in order to obtain risky utilities, 
'he SG cannot be applied as a self-administered questionnaire, but requires individua 
íterviews, which are time-consuming and expensive [26]. It has been reported to b 
ifficult to understand for respondents [1, 23]. 
Time tradeoff test 
Ъе time-tradeoff technique has been introduced by Torrance [26]. The subject i 
ffered two alternatives: health state A for time t,, followed by death or a better healtl 
tate В for a shorter time t2, followed by death. Time t2 is varied until the subject i 
idifferent between the two alternatives. The utility of health state UA is then compute 
s follows: 
UA = (UB * t2)/t, 
ι order to solve this equation, the value of health state В should be known. Since thesi 
alues are supposed to be values on an interval scale, the scale unit and zero can b 
hosen arbitrarily. By choosing the best health state as health state B, in our exampl· 
ure after BCT, which is assigned an arbitrary utility, usually 1 or 100, the equation cai 
e solved. 
'he patient in our clinical example could be offered the following question: Suppose yoi 
ould choose between 10 years of life after a mastectomy (health state A, time t,) or I 
ears of life after BCT (health state B, time t2). What would you prefer? This questioi 
» repeated with different numbers of life years for time t2 until the patient is indifférer 
etween the two alternatives. If this would be 9.3 years after BCT and we assign thi 
ealth state BCT the arbitrary value 1, the utility of mastectomy is 9.3/10 = 0.93. 
,ike the SG, the TTO cannot be applied as a self-administered questionnaire bu 
îquires individual subject interviews [26]. A more extensive description of this tes 
ìethod can be found in [6, 24, 38]. 
Additive conjoint measurement 
idditive conjoint measurement (ACM) is a decompositional method, in which two о 
юге attributes are valued [39, 40] while, furthermore, the assumptions on which th 
ìethod is based are tested. It is therefore particularly suited for use in individui 
decision making since the validity of the assumptions can be tested for each individual. 
Also, the reliability and consistency of the subjects' answers can be measured. 
ACM is based on assumptions, which are explained here, using two attributes: (i) 
longevity with levels: 2 years (denoted by 2), 4 years (4), 6 years (6), 8 years (8) and 10 
years (10) and (ii) the quality of life, with levels: healthy after BCT (BCT), healthy after 
(salvage) mastectomy (M), and distant metastases (DM). If these three assumptions are 
not satisfied, a perfect additive representation of the preferences given by the respondent 
cannot be found. In such a representation we have, for example: 
U(2,BCT) = U(2) + U(BCT) 
in which U(2,BCT) is the utility of two healthy years after BCT, followed by a sudden 
death. For this approach to be valid, the following assumptions should be satisfied: 
1. Preferences are transitive. That is, if you prefer (10,M) to (2, BCT) and (2.BCT) to 
(4,DM), then this implies that you also prefer (10,M) to (4,DM). If this assumption is 
violated, preferences show circularity. 
2. Preferences must satisfy double cancellation for all levels of longevity and quality of 
life. Double cancellation can be viewed as transitivity of utility differences. Suppose the 
following preferences: 
U(2, M) _> U(4, DM) 
U(4, BCT) >_ U(6, M) 
+ 
U(2) + U(M) + U(4) + U(BCT) >_ U(4) + U(DM) + U(6) + U(M) 
If the additive model is valid, then it follows by cancellation that U(2, BCT) > U(6, 
DM. 
3. Independence means that the preference ordering of levels within one attribute should 
not depend on the level of the other attribute. For instance, if 6 years after BCT is 
preferred to 6 years after mastectomy, this implies that 2 years after BCT is also preferred 
to 2 years after mastectomy. 
4. A fourth assumption is solvability, an untestable assumption which requires all 
attributes (in our example quality of life and longevity) to be sufficiently dense to find 
numerical values for the levels of the attributes. 
In our example, with 3 health states and 5 longevities, 3 χ 5 = 15 combinations of both 
attributes are possible. A hypothetical preference ranking of these combinations is given in 
table 2. In such a preference ranking, violations of independence can be seen by 
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Table 2 
Quality of life 
2 
4 
6 
8 
10 
DM 
0 
1 
2 
5 
7 
M 
3 
6 
9 
11 
12 
BCT 
4 
S 
10 
13 
14 
Table 2. Hypothetical preference ranking for the patient in the clinical example. DM 
denotes 'distant metastases', M 'life after mastectomy,' and BCT 'life with preserved 
breast after breast conserving therapy'. The numbers are rank numbers, denoting 
combinations of levels of quality of life and life years in increasing order of desirability. 
Two years with DM is the worst alternative, and 10 years after BCT is the best. 
inspection (table 2), but violations of transivity and most violations of cancellation 
cannot be found in this way. In order to test transitivity, the method of paired 
comparisons is used. An example is: 
What do you prefer? 
6 years after M 
or 
4 years after BCT 
The number of paired comparisons depends on the number of levels in each attribute. 
With 15 combinations, ( ] = 1 0 5 different paired comparisons exist. Seventy-five 
paired comparisons are trivial in the sense that they do not yield new information, e.g.: 
6 years after BCT 
or 
3 years after M 
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In this comparison, both the longer life-expectancy and the better life quality are 
combined in one alternative, so that no choice problem exists. Thirty non-trivial 
comparisons are left, representing tradeoffs between quality and quantity of life. When a 
respondent has answered all 30 non-trivial comparisons without violating the 
assumptions, a preference ranking of the 15 pairs is obtained, which forms the input for 
the computer program ORDMET3 [41]. This program represents the preference ranking 
by linear inequalities. By solving the system of inequalities, it computes a solution space 
from which values for the different levels of both attributes can be derived, such, that 
the preference ranking is kept intact. The numeric values for each level of each attribute 
can (additively) be combined (fig. 5). This task can be performed by any program that 
assumes data to be represented by the additive conjoint effect of several attributes. By 
optimizing a measure of goodness-of-fit such as Kruskal's stress the observed ordinal 
preference ranking is transformed into the best-fitting scale values. A well-known 
program such as MONANOVA can do this [42, 43]. 
Figure 5 
breast conserving treatment (salvage) mastectomy 
metastasized breast cancer 
8 10 
life years 
Figure 5. Additive conjoint measurement. Additive solution for the preference matrix of 
table 2. There are five levels of longevity (2, 4 ,6, 8, 10 years) and 3 levels of quality of 
life (life after BCT, life after mastectomy, life with distant metastases). The data points 
are found by adding the value of each level of longevity and each level of quality of life. 
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The application of paired comparisons requires only ordinal preference judgments, 
which is a relatively easy task for the respondents. The number of paired comparisons, 
however, is the major practical limitation of this method. In our simplified example, 
only 30 paired comparisons are used, but the number of paired comparisons increases 
exponentially with more attributes, or more levels within each attribute. One hundred 
paired comparisons is about the maximum number that can be processed by most 
respondents, and less comparisons are preferable. The paired comparisons are judged 
three times in order to account for random mistakes or shifts in preferences during the 
assessment period. If differences between these three replications occur, the alternative 
that is preferred three or two times over the other alternative, the so-called majority 
preference, is used as the "true" preference. If intransitivities in majority preferences 
show, then Maas' method of solving intransitivities can be applied [44]. In this method, 
so-called "stable preferences" (preferences that have not changed during three 
replications) are being preserved while remaining contradictory preference relations are 
then corrected such that a transitive pattern results. If intransitivities in stable 
preferences are found, these inconsistencies can be discussed with the respondent, and if 
(s)he confirms the intransitive preferences, the additive model is rejected as an 
acceptable representation of the subject's preferences. Another possibility to solve 
intransitivities is to ask the respondent a direct preference ranking of the combinations 
that are involved in circularities. 
The actual testing task does not require the individual assistance of an interviewer, as in 
the TTO and SG. It may be useful to perform at least one test replication in the 
presence of a research assistant in order to ensure that the task is well understood. A 
classroom setting has been quite convenient, in our experience. 
Reliability 
Reliability refers to the extent to which a subject gives the same responses in repeated 
trials of a test. This is not the same as reproducibility. Reproducibility refers to the 
extent to which a test or assessment procedure will yield the same results in repeated 
trials, when measuring an unchanged characteristic [45]. High reproducibility implies 
that one test replication is sufficient to obtain an accurate estimate of the utility. 
Since preferences may change in time [30], the term reproducibility in a strict sense 
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does not apply to utility assessment. Any assessment of reliability will in fact reflect two 
phenomena: 1. the extent to which the test is free from random error, e.g. measures 
utilities accurately and 2. the extent to which subjects change their attitude towards the 
valued health state between two replications. In most papers about the subject, this 
distinction between reproducibility and reliability is not made. Von Winterfeldt and 
Edwards argue that low reliability will often occur if respondents are unfamiliar with the 
type of decision considered. In such cases, "the utility and value measurement process 
should be viewed as a constructive process rather than as an elicitation process" [30]. As 
a consequence, high reliability cannot be expected when utilities are measured without 
sufficient provision of information and explanation. Most patients who face a treatment 
decision are not familiar with the kind of decision at hand. Therefore, they may not have 
very clear preferences to start with, and preferences are constructed rather than elicited 
during the assessment process [30]. In the clinical situation, when a patient is confronted 
with a diagnosis of for example breast cancer, it is not realistic to assume that utilities 
are present in her head, waiting to be elicited. Furthermore, one might assume that the 
emotional distress of such a situation might lead to lability of values. On the other hand, 
Llewellyn-Thomas et al. found that patients who rate their current health state on rating 
scales and who are thus fully informed about that health state, showed no significant 
shifts in values over time [46]. In this study, performed in irradiated patients with 
laryngeal cancer, reliability coefficients ranging from 0.61 to 0.78 were found, 
suggesting that random variations are more important than lability of values, at least in 
this patient group. Llewellyn-Thomas et al. found in a later study that mood disturbance 
did not cause lability of values [47], suggesting that if respondents are sufficiently 
informed, lability of values is not a critical issue. Random variation remains a problem, 
however. 
Critical values that establish consistency have not been provided in the literature. In his 
standard book of psychometry, Nunnally proposed that for the purpose of individual 
decision making a reliability coefficient should not be lower than 0.90 [48]. No utility 
assessment method has repeatedly shown such a high reliability. Reliability coefficients 
(Pearson's correlation coefficients) for the TTO ranged from 0.62 to 0.87, for the SG 
from 0.53 to 0.95 and for direct rating from 0.47 to 0.94 [24, 26, 46, 49, 50]. Although 
Torrance stated in his paper that his results were "satisfactory" [26], a critical value 
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justifying this qualification does not exist. The proportion of answers that were the same 
in three replications of ACM ranged from 0.81 to 0.90 in three groups of respondents 
[51]. These proportions are, however, not directly comparable to the reliability 
coefficients mentioned above. 
Validity 
A test is valid if it measures what it intends to measure. Although reproducibility is a 
necessary prerequisite for use of a test, the results can be invalid due to systematic bias. 
The simplest way to investigate validity is criterion validity: the test results are 
compared to a golden standard. The SG has been considered as golden standard because 
of its direct basis in utility theory, and has been used to validate other methods [26]. 
However, the SG has been shown to generate violations of utility theory and is sensitive 
to framing effects. A framing effect means that a different formulation of the same 
question provokes a different answer. For example, if life expectancies are formulated 
as a probability to die rather than as a probability to survive, then the respondents will 
be less likely to choose the option [52]. Therefore, no test can be accepted as criterion 
[52, 53, 54, 55] 
Several other types of validity have been investigated and will be discussed below in 
further detail: convergent validity (a specific form of construct validity) and predictive 
validity (a specific form of criterion validity) [24, 45, 56]. Axiomatic validity is a type 
of validity that is particularly suited for utility assessment [30]. 
Convergent validity 
Convergent validity is based on the assumption that different methods of measuring the 
same quantity (utility) should covary [30]. Reported correlations are listed in table 3. 
The interpretation of these results have been contradictory. For example, Torrance [26] 
states that his results with the TTO and SG support convergent validity (r=0.65), 
whereas Wolfson et al. [23] argue that their results do not support convergence between 
SG and VAS and between SG and TTO (r=0.76 and 0.84, respectively). 
Most studies agree that the (variable probability) SG yields systematically higher values 
than the TTO and that the TTO yields systematically higher values than VAS [23, 26, 
37, 49, 57]. The difference between SG and TTO is attributed to the difference between 
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Table 3 
TTO SG 
VAS 0.65**[57] 0.76*[23] 
0.89**[23] 0.36*[26] 
0.22 [49] 0.63*[57] 
0.40**[26] 
ΤΤΟ 0.65 [26] 
0.65* [5η 
0.84* [23] 
Table 3. Convergera validity of preference assessment methods; the numbers are 
Pearson correlation coefficients. 
* The SG-values were systematically higher than TTO- and VAS- values, respectively. 
**The TTO-values were systematically higher than VAS-values. 
risky and riskless utilities. In the SG the point of indifference will be higher than in the 
TTO, because subjects usually prefer certainty to uncertainty. For example, the patient 
from the clinical example is offered the following choice: a gamble with probability Ρ 
that 10 years, healthy after BCT will occur and probability 1-P that immediate death will 
occur or the certainty equivalent 10 years, healthy after mastectomy. If the patient is 
indifferent between the two alternatives at P=0.95, the utility of healthy after 
mastectomy is 0.95. If the same patient is offered a comparable TTO-question (see for 
the example the section Time tradeoff test), the resulting TTO-utility will typically be 
lower, in our example 0.93. The difference between the SG-utility and the TTO-utility is 
attributed to risk aversion. It has been shown that adjusting TTO-values by a risk 
parameter derived from certainty equivalent gambles can cancel this difference [37]. 
VAS-values are usually lower than TTO-values, which is attributed to the fact that in the 
TTO a tradeoff is made with life years, whereas in VAS the outcomes or health states 
are valued without a tradeoff. A supplementary explanation for the difference between 
VAS on the one hand and TTO and SG on the other is the phenomenon of salience [40]. 
Salience means that the attribute that is traded off or gambled with receives particular 
attention from the respondent and therefore seems more important. Salience can, 
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however, not explain the difference between TTO and SG. A monotonie relationship is 
usually assumed between results of these three tests, which supports the viewpoint that 
all three tests measure closely related constructs, although they do not yield the same 
values. 
Predictive validity 
Predictive validity is the extent to which an instrument is able to predict a certain 
criterion, without specifying theoretical relations between the mentioned criterion and 
what the instrument is meant to measure. For example, patients who value healthy after 
BCT very high, should more often experience a good quality of life when they actually 
live in this health state, than patients who have previously valued this state low [30]. 
Thus, the preference assessment method under study should adequately predict current 
or future quality of life. Since quality of life is influenced by many factors of which 
health status is only one, establishing predictive validity will be cumbersome. If, for 
instance, the previously mentioned patient, who valued healthy after BCT very high, is 
widowed just after the treatment, her subjective quality of life will probably not be very 
good although her health status may be alright. 
Depending on the decision problem under study, a more specific measure than overall 
quality of life could be used in establishing predictive validity. In our example, the 
prediction of body image after mastectomy might be a useful criterion. It is expected 
that women who value healthy after mastectomy low will experience a greater decrease 
in body image after mastectomy, than women who value this health state high. 
Predictive validity can also be tested by comparing ал intuitive choice with the choice 
following from the health state preferences [58]. This way of testing validity carries two 
obvious disadvantages: 1. the use of the patients' intuitive judgment as a criterion will 
implicitly declare utility assessment superfluous. If intuitive judgment would be as 
adequate as a choice based on utility assessment, why measure utilities at all? Because it 
is anticipated that the patient neither can nor wants to take the entire responsibility for 
the choice of her/his treatment [59], utility assessment is advocated. It is inconsistent 
with this view to use the intuitive judgment of the patient as a criterion of validity of 
utility tests. 2. On the other hand, using the intuitive choice of a third party, for 
example the clinician, as a criterion does nol comply with the aim of basing the choice 
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on the patient's own preferences. Discrepancies between doctor's choices and patient's 
preferences can be caused by interpersonal differences in preference as well as by 
invalid preference assessment. 
Therefore, the best measure of predictive validity in utility assessment is the degree to 
which a preference measurement method can predict (indicators of) quality of life in 
health states that have been valued previously. 
Axiomatic validity 
Axiomatic validity is based on the notion that if a subject satisfies the axioms on which 
the test is based, then her/his statements made in the test are rational [30]. Some of the 
axioms on which additive conjoint measurement is based (independence, transitivity and 
cancellation), are very strong and violations are often encountered. Usually minor 
violations are disregarded, but it is clear that this weakens the establishment of validity 
on an axiomatic basis. 
Axiomatic validity can also be assessed in other measurement methods. For example, in 
order to test utility independence of health status from survival duration, a gamble of the 
form: a probability Ρ to live 10 years, healthy after BCT or a probability 1-P to die 
immediately versus a certainty equivalent 8 years, healthy after ВСГ, could be repeated 
for various different health states, while keeping the numbers of life years constant [34]. 
Utility independence requires that the certainty equivalent does not depend on health 
status. At group level, this property can easily be tested. At the individual level, 
however, it is cumbersome to distinguish between random error and violation of utility 
independence. 
Another way to test axiomatic validity of subjects' responses in the TTO and SG is to 
use not only the best and the worst outcome as anchors, but also intermediate outcomes. 
After correction for the relative value of the anchors, the resulting utilities should be the 
same as the utilities found with the original anchors. Llewellyn-Thomas et al. found that 
in this respect the responses to the variable probability SG did not satisfy utility 
independence [55]. The hypothesis that values found in the consistency checks are the 
same as the original values, can be tested with ANOVA at group level. However, at the 
individual level, no criterion exists that establishes whether two values, measured in 
consistency checks of a test, can be accepted as consistent. 
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Discussion 
The appropriate way to measure patient's preferences for use in individual decision 
making remains controversial. The most frequently used methods (VAS, TTO, SG) have 
all been shown to be subject to biases and inconsistencies and different methods, which 
are often assumed to measure the same entity, yield different results as is illustrated in 
table 3. If the results of these methods are used to make real life decisions, either at 
group level (for example in the allocation of health care resources, the development of 
treatment protocols, and in the evaluation of new treatments for their effects on quality of 
life) or at the individual level, it is highly important to use a valid test. Many difficult 
problems in medicine, for example, whether or not to give adjuvant chemotherapy to 
women with node-negative breast cancer or whether or not to perform breast conserving 
therapy are medically nearly equivalent; small changes in utility will therefore easily 
cause a switch in treatment preference. The thrustworthiness of utilities is thus of vital 
importance. 
In the introduction, a number of criteria, required for quality of life tests are mentioned. 
Spitzer mentioned simplicity, understandability and acceptability, aspects that are covered 
by the term feasibility. Both Torrance [6] an Spitzer [5] consider validity a criterion and 
Spitzer explicitly mentions content validity ("cover an adequate range of dimensions of 
quality of life"). Torrance adds reliability to the list of desired test properties. In our 
opinion, these criteria also apply to utility assessment, if the property of content validity 
is rephrased as "cover all attributes relevant to the decision". All utility tests have been 
reported to be feasible, provided that individual interviews are performed [23, 25, 26, 34, 
35, 37, 40, 49, 50, 55, 57]. VAS is the only test that can be performed by self-
administered questionnaires [29, 31] and is therefore the most feasible test. It is important 
to cover all attributes that are relevant to the decision in a utility test, in order to prevent 
the omission of important aspects in the decision making process. This is, however, 
rather a question of problem definition than of test method, since all tests can be used in 
both multiattribute and single attribute measurement. 
Validity is not an unequivocal entity: to what extent should validity be tested before a test 
is accepted as valid? As we have pointed out above, criterion validity cannot be obtained 
due to the lack of a golden standard, and conflicting opinions about convergent validity 
have been published in the past [23, 26]. Furthermore, predictive validity of utility 
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assessment has to our knowledge not been assessed in medicine, with one exception 
[58]. Some research has been carried out to establish axiomatic validity. For both SG 
and ΊΤΟ, evidence exists that underlying assumptions are not satisfied. In the SG utility 
independence was violated [54, 59]. Stalpers [1] showed that the utilities found with the 
TTO depend on the number of life years with which the tradeoff is made (violations of 
proportionality). This is important for the application of utilities in the computation of 
QALYs and in decision trees. ACM does not prevent violations, but offers the 
opportunity to check whether the assumptions are valid at the individual level. This 
offers the possibility to prevent the unjustified use of invalid test results, and the 
possibility to correct inconsistencies and violations, if the respondent agrees with these 
corrections. 
Reliability coefficients reported so far have been fairly low (table 3), as compared to 
Nunnally's proposed 0.90 [48]. On the basis of reliability alone, it is not possible to 
express a clear preference for any of the test methods. We suggest that if accurate 
values are necessary, in the sense that small variations in values will change the 
treatment preference, test replications be performed in order to enhance accuracy. 
We suggest two additional criteria for judging whether a particular test is suitable for 
use in medical treatment choices: 
1. Do the choices in the tests resemble the real life tradeoff? If there is a tradeoff 
between life-expectancy and quality of life the questions should reflect this tradeoff. 
2. If the choice under study is risky, is risk attitude incorporated into the assessment 
method? In medicine most treatment choices that involve a tradeoff between conflicting 
risks and benefits are risky, so that the point could be made that risk attitude should be 
incorporated in utility assessment for this purpose. 
The relevance of these additional criteria can be illustrated with the published results of 
utility assessment. Many investigators have shown that there are real differences 
between the utilities resulting from the different test methods (table 3). 
The method that yields the lowest values will yield the maximal quality adjustment of 
life years, so that in a tradeoff between quality of life and life expectancy, VAS-scores 
will most easily yield a preference for the treatment with the shorter life-expectancy, in 
our example BCT. TTO will be somewhat more conservative with respect to life-
expectancy and SG is the most conservative test. Thus, the treatment choices will shift 
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towards more conservative treatment choices with respect to life-expectancy along the 
line VAS-TTO-SG. Where ACM is in this line is not yet empirically clear, but the 
essential tradeoff is the same as in the TTO. 
If VAS-scores are to be used for risky tradeoffs between life-expectancy and quality of 
life, a transformation is necessary in order to obtain values equivalent to TTO-values, 
followed by a second transformation in order to incorporate risk attitude. The 
propagation of inaccuracies, present in each step of transformation poses serious 
questions on such a procedure. Furthermore, the functional relationship between VAS-
scores and TTO-values is based on averaged group level measurements, and Torrance 
reported that this transformation did not fit the individual tradeoffs [26]. 
Thus, on the basis of adequately reflecting the risky tradeoff, three options are left: SG, 
TTO adjusted for risk attitude, and ACM adjusted for risk attitude. There is some 
preliminary evidence that the adjusted TTO yields values comparable to the standard 
gamble [39], but no such evidence exists for the other options. Of these options, ACM 
is the most feasible, since the test can be performed in a classroom setting, although the 
elicitation of a risk parameter will require (short) individual interviews. An advantage of 
ACM is the possibility to test basic assumptions; in view of the reported violations of 
these assumptions this property is important. 
It may be useful to elaborate here on the meaning of violations of assumptions. If the 
results of a test procedure indicate a violation of, for example, utility independence, this 
does not necessarily mean that the test procedure provokes such violations and that 
therefore the test should not be used. Indeed, the 'true' preferences of the respondent 
may not accord with the basic axioms. For example, Sutherland et al. found evidence 
that violations of utility independence could be explained by the concept of 'maximal 
endurable time' [60], which means that for example 3 years in a bad health state is 
preferred to 4 years. However, 3 years is preferred to 2 years. This implies that 
respondents think that they cannot endure a longer time in that health state. The 
assumption of utility independence is invalid in such a preference structure, and 
resulting utilities cannot be used in the computation of QALYs. It is, however, 
desirable, that we are able to model such a preference structure in order to account for 
them in our decision models. With ACM, the systematic investigation of patterns of 
violations at the individual level is possible and this method opens perspectives on 
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investigating not only subjective values but also the patterns that underlie those values 
and, eventually, incorporating more complicated preference structures into our decision 
models. 
In our opinion, a fruitful future direction of research is to unravel the reasons why 
people violate basic assumptions, and to capture systematic and motivated violations in 
adjusted preference models. 
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Abstract 
In order to investigate the possibility for applying utility assessment in treatment decisions, 
the test-retest reliability and intentai consistency of the time tradeoff test (TTO) and the 
certainty equivalent method (CE) were investigated. The clinical problems addressed were 1. 
the choice between breast conserving therapy and mastectomy and 2. the decision whether or 
not to perform prophylactic mastectomy in women who are descendants from a family with 
hereditary breast cancer. The TTO was applied to elicit riskless utilities for health states and 
the CE to measure risk attitude for life years. These methods were applied in three groups of 
volunteers: two groups of students in health science (groups A and Β, η=14 and η=17, 
respectively) and a group of healthy volunteers (group C, η=30). The respondents 
performed two (groups A and C), or three (group B) replications of the TTO and CE. 
Highly significant systematic differences were found in groups В and С between replications 
1 and 2. This difference was not found between replication 2 and 3 in group B, suggesting 
that utilities stabilize after two replications. The standard error of measurement varied 
between 0.109 and 0.144. Furthermore, responses to the TTO were inconsistent (group C) 
in the sense that different utilities were found if the assessed health states were compared 
with another, non-optimal health state in stead of perfect health. No evidence for violations 
of the property of constant proportional tradeoff was found. Reliability of the CE was 
satisfactory, as was internal consistency. We conclude that the responses to the TTO are 
neither reliable nor consistent, and that the use of the TTO in utility assessment is 
questionable. 
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Introduction 
In clinical decision analysis, utility assessment is applied to measure the subjective 
desirability of health states that may result from one of the possible options. By 
incorporating utilities into a decision analysis, not only life-expectancy but also subjective 
desirability of health states plays a role in the decision which option is best. A simple and 
wellknown method to integrate life-expectancy and desirability of health states, is the 
computation of Quality Adjusted Life Years (QALYs). The number of life years in a certain 
health state is then multiplied by a utility value that is scaled between 0 and 1. The option 
which yields the highest number of QALYs is the best option. This model will be referred to 
as the riskless QALY-model. 
Extensions of the QALY-model have been published by Pliskin, Shepard & Weinstein [1], 
Miyamoto & Eraker [2], and by McNeil & Pauker [3]. These models will be referred to as 
risky QALY-models. In risky QALY-models the numbers of life years are adjusted for risk 
attitude. Both types of models require that the utility of health states is independent of the 
utility of life years. The riskless QALY-model further implies that the decision maker is risk 
neutral. 
In order to obtain riskless QALYs, the time tradeoff test (TTO) is often adopted [4, 5]. In 
the TTO, the respondent is asked how many of a certain amount of life years in ill health he 
or she is willing to trade off in order to live in complete health. The TTO has been 
questioned, because the property of constant proportional tradeoff (the requirement that the 
number of life years that is traded off be a constant proportion of the numbers of life years 
in ill health), is violated easily [6]. The property of constant proportional tradeoff is is a 
necessary prerequisite for the computation of QALYs. Risky QALYs can be obtained by 
using the standard gamble as measurement instrument [7]. However, standard gambles are 
difficult to understand for respondents and yield inconsistent results [6,8]. Furthermore, a 
number of biases has been shown to be present in judgments in which probabilities are 
involved [9, 10]. Another possibility to obtain risky QALYs is to measure riskless utilities 
by the TTO and to measure risk attitude for life years separately by the certainty equivalent 
method for life years (CE), as has been proposed by McNeil & Pauker, and Miyamoto & 
Eraker [2, 3]. In the CE, the respondent is offered a lottery with equal probabilities to live 
out a short and a long life span. The respondent is then asked how many certain life years 
are of equal value to him or her as the lottery. This number is called the certainty 
equivalent. This procedure is easier to understand for the respondents than the standard 
gamble, since only 50-50 gambles are involved and probability distortion is then minimal. 
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The procedure proposed by Miyamoto and Eraker, however, also requires utility 
independence to hold. 
At our institution, the possible application of utility assessment in breast cancer treatment 
selection is investigated. The study reported here is part of a larger study conducted to test 
the feasibility, reliability and consistency of utility assessment methods for this purpose. In 
this paper, the results with respect to the reliability and internal consistency of the certainty 
equivalence method (CE) for the assessment of utility of life years and the TTO [3, 4, 5] are 
reported. The TTO and CE were offered to two groups of students at two and three 
occasions, respectively, in order to detect possible shortcomings in the test procedure. In 
both tests, additional questions were asked to test internal consistency. Subsequently, the 
tests were offered to a group of female healthy volunteers. We chose to offer the test to 
volunteers rather than to patients, who have been treated for breast cancer in the past, 
because it was felt that these women most closely resembled the target population: women 
without any special education or experience in health care who face a breast cancer treatment 
choice. 
The purpose of the study was to investigate feasibility, test-retest reliability and internal 
consistency of TTO and CE. 
Methods 
General study design 
Three groups of respondents participated in the study: two groups of students in health 
science (groups A, n=14, and B, n=17) who performed the test procedure in a class-room 
setting, and a group of healthy volunteers from the general population (group C, η=30) who 
were interviewed by the first author. Two clinical problems were addressed: the first 
problem, the management of hereditary breast cancer, was presented to group A. The 
second problem, the management of early breast cancer, was presented to groups В and С 
The respondents were asked to complete the questionnaires as if they were a patient facing 
the described choice problem (see section 'Clinical problems' below). 
In order to inform the respondents about the possible consequences of the decision, groups A 
and В were shown a video film about breast cancer. Topics that were mentioned in the film 
were coping with mastectomy, the use of prostheses, the possibilities and drawbacks of 
breast reconstruction, the possible occurrence of lymfedema of the arm after axillary 
dissection. Additionally, they were provided with short written health state descriptions for 
each of the four health states to be assessed. Opportunity to discuss obscurities with respect 
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Table 1 
session 1 
session 2 
session 3 
session 4 
session 5 
Group A 
video (day 1) 
TTO 
CE 
ACM (day 5) 
ACM (day 10) 
ACM (day 14) 
(day 21) 
solving 
intransitivities 
TTO 
CE 
Group В 
video (day 1) 
TTO 
CE 
ACM (day 2) 
ACM (day 5) 
TTO 
CE 
ACM (day 10) 
(day 15) 
solving 
intransitivities 
TTO 
CE 
Group С 
video 1 (day 1) 
video 2 
TTO 
CE 
ACM (day 6) 
ACM (day 12) 
ACM (day 19) 
TTO 
CE 
(day 24) 
solving 
intransitivities 
Table 1. Testing schedule. Between parentheses, the number of days from the starting day is 
given. For group C, in which each respondent was tested individually, the median number 
of days from the starting day is given. 
to the descriptions or the film was given. The respondents performed two (groups A and C) 
or three (group B) replications of the certainty equivalent method (CE) and the time tradeoff 
test (TTO). All three groups further performed three replications of additive conjoint 
measurement, about which we will not report here (table l)1. 
The group of volunteers (n=30) consisted of women who had responded to an 
announcement in a local newspaper. They were all aged 40 or older, and had no history of 
breast cancer or psychiatric illness. These women were interviewed individually. They were 
asked to imagine that they faced the same problem as the students in group B. To them, two 
other video films were shown. These films were preferred for use in this group, because 
they were easier to understand for lay people and because metastasized breast cancer was 
1
 See chapter 4 of this thesis. 
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highlighted more adequately. Extensive time for questions and discussion was given, and 
additional written information on specific topics was available upon request. There were 
slight differences in the testing schedule between the groups (table 1). 
Clinical problems 
Hereditary breast cancer 
Women belonging to families in which breast cancer is segregating in a dominant Mendelian 
fashion are at high risk to develop breast cancer, often at a relatively young age. Their life 
time risk to develop breast cancer is around 50 %. Two strategies are advocated: 1. Close 
monitoring by palpation of the breasts at regular intervals and yearly mammography or 2. 
prophylactic mastectomy followed by reconstruction. If close monitoring is chosen, no 
guarantee exists that a developing tumor will be detected in time (i.e. before the 
development of (micro)metastases), so that the patient might die from breast cancer despite a 
close follow-up. If prophylactic total mastectomy is chosen, the risk to develop breast cancer 
is minimized, but it is possible that the woman would never have developed breast cancer at 
all so that mastectomy is an overtreatment. Of course, the best life-expectancy can be 
expected after mastectomy but it is the woman who should make the ultimate tradeoff 
between life-expectancy and the preservation of both breasts. 
Four possible health states were defined: 1. Life under close medical follow-up, 2. Life after 
prophylactic mastectomy followed by reconstruction 3. Life after mastectomy for breast 
cancer and 4. Life with metastasized breast cancer. 
Treatment of early breast cancer 
Patients with a T, or a small T2 breast tumor have two treatment options: breast conserving 
treatment or mastectomy. Although life expectancy after both treatments is equal in the first 
ten years of follow-up, a rather high frequency of local recurrences after breast conserving 
therapy has been reported. It is expected that in the long run the local recurrence rate will 
affect survival [11, 12, 13]. Thus, a tradeoff exists between local recurrence risk (and 
eventually survival) and the preservation of the breast. Four possible health states were 
defined: 1. Life with preserved breast after breast conserving therapy for breast cancer, 2. 
Life without breast after mastectomy for breast cancer, 3. Life without breast after 
mastectomy for a local recurrence after initial breast conserving therapy and 4. Life with 
metastasized breast cancer. 
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Test methods 
Both problems were viewed as a tradeoff between quality of life Q and longevity L. For 
each problem, four levels of Q were defined (see section 'clinical problems'). Levels of L 
were dependent on the age of the respondent and the test method (table 2). 
The maximum number of life years (MLY) in the tests was based on the current age-specific 
life-expectancy of the Dutch female population (CBS, five-year-strata)[14]. 
Table 2 
respondents'age 
age <. 22 
23 <. age <. 27 
28 <. age <. 32 
33 <. age <. 37 
38 <. age <. 43 
44 <_ age <. 48 
49 <. age <. 54 
55 <. age <. 59 
60 <. age <. 65 
66 <. age <. 72 
age >_ 73 
MLY 
60 
55 
50 
45 
40 
35 
30 
25 
20 
15 
10 
levels of longevity 
TTO 
5, 
5, 
5, 
5, 
5, 
5, 
5, 
5, 
5, 
10, 35, 60 
10, 32.5, 55 
10, 30, 50 
10, 27.5, 45 
10, 25, 40 
10, 22.5, 35 
10, 20, 30 
10, 17.5, 25 
10, 15, 20 
2.5, 5, 10, 15 
2.5, 5, 7.5, 10 
Table 2. The maximum number of life years (MLY), used in the utility tests. For 
explanation, see the text. 
Time tradeoff test 
The TTO was performed by groups A and В in a classroom setting. The respondents first 
gave a preference ranking of the four health states to be assessed, i.e. they ranked Q,, Oj, 
Q3 and Q4 in increasing order of preference. After an explanation of the questions, they 
filled out a questionnaire with 16 TTO-items. The basic items were of the following form: 
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(x¡) years in complete health (Qa^) is equivalent to L, years after mastectomy for 
breast cancer (Q). 
Because we will later explain the construction of consistency checks, we refer to these items 
as 'basic' TTO-questions. The utility of living with mastectomy for breast cancer (Q,) is 
x/L,; in general: 
UQj/UQniM= x/L, {1} 
where U Q ^ is the utility of complete health, which is, by convention, assigned the value 1, 
so that equation {1} can be solved for UQJ. In order to test the proportionality of tradeoff, 
each level of Q, was tested with 4 levels of L„ dependent on the respondent's age (table 2). 
The combination of four levels of L¡ (i=1...4) with four levels of Q, (j= 1...4) resulted in 
16 TTO-items (table 3). 
The respondents of group С were interviewed individually. They were shown a sheet of 
paper with an item, for example: 
years in complete health is equal to 25 years after mastectomy for breast cancer 
The questions were formulated as follows: 
'Suppose you would have to choose between two alternatives: 20 years in complete 
health or 25 years after mastectomy for breast cancer. After mastectomy, you are 
otherwise healthy. After the mentioned time periods you will die suddenly and unnoticed. 
Which alternative would you prefer?' 
The number of life years in complete health was then varied until the respondent was 
indifferent between the two alternatives. 
For group C, additional items were incorporated in order to check internal consistency. We 
refer to this type of question as the 'consistency check'. In the consistency checks, the 
respondent is asked, just as in the basic questions, to equate a certain number of life years in 
one health state to a number of life years in another health state. In the basic questions, a 
non-optimal health state is always compared to complete health. In the consistency checks, 
however, each non-optimal health state is compared to another non-optimal health state. 
Each level of Q was compared with one other level of Q, not only with perfect health 
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Table 3 
Qi Qi Q> Q< 
L, 
и 
L, 
L4 . . . 
basic Q
m
 O,,«, CL« Q ^ 
consistency 
check Q2 Q3 Q4 Qj 
Table 3. Construction of basic items and consistency checks in the TTO. In the basic 
questions, every level of health Q, was tested with every level of longevity L„ denoted by 
periods in the table, yielding 16 items. The two lower rows indicate the health state that was 
used to compare the assessed health state with. In the basic questions, this was complete 
health (Q^. In the consistency checks, the health states were compared with one other 
health state, again for every level ofL, as indicated, yielding another 16 items. For further 
explanation, see text. 
((able 3). Most consistency checks were of the general form: 
....(x
ci) years in health state QJ+1 is equal to L, years in health status Q r 
If we apply formula {1} to this question, we find: 
U Q / I V . = x
cl/L, {2} 
In words, the ratio of the utilities of health state QJ+1 and Q, is equal to xtl/L,. Thus, we 
cannot derive a simple utility value from these questions. If, however, utilities do not 
depend on the framing of the questions, we expect that the ratio of the utilities UQ, and 
UQ,+I, which were previously found in the basic questions, will be equal to the ratio x
c
,/L, 
derived from the consistency checks. If there is a framing effect, however, both ratios will 
not be the same. 
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The consistency checks were repeated for four levels of L, (table 3) for each health state, 
which yields a total of 16 consistency checks. Note that, for the consistency check for Q4, 
Оз is worse than Q4. Hence, the number of life years xci in health state Q3, that is judged to 
be equal to L, years in Q4, should be greater than L¡. 
Applying formula {2} to this variant yields: 
IVUQ3 = xc/L, {3} 
Thus, we find UQ/UQ,·.,.! in the consistency checks of health states Q„ Q2, and Q3, and 
UQ4/UQ3 in the consistency checks of Q4. The interview format of the consistency checks was 
the same as in the basic TTO questions. 
Certainty equivalent method 
Groups A and В performed out the gambles 1, 2, and 3, as displayed in figure 1. The 
groups received an explanation of the question and subsequently produced certainty 
equivalents for the three gambles. In group C, the respondents were interviewed 
individually. Each gamble was presented to the respondent as follows: 
The respondent was shown a sheet of paper with the following text (gamble 1, figure 1, the 
maximum number of life years (MLY) is 25 years): 
A: 50 % chance to die within one month 
50 % chance to live 25 years in complete health 
or 
B: healthy years for sure 
The questions were posed as follows: 
'Suppose you would have to choose between alternatives A and B. A is an uncertain 
option. If you choose A, you have a chance of 1 in 2 to die within one month, and a 
chance of 1 in 2 to live 25 years in complete health. It is not possible to choose for the 
25 years of survival for sure. If you pick A, it is like a lottery: you may live 25 years, 
but you may also die within one month, and you do not know beforehand which of the 
two possibilities will come true. Therefore, you might prefer to choose B. If you pick B, 
you are sure to live for example 20 years in complete health, no more and no less. Thus, 
the question is: Do you prefer A, which means that you might live 25 years in complete 
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health, but which also carries the risk to die within one month, or do you prefer B, 
which means that you will live 20 years in complete health for sure?' 
If the respondent stated that she preferred B, the question was repeated, but now with a 
certainty equivalent of 5 healthy years. (If she preferred A, the question was repeated with a 
certainty equivalent of 23 years.) If the respondent now stated that she preferred A, the 
question was repeated with 15 years as a certainty equivalent. This bracketing procedure was 
repeated until the respondent was indifferent between A and В and the certainty equivalent 
was found. 
If the maximum number of life years is assigned an arbitrary utility value of 1, and dying 
within 1 month a value of 0, then the certainty equivalent is worth 0.5 utility units or 50 % 
of the maximum achievable utility according to expected utility theory. Therefore, it is 
called the CES0 in figure 1. The CE» is used to construct a second and third question, 
gambles 2 and 3 in figure 1. In this way the СЕц and CE^ were elicited. In group C, the 
CE1 2 5, СЕз75, CEJ2J, and CE,7 J were also elicited. The CE 1 I 5 and CEj75 were subsequently 
used to elicit a second CE» (gamble 6, consistency check). Analogously, consistency checks 
Figure 1 
CE 25 
0.5У 
~ < 
о.Л 
/ CE» 
1 month 
CE» 
o.y 
- < 
0.N 
f MLY 
1 month 
CE 75 
°У 
~ < 
0.N 
f MLY 
4
 CE» 
Gamble 1 Gamble 2 Gamble 3 
CE 125 
0.5У 
- < 
oiS 
f CE 25 
1 month 
CE 37.5 
0.5У 
< 
O.N 
f CE» 
4
 CE25 
CE 25 
0.5У 
- < 
оД 
^ CE 115 
4
 CE 37.5 
Gamble 4 Gamble 5 Gamble 6 (consistency check) 
Figure 1. Certainty equivalent method. For further explanation, see text. 
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were constructed for the CE^ and the CE,,, yielding a total of 10 gambles for group C.The 
construction of a utility function is illustrated in figure 2 (2 lines with solid dots, each 
denoting one replication of the CE). If the maximum number of life years in the test was for 
example 25 years, and the CE*, was 9 years, then this implies that 9 life years have a utility 
value of O.S. If the СЕц was 7 years, this implies that the utility of 7 life years is equal to 
0.25. The latter point is indicated in figure 2 by arrows. The other points in the curve are 
found analogously and the utility function is constructed by interpolation. 
Test duration 
The duration of each interview was recorded in group С in order to obtain an impression of 
the time needed to perform the tests. In groups A and B, this was not done, because of the 
classroom setting. 
Statistical analyses 
The three groups were analyzed separately, for obvious reasons: the student groups A and В 
and the group of volunteers С are demographically and educationally quite distinct groups. 
Furthermore, the clinical problems offered to the two student groups were different and 
there were differences in testing schedule between the two groups. 
Test-retest reliability 
Test-retest reliability of the TTO was investigated by performing an analysis of variance for 
each respondent group in order to answer the question whether a difference between 
replications existed. Factors were person-effect, item-effect and time-effect, and the 
dependent variable was utility (UQ¡). 
The root of the mean squared error (root MSE) is an estimate of the standard deviation of 
the responses [15] and gives an impression of the precision of the responses. In order to give 
a more detailed impression of the precision of the TTO, the root MSE's were estimated for 
each item separately by performing separate ANOVA's for each item with factors person-
effect and time-effect and dependent variable utility (UQJ). 
Test-retest reliability of the CE was characterized by the area between the two solid-dotted 
utility curves (5ABC.J, resulting from each replication (see figure 2). 6ABC„, was 
calculated after normalization of the raw CE-scores by dividing them by the MLY of the 
respondent (table 2). This approach was chosen, because the CE-questions cannot be viewed 
independent observations due to chaining of the questions. Because the maximal possible 
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Figure 2 
O-f"21 1 ι 1 1 1 1 
Ο 5 10 15 20 25 
life years 
Figure 2. Utility fonctions resulting from the certainty equivalent method. On the Y-axis, the 
utilities of the gambles are indicated on a scale from 0 to 1. On the X-axis, the 
corresponding certainty equivalents in terms of life years are indicated. For example, in 
both replications, the CE^ (utility 0.25) was 7 years. The solid dots denote the utility 
functions resulting from two replications of the CE. The area between these two lines, 
normalized by the maximum number of life years in the test (MLY) is a measure of test-retest 
reliability (5ABC
rtl). In this figure, the MLY is 25 years. The open dots denote the utility function resulting from the consistency checks, in this figure only drawn for one replication. 
The area between the dashed open-dotted line and the dashed solid-dotted line, which is 
also normalized by the MLY, is a measure of the difference between the consistency checks 
and the original questions (6ABC
coa
). 
area between the curves is normalized to 1, the difference between the two replications can 
be viewed as a relative measurement error. 
Internal consistency 
Internal consistency of the TTO was tested by assessing whether the ratios UQ/UQJ+1 and 
UQ4/UQ3 respectively, derived from the basic questions were the same as the ratios xc/L¡, 
derived from the consistency checks (group C). This was tested by performing an ANOVA 
over both replications with factors person-effect, item-effect, replication-effect and framing-
effect (basic TTO or consistency check) and dependent variable UQ/UQJ.,., and U^/UQJ 
respectively. 
The assumption of constant proportional tradeoff was investigated by estimating the slope of 
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a regression line, fitted through the utilities of one health state Q assessed at four different 
levels of L in the basic TTO-questions (figure 3). The slope was estimated for each 
individual respondent. A three-way ANOVA was performed to test whether the slopes were 
different from zero and whether slopes were different for different health states. Factors 
were person-effect, replication-effect and health state effect and dependent variable was 
slope. 
Internal consistency of the CE was characterized by the area between the utility curves 
(ôABCaJ, resulting from the certainty equivalences and the consistency checks (open dots, 
see figure 2). ÔABC,^ , was calculated after normalization of the raw CE-scores by dividing 
them by each respondent's MLY (table 2). The procedure was repeated for both replications. 
Figure 3 
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Figure 3. Assessment of the property of constant proportional tradeoff. On the Y-axis, the 
utility of health state Qt is indicated on a scale from 0 to 1. On the X-axis, the levels of 
longevity L¡...L4 are indicated. If the property of constant proportional tradeoff holds, the 
utility UQ¡ will be the same for every L¡. Therefore, the slope of a regression line, fitted 
through the four utilities, should be zero if proportionality holds. 
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Results 
Group characteristics 
Characteristics of the groups are listed in table 4. All respondents in the student groups 
completed the full test seríes. In the group of volunteers, three respondents were not able to 
perform the CE because these questions were not meaningful to them. 
number 
completed test 
procedure 
age (range) 
sex 
level of education 
Group A 
14 
14 
26.0 (20 - 34) 
7 female 
7 male 
university level 
Table 4 
Group В 
17 
17 
23.1 (20-30) 
14 female 
3 male 
university level 
Group С 
30 
27 complete 
3 partially (no CE) 
52.6 (42 - 73) 
all female 
0 university level 
11 high level 
7 medium level 
12 low level 
Table 4. Characteristics of the respondents. 
Test duration 
The median time needed for the first interview was 78 minutes (range 30-120) and 45 
minutes (range 20-105) for the second interview (group C). In these durations, the time 
needed to watch the video films is not comprised. 
Test-retest reliability 
The results of the analysis of variance are given in table 5. In group A, no systematic 
difference was found between test replications, while in groups В and С a highly significant 
difference between replications was found. The size and the direction of the differences 
(towards a higher or a lower utility in the later replications) is given in table 6. In groups A 
and В very small differences are found, that are directed towards a higher utility in the 
second replication. In group C, a trend towards a lower utility in the second replication is 
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Table 5 
Source of variance Degrees of Mean squares F-value p-value 
freedom 
GROUP A 
between persons 
between items 
between replications 
error 
13 
15 
1 
418 
0.291 
0.543 
0.006 
0.020 
14.63 
27.27 
0.30 
<0.0001 
<0.0001 
0.59 
total 447 
GROUP В 
between persons 
between items 
between replications 
error 
16 
15 
2 
782 
0.416 
1.421 
0.120 
0.012 
34.69 
118.58 
10.02 
<0.0001 
<0.0001 
<0.0001 
total 815 
GROUP С 
between persons 
between items 
between replications 
error 
total 
29 
15 
1 
914 
959 
0.540 
0.657 
1.029 
0.021 
26.01 
31.65 
49.60 
<0.000l 
< 0.0001 
<0.0001 
Table 5. F-statistics of the analysis of variance, performed to test whether a systematic 
difference between replications existed. 
Table 6 
Group Between which Size of difference p-value 
replications: 
A 1 and 2 0.007 0.59 
В 1 and 2 0.035 0.0002 
1 and 3 0.038 0.0001 
2 and 3 0.003 0.76 
С 1 and 2 -0.065 0.0001 
Table 6. Size of the differences found between replications of the TTO. 
seen. A remarkable phenomenon is seen in group B, who performed 3 replications of the 
TTO: although there is a highly significant difference between replications 1 and 2, and 
between replications 1 and 3, no difference is seen between replications 2 and 3. 
The roots of the mean squared error per group, which are estimates of the degree of 
inaccuracy of one assessment in one individual respondent or of the standard error of 
measurement were 0.141 for group A, 0.109 for group В and 0.144 for group C. The roots 
MSE per item are listed in table 7. 
Test-retest reliability of the CE, estimated as the mean area between the utility curves 
5ABC
rel, was 0.07 (range 0.00 - 0.26) in group A, 0.06 (range 0.00 - 0.20) and 0.04 (range 
0 - 0.14) in group В between replications 1 and 2 and 2 and 3, respectively, and 0.09 (range 
0 - 0.32) in group С 
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Table 7 
GROUP A 
Duration 
1 
2 
3 
4 
GROUP В 
metastasized 
0.096 
0.149 
0.153 
0.193 
mastectomy for 
breast cancer 
0.059 
0.109 
0.073 
0.096 
prophylactic 
mastectomy 
0.084 
0.129 
0.124 
0.124 
follow-up 
0.051 
0.069 
0.043 
0.036 
Duration 
1 
2 
3 
4 
GROUP С 
1 
2 
3 
4 
metastasized 
0.115 
0.086 
0.087 
0.113 
0.150 
0.204 
0.162 
0.200 
local recurrence 
0.093 
0.079 
0.061 
0.052 
0.072 
0.125 
0.113 
0.099 
mastectomy 
0.062 
0.064 
0.056 
0.054 
0.068 
0.125 
0.137 
0.110 
breast 
conserving 
therapy 
0.076 
0.076 
0.031 
0.038 
0.061 
0.119 
0.125 
0.118 
Table 7. Root MSE's of the TTO. 
Internal consistency 
The results of the ANOVA, testing whether differently framed questions induce different 
utilities, are given in table 8. A highly significant difference attributed to the differently 
framed questions was found. In the consistency checks the ratio χ,,/L, was lower than 
UQ/U^+I, i.e. the number x
ci of life years in health state QJ+1 that is judged to be equal to L, 
years in health state Q, was relatively low. These data are only available for group С 
Table 8 
Source of variance 
between persons 
between items 
between replications 
between types of 
questions 
error 
missing observations 
Degrees of 
freedom 
29 
15 
1 
1 
1865 
1911 
8 
Mean squares 
0.224 
1.587 
0.126 
0.540 
0.033 
F-value p-value 
6.75 
47.79 
3.80 
<0.0001 
<0.0001 
0.0515 
16.26 <0.0001 
total 1919 
Table 8. F-statistics of the analysis of variance, performed to test whether differently framed 
questions influenced the assessed utilities. In this analysis, 8 observations were missing. 
The results of the ANOVA testing the property of constant proportional tradeoff are given in 
table 9. No evidence of systematic violations of constant proportional tradeoff in the TTO 
were found. 
The area between the utility curves 5ABCC0O was 0.02 (range 0-0.05) in the first replication 
and 0.02 (range 0-0.05) in in the second replication. These data are only available for group 
С 
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Table 9 
Source of variance Degrees of 
freedom 
Mean squares F-value p-value 
GROUP A 
between persons 
between replications 
between health states 
error 
13 
1 
3 
94 
0.00004 
0.0000009 
0.000003 
0.000005 
7.48 
0.17 
0.62 
< 0.0001 
0.68 
0.60 
total 111 
GROUP В 
between persons 
between replications 
between health states 
error 
16 
2 
3 
182 
0.00001 
0.00002 
0.000004 
0.000004 
3.40 
6.18 
1.15 
<0.0001 
0.003 
0.33 
total 203 
GROUP С 
between persons 
between replications 
between health states 
error 
total 
29 
1 
3 
206 
239 
0.0004 
0.0002 
0.00007 
0.00005 
7.45 
3.91 
1.36 
<0.0001 
0.05 
0.26 
Table 9. F-statistics of the analysis of variance, performed to test whether systematic 
violations of proportionality existed. 
Discussion 
Test-retest reliability 
In the TTO, systematic differences attributed to the date of testing were found in groups В 
and С (table 5). In group B, however, the difference was only found between replications 1 
and 2 and 1 and 3, not between replications 2 and 3, suggesting a stabilization of utilities 
after the second replication. Although the student groups were smaller than the group of 
volunteers so that statistical significance of differences will less easily be reached, the 
estimated difference between replications was about a factor 20 smaller in the student groups 
than in the group of volunteers. This finding suggests that utilities were stabler in the student 
groups than in the group of volunteers. As is indicated in table 4, the education level of the 
volunteers was considerably lower in group С than in the student groups, which might be a 
possible explanation for our finding. 
An additional explanation is that the students were more familiar with health care problems, 
and therefore produced more reliable answers. If respondents are not familiar with the type 
of decision considered, low reliability will often occur, since in such a case utilities are 
constructed rather than elicited during the assessment procedure [16]. In such a constructive 
process, the respondent reflects on the decision problem between replications and changes 
his/her answers in the second replication. Once a stable opinion has been formed, this is 
reflected in stabilization of the utilities. The findings in group В confirm this hypothesis, as 
the utilities did not change after the second replication. 
Torrance [4] also found a significant difference between two replications of the TTO, but in 
this study the time between test and retest was one year, while in our study this time varied 
from 4 to 20 days. The overall standard error of measurement varied from 0.102 in a group 
of college alumni to 0.139 in the general public; these are comparable to our overall 
standard errors (from 0.109 in student group В to 0.144 in the group of volunteers). The 
precision of the TTO is, however, low for use in individual decisions, since very small 
differences in utilities can change the treatment preference when the utilities are used in a 
decision model (chapters 6 and 7). 
The roots MSE per item were fluctuating, and tended to be higher in the group of volunteers 
and in the health state "metastasized breast cancer". Since the volunteers were not familiar 
with health care problems and were less educated, it is not surprising that in this group 
greater variability of responses was seen. The health state "metastasized breast cancer" is a 
very complex health state, that can manifest itself in various ways; it depends strongly on 
the respondents how the health state is perceived. Hence, it is not surprising that the 
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variability in preferences is relatively large. 
The variability in utility of healthy life years, expressed as the area between the utility 
curves, ranged from 0.04 (group B) up to 0.09 (group C) on a scale from 0 to 1, between 
two replications. These values can be viewed as a relative measurement error. We do not 
know of similar research with which we can compare our findings. Some authors report a 
reliability coefficient but, because of the study design, the responses cannot be viewed as 
independent observations, and therefore the computation of a reliability coefficient is not 
possible. 
Internal consistency 
In the TTO, internal consistency in the sense of the validity of the proportionality of the 
time tradeoff was not violated. Internal consistency in the sense of robustness of utilities 
across differently framed questions was only tested in group C. We found that internal 
consistency was violated: in the consistency checks, the number of life years x„ in health 
state QJ+1 that matched L¡ years in health state Qj was relatively low. This indicates a failure 
of the respondents to adjust the number of life years x„ for the fact that health state QJ+1 was 
no longer complete health, but some other, less desirable health state. If in a previous 
question complete health was compared to for example 10 years after mastectomy, and in a 
consistency check life after breast conserving therapy was compared to 10 years after 
mastectomy, the women tended to give a relatively low number of life years in the 
consistency check. That this is clearly undesirable can be illustrated with the following 
example: Whether the height of a mountain is expressed in centimeters or in meters should 
not influence the measurement result. 
Three possible explanations for this observation come into mind: 1. a method-order effect, 
2. anchoring and adjustment [9], and 3. salience of attributes [17]. A method-order effect 
could be responsible for the tendency to give a relatively low number of life years; to be 
consistent, the number in the consistency check should be higher than the number in the 
corresponding basic question. Since the basic questions always preceded the consistency 
check, the women may have given approximately the same number of life years in the 
consistency check as in the (preceding) TTO-question. Closely related to this hypothesis is 
anchoring and adjustment. Possibly, the answer to the preceding basic TTO-question could 
serves as an anchor in the consistency check, that is adjusted in order to account for the new 
element in the consistency check. The administration of the questions in a random sequence 
would have been better in order to prevent such an effect. The basic TTO-questions, 
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however, did not immediately precede the corresponding consistency checks. In the 
interviews, all original TTO-questions were posed first, and followed by all consistency 
checks, in an order that was the same for all respondents. Thus, some time passed in which 
16 other questions were posed before a TTO-question was followed by its corresponding 
consistency check. This makes both a method order effect and anchoring and adjustment less 
plausible explanations for the demonstrated inconsistencies, although they cannot be ruled 
out completely. 
The third possible explanation, salience, means that the attribute with which is traded off 
gains more attention from the respondent than the other attribute. This might explain why 
respondents seemed to neglect the fact that in the consistency check two non-optimal health 
states were compared. Salience could be avoided by using paired comparisons rather than 
matching questions [18]. Neither of the two attributes are then emphasized a priori. 
Internal consistency of the certainty equivalent method was satisfactory. Llewellyn-Thomas 
et al., however, demonstrated considerable internal inconsistency in the standard gamble [8]. 
However, in the latter study, no certainty equivalents were elicited, but probability 
equivalents, i.e. the certainty equivalent is held fixed and the probabilities are varied until 
the respondent is indifferent between the alternatives. The respondent's task in the certainty 
equivalent method is easier, since only equiprobability gambles are involved, which might 
explain the relatively consistent responses in our study. Distortion of probabilities, an 
important source of bias in standard gambles, will therefore play a less important role [10]. 
Concluding remarks 
The findings in our study pose serious questions on the application of the TTO in utility 
assessment. Systematic differences between test replications were found. The finding that no 
difference existed between replications 2 and 3 in group B, suggests that the assessment 
procedure initiates the construction of utilities, which do not change after the second 
replication. If this would also be true for less educated respondents, the administration of at 
least two test replications might solve this problem: a first one to initiate the construction of 
utilities, and a subsequent replication to assess useful utilities. 
A second point is the imprecision of the utilities assessed by the TTO. A measurement error 
of 10-15% will not always be problematic in clinical decision analysis, if a sensitivity 
analysis shows that the decision does not change with such a variability in utilities. In a 
decision analysis performed by us, however, changes in utilities as small as 2% might 
already cause a switch from one treatment to another (chapter 6). Precision could be 
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improved by performing three replications and using the utility found by averaging the last 
two values, but such a procedure would be quite inconvenient. 
The internal inconsistency found in the TTO is also problematic: apparently, utilities change 
if questions are framed differently. Do such utilities reallf reflect underlying values or are 
we confronted with numbers generated by a test procedure that reflect skill compatibility 
rather than true value judgments? 
Test-retest reliability and internal consistency of the CE was judged to be satisfactory in our 
study. This indicates that the CE is useful method to elicit utilities for life years. 
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Abstract 
In clinical decision analyses, utilities are used as a measure of subjective desirability of 
outcomes. Most wellknown utility assessment methods have shown to induce biases and to 
rest on unjustified basic assumptions. Therefore, we studied the realibility and internal 
consistency of additive conjoint measurement (ACM). The method of paired comparisons 
was used to simultaneously measure utilities and to test the underlying assumptions. The 
clinical problems addressed were 1. the choice between breast conserving therapy and 
mastectomy and 2. the decision whether or not to perform prophylactic mastectomy in 
women who are descendants from a family in which hereditary breast cancer is segregating. 
ACM was applied in three groups of volunteers: two groups of students in health science 
(n=14 and n=17, respectively) and a group of healthy volunteers (n=30). The respondents 
performed three replications of ACM. In about 45% of respondents in all three groups 
violations of internal consistency, particularly of independence in the health state 
"metastasized breast cancer" were seen. Reliability was sufficient in all but one respondent 
in additive conjoint measurement. The observed pattern of violations of independence 
supports the concept of "maximal endurable time*, that is, more than a certain amount of 
time in the health state "metastasized breast cancer" is undesirable. We conclude that 
applicability of utility assessment is seriously hampered by the demonstrated violations of 
independence, especially in health states with a considerable degree of disability. 
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Introduction 
Subjective desirability of outcomes is an important factor in choosing between treatment 
options in medicine. Therefore, in clinical decision analysis, efforts have been made to 
represent subjective desirability in a valid way. Our research has been focused on the 
development of a utility assessment procedure for normative, individual decision making. 
That is, the intentional use of utility assessment is to decide which treatment alternative is 
best for one particular patient, given his or her subjective preferences for the possible 
outcomes of the alternative treatments. 
The most wellknown methods for this purpose are the standard gamble (SG) [1] and the time 
tradeoff-test (TTO) [2, 3, 4]. Both methods, however, have shown to suffer from serious 
drawbacks [5, 6]. Both TTO and SG have shown violations of utility independence [6,7], 
one of the basic assumptions in utility assessment. Furthermore, a number of biases is 
provoked by gamble-based measurement methods [8]. The TTO might further induce 
overvaluation of life-expectancy due to saliency of the attribute with which the tradeoff is 
made [9]. 
Therefore, part of our research has been focused on a relatively unknown utility assessment 
method, additive conjoint measurement (ACM). If ACM is applied using the method of 
paired comparisons instead of indifference questions, it is possible to assess utilities and to 
test the validity of the underlying assumptions at the individual level simultaneously. In an 
indifference question, one attribute is varied until the respondent is indifferent between two 
alternatives. In paired comparisons, the respondents is asked to choose between two 
alternatives, thereby preventing induced saliency of attributes. 
The three tests here considered (SG, TTO, and ACM) were offered to two groups of 
students in order to uncover possible shortcomings of the test procedure and subsequently to 
a group of healthy female volunteers of the age groups in which breast cancer is usually 
encountered. The latter group was selected because we intended to investigate whether 
women without any special education in health care were able to perform these tests. It was 
felt that a sample of women from the general population most closely resembled the eventual 
target group, namely women without any special education in health care who faced a breast 
cancer treatment choice. We chose not to perform the study in women who were already 
treated for breast cancer for two reasons: 1. many of these women were not offered a choice 
in the past and it might be distressing to be confronted later with a second treatment option; 
2. the past experience might bias the women towards the test procedure. 
The here-reported study is part of a larger study conducted to test the feasibility, reliability 
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and internal consistency of utility assessment methods. In this paper, our results with respect 
to the reliability and internal consistency of additive conjoint measurement in the above 
mentioned three groups of respondents. The purpose of the study was twofold: 1. to 
investigate the feasibility of ACM in different respondent groups and 2. to investigate 
whether violations of basic assumptions were encountered and if so, whether a systematic 
pattern was present in these violations. 
Methods 
General study design 
Three groups of respondents participated in the study: two groups of students in health, 
science (groups A and B), who performed the test procedure in a class-room setting and a 
group of healthy volunteers from the general population (group C) who were interviewed by 
the first author. Two clinical problems were addressed: the first problem, the management 
of hereditary breast cancer, was propounded to group A. The second problem, the 
management of early breast cancer, was propounded to groups В and C. The respondents 
performed two (groups A and C) or three (group B) replications of the certainty equivalent 
method (CE) and the time tradeoff test (TTC·), and three replications of additive conjoint 
measurement (ACM) with short time intervals. After completion of three replications of the 
ACM, the results of the tests were analyzed and in a subsequent session a preference ranking 
was obtained of alternatives involved in circularities (see section additive conjoint 
measurement)(Chapter 3, table 1). The results of the TTO and the CE are not elaborated on 
here, but have been reported separately [6]. A more extensive description of the respondent 
groups, the testing schedule and the clinical problems can be found in chapter 3, section 
Methods. 
Test methods 
Both problems were defined as a tradeoff between quality of life Q and longevity L. For 
each problem, four levels of Q were defined (see section 'clinical problems'). Levels of L 
were dependent on the age of the respondent (Chapter 3, table 2). The maximum number of 
life years in the test was based on the current age-specific life-expectancy of the Dutch 
female population (five-year strata) [13]. 
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Time trade-off test 
The first replication of the TTO was used as an indicator of how many life years the 
respondent was willing to tradeoff and this information was used to develop an individual 
variant of the ACM-test for each respondent (see also section 'Additive conjoint 
measurement). 
In the TTO, the respondent is asked how many life years (s)he is willing to give up in order 
to live in a state of complete health. An example of an item is: 
(x) years in complete health is equal to L years after mastectomy for breast cancer. 
Additive conjoint measurement 
In ACM, the utility of a particular combination (q, n) of quality of life (q) and a number of 
life years (n) is found by addition. Thus, in the model of ACM the utility of such a 
combination U(q, n) is taken as the sum of the utilities of the embedded elements, namely, 
U(q) and U(n), respectively. In the present study, four levels of quality of life q were 
defined: preserved breast (B), mastectomy (M), salvage mastectomy (S) and metastasized 
breast cancer (M). Several numbers of life years (n) were combined with these levels of 
quality of life. For instance, U(B, 18) = U(B) + U(18), i.e. the utility of (B, 18) is taken 
as the sum of the utilities of quality q and number of life years 18. For this approach to be 
valid, the following assumptions should be satisfied: 
1. Preferences must be transitive. That is, if you prefer В to M and M to S, then this 
implies that you also prefer В to S. If the implication does not hold, i.e. S is preferred to B, 
then the preferences show circularity. 
2. Preferences must satisfy double cancellation. Double cancellation can be viewed as 
transitivity of preference differences. If combinations of quality of life and longevity are 
denoted by (quality of life, longevity), and the following preference relations are observed: 
U(B, 4) > U(M,2) 
U(M,8) > U(S,4) 
then this implies by cancellation that (B,8) is preferred to (S,2), if the additive model is 
valid. To be sure, following the additive model and adding the just given inequalities, we 
have U(B) + U(4) + U(M) + U(8) > U(M) + U(2) + U(S) + U(4). After cancellation 
the inequality U(B) -I- U(8) > U(2) + U(S) remains and thereby the preference of (B, 8) to 
(S, 2). The cancellation axiom implies independence for all levels of longevity and quality 
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of life. Suppose the following preferences: 
U(M, 6) >. U(M, 2) 
U(BCT, 4) = U(BCT, 4) 
+ 
U(6) +U(M) + U(4) + U(BCT) >_ U(2) + U(M) +U(4) + U(BCT) 
By cancellation we find that U(6) + U(BCT) >. U(2) + U(BCT). Independence means 
that the preference ordering of levels within one attribute should not depend on the given 
attribute. For instance, if 6 years is preferred to 2 years, given that these years are spent in 
heath state BCT, then this preference ordering should not change if both durations would be 
spent in health state M. 
3. A third assumption is solvability, an untestable assumption which requires all attributes 
(in our example quality of life and longevity) to be sufficiently dense to find numerical 
values for the levels of the attributes. 
If these assumptions are satisfied, then an additive solution exists. This solution is such, that 
the utility U(q, n) of the combination of attribute levels, is equal to the sum of the utilities 
of the attribute levels U(q) and U(n), and shows the same order as the preferences over the 
combinations (q, n) [14]. 
Before the start of the actual test, the order of preference of the levels within each attribute 
was verified. For example, some women a priori prefer mastectomy to breast conserving 
therapy, because they do not want to undergo irradiation, or because they despise the breast 
that threatens them with a dangerous disease. Then the tradeoff is reversed. The assumptions 
are tested by using the method of paired comparisons. An example is: 
What do you prefer? 
A. 20 years without breast after mastectomy for breast cancer 
or 
B. 18 years with breast after breast conserving therapy for breast cancer 
By varying the levels of L and Q we can present more paired comparisons and test the 
assumptions. The number of paired comparisons follows from the number of levels in each 
attribute. In the present investigation, 4 levels of Q and 6 levels of L were valued , thus 4 
χ 6 = 24 combinations are possible, and I 1 = 276 different paired comparisons. Of 
these, 186 are trivial in the sense that they do not yield new information, such as, for 
instance: 
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12 years with breast 
or 
8 years without breast 
In this comparison, both the longer life-expectancy and the better life quality are combined 
in one alternative, so that it does not represent a choice problem. Ninety non-trivial 
comparisons are left, for example: 
12 years without breast 
or 
10 years with breast 
For answering this question, a tradeoff must be made between quality and quantity of life. 
In order to keep the number of comparisons reasonably low (according to our experience 
this number should not exceed 100), at 4 levels of Q, the maximum number of levels of L is 
6. Because the highest level of L varied between 10 and 60 years, an equal spacing of the 
levels of L would make small tradeoffs impossible for the younger respondents. If life-
expectancy is 60 years, the levels of L would be: 10, 20, 30, 40, 50, 60 years. Therefore, 
we used the TTO as an indicator of the willingness to tradeoff life-expectancy. The heuristic 
used to decide which step size was appropriate was as follows: the nearest higher integer of 
СГТО
шх
/А) + 1, in which TTO,^,; is the maximum number of life years traded off in the 
TTO. For example, if a respondent with a life-expectancy of 60 years states that she will 
tradeoff 8 years in order to preserve her breast, the step size was 8/4 + 1 = 3 . The levels of 
longevity were then spaced as 2, 48, 51, 54, 57 and 60 years. The level of 2 years was 
added as a zero-value for longevity. Consequently, every respondent performed an 
individual variant of the ACM-test, which was replicated three times. After three test 
replications, results were analyzed, and if circularities were observed, the alternatives 
involved in circularities were put in order of preference ("solving intransitivities", chapter 3, 
table 1). 
Test duration 
The duration of each interview was recorded in group С in order to obtain an impression of 
the time necessary to perform the tests. In groups A and B, this was not possible, because of 
the classroom setting. 
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Analyses 
Additive conjoint measurement 
If a respondent has answered all comparisons without violating the axioms, a preference 
matrix of the alternatives is obtained. The algorithm ORDMET [15] derives Í2 4] = 276 
linear inequalities from the preference matrix and solves the system of inequalities in such a 
way that the preference ranking is kept intact. 
Reliability 
Reliability was expressed as the proportion of paired comparisons, to which the same answer 
was given in all three replications. If the answers to the paired comparisons were given 
randomly, the proportion agreement over three replications would be 0.25. Arbitrarily, we 
chose to accept the responses as sufficiently reliable, if the proportion agreement would be 
better than random to the extent of three standard deviations. For a test with 90 comparisons 
and 3 replications this is 0.25+3* 
of 0.39 or more. 
' [16], which is equal to a proportion agreement 
> 90 
Internal consistency 
Internal consistency refers to the extent to which responses are consistent with previously 
formulated assumptions or axioms. Internal consistency of ACM was assessed by testing the 
assumptions transitivity, independence and cancellation. Transitivity was tested by computing 
a measure of circularity, ζ
α
 . This measure reflects the percentage of circular triads of the 
maximum number of possible circular triads [9, 17, 18]. We have arbitrarily chosen to 
accept intransitivities if they involve 5 % or less of all possible circular triads. Respondents 
with minor violations of transitivity ( ζ
α
 >_ 0.95) put the alternatives, involved in 
circularities, in order of preference (transitivity imposed for the alternatives involved in 
circularities, C„ =1). Although no measure of dependence or double cancellation exists, 
violations of these assumptions will result in rejection of the additive model as a good 
representation of the data; independence can easily be seen at inspection of the preference 
ranking. If this was the case, the meaning of a violation of independence was explained to 
the respondent and he/she was asked whether these preferences were his/her true 
preferences. 
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Results 
Group characteristics 
Characteristics of the groups are listed in chapter 3, table 4. All respondents in the student 
groups completed the full test series. In the group of volunteers, 3 respondendents were not 
able to complete the CE, but all repondents completed the TTO and ACM. 
Test duration 
The median time needed to perform the test was 40 minutes (range 10-60) for the first 
replication, 25 minutes (range 10-50) for the second replication, and 20 minutes (range 10-
45) for the third replication of ACM. These data are only available for group С 
Reliability 
Proportion agreement in the ACM was 0.90 (SD 0.08) in group A, 0.87 (SD 0.09) in group 
В and 0.81 (SD 0.11) in group С The value 0.27, found in one respondent, indicated that 
her reliability was not better than random; after exclusion of this respondent, proportion 
agreement ranged from 0.61-1 in group C. 
Internal consistency 
Internal consistency of the ACM is summarized in table 1. It is possible to violate more than 
one assumption at the same time, but it is not possible to distinguish between different 
violations from the preference ranking. Violations of independence will result in apparent 
circularities. Therefore, we applied a 'hierarchy' of violations for this analysis. First, the 
respondents who showed insufficient reliability or transivity were discarded from further 
analysis. Some of the remaining respondents showed violations of independence, and these 
were discarded subsequently. In all other respondents for whom no additive solution was 
found, this was attributed to violations of cancellation. 
All but two non-additive respondents who violated independence, violated this assumption in 
the tradeoffs involving the health state "metastasized breast cancer" , i.e. the respondent 
preferred a short time in this health state to a long time. However, a very short time in the 
health state "metastasized breast cancer" was usually not preferred to a short time. An 
example of such a preference ranking is shown in table 2. This pattern of preferences is 
consistent with the concept of "maximal endurable time " (MET) as described by Sutherland 
et al. [19], which means that additional time in a certain health state, exceeding the MET, 
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Table 1 
insufficient reliability (proportion 
agreement < 0.39) 
insufficient transitivity ( ζ
Λ
 <0.95) 
violations of independence 
violations of cancellation 
no violations after 3 replications 
group A 
0 
1 
4 
1 
4 
group В 
0 
0 
2 
5 
4 
group С 
1 
1 
9 
3 
8 
no violations after solving 
intransitivitics 
total 14 17 30 
Table 1. Violations of assumptions in the ACM. Numbers denote numbers of respondents. 
is considered less preferable than death. This pattern of preference does not fit in an additive 
utility model. 
Violations of double cancellation, i.e. the degree of preference between alternatives is not 
consistent, have also been encountered frequently. In toto, the numbers of respondents that 
showed an acceptable fit into the additive model were 8 of 14 (57 %) in group A, 10 of 17 
(59 %) in group B, and 16 of 30 (53 %) in group С 
Discussion 
Reliability 
Although the threshold for acceptable reliability was set at a proportion agreement of 0.39 or 
higher, the lowest value found was 0.61, with one exception in group С Thus, variability of 
preferences was not a significant problem in our study, although some respondents seemed 
to vary somewhat in their preferences. 
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Table 2 
1 
3 
б 
9 
12 
15 
Metastazised 
breast cancer 
0 
4 
8 
7 
6 
5 
Salvage 
mastectomy 
1 
9 
12 
15 
16 
17 
Mastectomy 
2 
10 
13 
18 
20 
22 
Preserved breast 
3 
11 
14 
19 
21 
23 
Table 2. Example of preference ranking showing the pattern of 'maximal endurable time'. 
Every number denotes a combination of a certain number of life years (rows) and a certain 
level of quality of life (columns). Increasing numbers denote increasing desirability of the 
combination. No additive solution exists for such a preference structure. 
Internal consistency 
Transitivity was sufficient in the ACM, according to our preset criterium of ζ
α
 >. 0.95; 
only two respondents showed a relatively low degree of transitivity. In all three groups, 
about 55 % of respondents showed acceptable internal consistency. Thus, a large minority 
violated the assumptions of ACM, of which violations of independence were predominant. 
Respondents insisted on these preferences when asked whether these were their true 
preferences. Their motivation was, although not registered systematically, quite uniform, as 
far as the health state 'metastasized breast cancer' was concerned: the respondents expected 
not to be able to endure the health state 'metastasized breast cancer' any longer than a 
limited time period. As we have already mentioned in the results section, these preferences 
follow the concept of maximal endurable time (MET)[19]. As is illustrated in figure 1, this 
pattern could be described by a single-peaked utility function for duration in mediocre health 
(dashed line) and strictly increasing preference over duration in relatively good health (upper 
solid line). This poses a difficult problem, since it means, that all utility models that require 
utility independence cannot model this pattern of preference. We might consider a 
multiplicative model, which allows two kinds of health states, namely, states in which a 
longer duration of life is preferred to a shorter one, and states in which a shorter life 
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duration is preferred to a longer one [20]. For a multiplicative utility model to apply, death 
should be preferred to any amount of time, however short, in the health state that is worse 
than death. The lower solid line in figure 1 illustrates a utility function of a health state 
worse than death that does not violate utility independence. In the concept of MET, 
however, a short time in health state χ is better than immediate death, but once the time in 
health state χ is exceeding a certain survival time, a shorter time is preferred to a longer 
time. This implies, that a multiplicative model cannot model the pattern of preferences that 
we found and that follows the concept of MET. 
The additive model showed quite a few violations of cancellation, although they were less 
often seen than violations of independence. The meaning of violations of cancellation is 
intuitively more difficult to understand than the meaning of independence. Roughly 
speaking, one could say that the difference in utility between two alternatives is dependent 
on the context, but varies in different comparisons. 
Figure 1 
life years 
Figure 1. Single peaked preferences. Addition of the upper solid line, denoting a utility 
function of a relatively good health state and the lower solid line, denoting a utility function 
of a relatively bad health state, yields a single peaked preference function (dashed line). For 
farther explanation, see text. 
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Conclusions and future research 
The findings of this study have important repercussions for utility assessment in general. 
Underlying assumptions of utility asessment are not routinely tested in applications for the 
purpose of medical decision analysis, but taken for granted, for example in the use of 
QALYs as an outcome measure. The justification of these assumptions is questionable, 
especially in the assessment of relatively bad outcomes. Therefore, results of such analyses 
involving utilities of health states with a considerable degree of dysfunction should be 
regarded with caution. Our results with ACM indicate, that independence in such health 
states is often violated. This finding justifies additional research, directed towards the 
development of a utility model that incorporates the concept of "maximal endurable time". 
In our institute, research has been initiated to investigate two possible modeling options for 
the concept of MET. The first approach is to split the bad health state into at least two 
dimensions, such, that the good dimension is always better than death, and the bad 
dimension is always worse than death. Subsequent combination of these two dimensions 
yields a single-peaked utility function for mediocre health. In figure 1, this concept is 
illustrated: Addition of the upper solid line, denoting a utility function for the good 
dimension, and the lower solid line, denoting a utility function for the bad dimension, yields 
the single-peaked function denoted by the dashed line [21]. Another possible approach is to 
split the health state into, for example, two periods with different levels of health. A 
convenient approach to the health state 'metastasized breast cancer' could be to split it into 
an initial time period with metastases, in which daily activities are not yet restricted and pain 
and discomfort are not very prominent, and a subsequent time period with more extensive 
dissemination of disease, with severe complaints and restriction of daily activities. Both 
approaches imply, that more (dimensions of) health states must be valued, and thus that the 
number of paired comparisons will increase. Therefore, possibilities to decrease the number 
of comparisons, for example by presenting quadruple comparisons instead of paired are an 
important issue for further study. 
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support for prospect theory 
Lia CG. Verhoef 
Anton F.J. de Haan 
Willem A.J. van Daal 
Med Decis Making 1994;14:194-200 

Abstract 
According to prospect theory, risk attitude changes depending on whether a prospect is 
perceived as a gain or a loss relative to a reference or aspiration level. In order to 
investigate risk attitude with respect to years of life, we elicited utilities at two occasions 
by the certainty equivalent method in 30 women from the general population. The 
respondents gave certainty equivalents to gambles with years of life. The gambles were 
two-outcome gambles with equal probabilities to experience each outcome. A shift from a 
risk-seeking towards a risk-averse attitude was observed with increasing expected value of 
the gambles. For each individual, the averaged responses over two replications were fitted 
with an s-shaped logistic curve which showed an excellent fit (r2 >. 0.97) in all respon­
dents). The aspiration level (AL) of survival can be derived from this function and was 
negatively correlated with age (r= -0.43, ρ <0.025). Our data are consistent with 
prospect theory and may explain why patients opt for risky treatments, since most respon­
dents are risk-seeking in the short term. 
Acknowledgements 
We are indebted to W.Brouwer M.Sc, for his help with the mathematical derivations and 
91 
Introduction 
Risk attitude is an important parameter in measuring patient preferences. In many 
proposed models of risky utility, a risk parameter is used to describe a subjects' risk 
attitude, that is, a subject is assumed to be either risk-averse or risk-seeking, in a 
continuous degree (see for example Miyamoto & Erakerfl]). 
However, according to Tversky & Kahneman[2], risk attitude is more complex than the 
original concept of von Neumann and Morgenstern: relative to an individual reference 
point, outcomes are viewed as gains or losses, and risk attitude varies depending on 
whether the outcome is a gain or a loss. Typically, relative losses induce risk-seeking, and 
relative gains risk-averse choices. The corresponding utility function is an s-shaped 
curve[2]. In monetary decisions, the status quo often determines the reference point, 
which may further be adjusted by expectations and social comparisons. With respect to 
years of life it seems intuitively unlikely that the reference point is determined by the 
status quo. Kahneman and Tversky state in their paper [2]: "... there are situations in 
which gains and losses are coded relative to an expectation or aspiration level that differs 
from the status quo." It is appealing to assume that expectations with regard to life-
expectancy determine the labeling of a given number of expected life years as a gain or as 
a loss. Miyamoto tried to ask respondents directly about their "aspiration level of survi­
val "[3]; he reports that most subjects found these questions meaningful. The idea of a 
reference point with respect to years of life, separating the perceived relative gains and 
losses thus seems plausible. 
Prospect theory predicts that observed risk-attitude with respect to years of life will 
depend on the number of years that can be gained by accepting a gamble: the certainty 
equivalent that matches a gamble (m, p, n) (a probability ρ to obtain outcome m and a 
probability (1-p) to obtain outcome n), in which both m and η are lower than the 
reference level or aspiration level of survival will be relatively higher than the certainty 
equivalent that matches a gamble in which both m and η are higher than this reference 
level. When a series of gambles of the form (m, p, n) is evaluated, in which m and η 
represent progressively higher numbers of years of life, it is expected that the correspon­
ding certainty equivalents reveal a shift from a risk-seeking towards a risk-averse attitude. 
An experiment was carried out to test whether the pattern of choice, expected on the basis 
of prospect theory, was present in gambles with years of life. 
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Subjects and methods 
Respondents 
The respondents were women who had responded after a call for volunteers in a local 
newspaper (n=30). They were all aged 40 or older and had no history of psychiatric 
illness or breast cancer. They also performed other utility tests at the occasion, concerning 
their attitudes about breast cancer treatment, but here we will report about the results of 
the certainty equivalence method only. The women were interviewed individually. 
Figure 1 
Gamble 1 Gamble 2 
CE 75 
o.y 
- < 
0.N 
f MLY 
4
 CE» 
Gamble 3 
CE 12.5 _ 
Gamble 4 
CE 25 
1 month 
CE 37.5 ~ 
Gamble 5 
CE so 
CE 25 
CE 25 
o.y 
~ < 
ο.Λ 
f CE 12.5 
4
 CE 37.5 
Gamble 6 (cross checking) 
Figure 1. Certainty equivalent method. The answer to the first gamble, the CEX is med to 
construct a second indifference, gamble 2. In this way, the CE,iS, CEU, CE17S, CEX, 
СЕ
а
„ CE7S and CEIZS are elicited (7 gambles). The CE1Z) and CEJZ} are used to elicit 
the CEV a second time (gamble 6, cross checking). Analogously, cross checkings were 
constructed for the CE^ and the CE„, yielding a total of 10 gambles. 
Test method 
The respondents were asked to produce certainty equivalents for 10 gambles, which were 
repeated at two different occasions, with a median interval of 18 days. The maximum 
number of life years (MLY) in the gambles was variable, depending on the age of the 
93 
respondent. The MLY corresponded to the statistical life-expectancy of the respondents 
(five-year strata) [4]. For example, a subject at age 45 was offered gambles with a MLY 
of 35 years and a subject at age 63 was offered gambles with a MLY of 20 years. The 
construction of the gambles is graphically displayed in figure 1. The gambles were 
administered to the respondents in the form of paired comparisons of the following form 
(gamble 1, figure 1, MLY=25 years): 
The respondent was shown a sheet of paper with the following text: 
A: 50 % chance to die within one month 
50 % chance to live 25 years in complete health 
or 
B: healthy years for sure 
The questions were posed as follows: 
Suppose you would have to choose between alternatives, A and B. A is is an 
uncertain option. If you choose A, you have a chance of 1 in 2 to die within one 
month, and a chance of 1 in 2 to live 25 years in complete health. It is not 
possible to choose for the 25 years of survival for sure. If you pick A, it is like a 
lottery: you may live 25 years, but you may also die within one month, but you do 
not know beforehand which of the two possibilities will come true. Therefore, you 
might prefer to choose B. If you pick B, you are sure to live 20 years in complete 
health, no more and no less. Thus, the question is: Do you prefer A, which means 
that you might live 25 years in complete health, but which also carries the risk to 
die within one month, or do you prefer B, which means that you will live 20 years 
in complete health for sure? 
If the respondent stated that she preferred B, the question was repeated, but now with a 
very low certainty equivalent, for example 5 healthy years. (If she preferred A, the 
question was repeated with a very high certainty equivalent, for example 23 years.) If the 
respondent now stated that she preferred A, the question was repeated with an intermedia­
te certainty equivalent, for example 15 years. This bracketing procedure was repeated 
until the respondent was indifferent between A and В and the certainty equivalent was 
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found. 
According to expected utility theory, the expected utility (EU) of a gamble (m, p, n), is 
computed as follows: 
EU = p*u(m) + (l-p)*u(n) 
in which u(m) and u(n) denote the utility of m and η years of life, respectively. If the 
MLY is assigned an arbitrary utility value of 1, and dying within 1 month a value of 0, 
then the certainty equivalent to the gamble (1 month, 0.5, MLY) is worth 0.5*0 + 0.5*1 
= 0.5 utility units or 50% of the maximal utility. Therefore, it is referred to as the CEj,, 
in figure 1. Along the same way of reasoning, it follows that a gamble (1 month, 0.5, 
CEJO) is worth 0.5*0.5 + 0.5*0 = 0.25 utility units or 25% of the maximal utility, thus 
yielding the CEy. In the same way, the utilities of the CE 1 2 }, СЕз7 5, CE^, CEj2 5, СЕи 
and CEg7 j can be found. 
Analyses 
Since the stimulus gambles were different for each respondent, the raw certainty equiva­
lent does not give information about the risk attitude of a respondent. The calculation of a 
corresponding proportional match (PM) for each certainty equivalent solves this problem 
[3]. The PM for any specific gamble is the certainty equivalent for that gamble normali­
zed to the high and low values used in that gamble. It is computed as follows: 
pM_ CE-LOW 
HIGH-LOW {1} 
in which CE denotes the raw certainty equivalent, HIGH the higher duration and LOW 
the lower duration offered in a gamble (m, 0.5, n), in which m and η denote outcomes in 
terms of years of life that may occur with a probability 0.5. This procedure results in the 
conversion of a CE12,5 into a corresponding PM 1 2 5 , of a CEy into a corresponding РМ И 
etc. For example, if the certainty equivalent to a gamble (3, 0.5, 15) is 10 years, the PM 
is (10-3)/(15-3) = 7/12 = 0.58. 
In order to investigate test-retest reliability, the PM's for each utility (i.e. the PM I 2 > j's, the 
PMu's etc.) were separately averaged over the respondents and a linear regression 
procedure was performed in order to compute a product moment correlation coefficient. 
The PM can be used as an indicator of risk attitude. If the certainty equivalent is equal to 
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the expected value of the gamble, in this example 0.5*3 + 0.5*15 = 9 years, the subject 
is risk neutral, i.e. he is indifferent between playing a (risky) gamble and receiving its 
expected value with certainty. In such a case, the proportional match is 0.5. If the 
certainty equivalent is higher than the expected value of the gamble, for example 10 
years, then the subject is risk seeking: he prefers the (risky) gamble to its expected value. 
The proportional match is then higher then 0.5. in this example 0.58. If the certainty 
equivalent is lower than the expected value of the gamble, for example 8 years, then the 
subject is risk averse, since he is willing to sacrifice one year of the expected value of the 
gamble in order to avoid the risk. The proportional match is then lower than 0.5, in this 
example 0.42. Thus, a proportional match of 0.5 indicates risk neutrality, a proportional 
match > 0.5 indicates risk proneness and a proportional match < 0.5 indicates risk 
aversion. 
According to prospect theory, relative losses (i.e. outcomes lower than the reference or 
aspiration level) induce risk proneness and relative gains (i.e. outcomes higher than the 
reference or aspiration level) induce risk aversion. On the basis of prospect theory, it is 
therefore expected that, in general, the proportional match is higher than 0.5 for gambles 
with a low expected value and lower than 0.5 for gambles with a high expected value. 
Since aspiration levels will not be the same for different individuals, at group level a 
gradual shift from risk-proneness towards risk-aversion in gambles with increasing 
expected value (or with increasing expected utility) is expected. This hypothesis was 
investigated by performing an analysis of covariance with factor respondent and covariate 
expected utility of the gamble. 
A curve-fitting procedure was subsequently performed. For each individual, the average 
certainty equivalent for each utility value was calculated over two replications (i.e. the 
average CE12)5, СЕц etc. per respondent). In calculating these average certainty equiva­
lents, the certainty equivalents to the cross checking gambles were also included. For each 
individual a logistic curve was fitted on the data by means of nonlinear least squares 
regression. In the regression procedure the averaged certainty equivalents were used as the 
dependent variable and the utilities as the independent variable. Thus, although by 
convention, utility is indicated on the y-axis and life years on the x-axis (figure 4), the 
curve-fitting procedure was performed vice versa, because the measurement variability 
will occur in the certainty equivalents, not in the utilities, which are found by calculation. 
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The logistic form was selected because it is the simplest curve that satisfies the following 
criteria: 1. it is s-shaped, 2. it passes through the origin (zero life years cany a value of 
zero utility units), 3. it is asymmetrical, which is also predicted by prospect theory. The 
general form is: 
У =
" ~ ~ Г
+ а
 {2} 
in which y denotes utility, χ remaining number of years of life, a an asymptotic maxi­
mum, and b and с constants to be estimated. The goodness of fit (r2) was calculated as 
follows: 
SS 
in which RSS is the residual sum of squares and SS the sum of squares. 
The inflection point of the logistic curve is the point were the convex shape of the curve 
changes into the concave shape. According to prospect theory, this point exactly repre­
sents the reference or aspiration level [2]. Individual aspiration levels of survival can be 
inferred from these curves by setting the second derivative of the curve to zero: 
AL=. M * ' * ^ ) {4} 
\ c+1 
(AL= aspiration level of survival, b and с are the constants from formula {2}, see for 
derivation appendix). Finally, the correlation between age at the time of the assessment 
and aspiration levels of survival (AL) was investigated by means of a linear regression 
procedure. This was repeated with the AL expressed in life years, and with the AL 
expressed as a proportion of the MLY, to which we will refer as relative aspiration level 
or RAL. For example, a woman with an absolute AL of 15 years and a MLY of 40, will 
have a RAL of 15/40 = 0.375. It was expected that the AL would be influenced by age, 
and that by normalization of the AL by the MLY a possible relation between age and AL 
could be investigated more reliably. 
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Software 
Analyses were performed with the statistical software package SAS 6.06.01. 
Results 
Three respondents were not able to perform the certainty equivalent method, because the 
questions were meaningless to them (2), or because they did not want to gamble with 
years of life (1). 
Test-retest reliability, expressed as the product-moment correlation coefficient between the 
averaged certainty equivalents at two occasions, is illustrated in figure 2. The correlation 
coefficient was 0.93. 
Figure 2 
1 
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0.8-1 
0.6-
0.4-
0.2-
0 
r = 0.93 
0 0.2 ~0A 0.6 0.8 
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Figure 2. Test-retest reliability. The PM's, averaged per utility, found in the first 
replication are indicated on the x-axis and the averaged PM's in the second replication 
are indicated on the y-axis. 
Analysis of covariance resulted in a statistically significant trend towards a lower 
proportional match in the gambles with a higher number of years of life (p< 0.0001 in 
both replications, figure 3).The logistic fitting procedure yielded a good fit for all 
respondents. In all curve fits, r2 was 0.97 or higher. Figure 4 displays the curves of one 
intermediate and two extreme respondents. 
98 
mean 1 
proportional 
match 0.8-
0.6-
0.4 
0.2 H 
Figure 3 
• first replication 
О second replication 
' ' 
1 1 1 1 1 1 1 
0 0.125 0.25 0.375 0.5 0.625 0.75 0.875 1 
utility 
Figure 3. Mean proportional matches (+_ SD) in gambles with different expected utilities. 
Solid circles denote the first replication, open circles the second replication. 
Aspiration level of survival was negatively correlated with age (r=-0.43, p<0.025, figure 
5a). If aspiration level is expressed as a proportion of the MLY, the relative aspiration of 
survival, there is no relation with age (r=0.13, p>0.25, Figure 5b). In figure 5, only 25 
respondents are represented. No aspiration level of survival could be obtained from two 
respondents since they were either completely risk-averse or completely risk-seeking. 
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Figure 4 
0.6 0.8 1 
proportion of MLY 
Figure 4. Fitted utility functions of three respondents; the responses were averaged over 
two replications. In order to compare the utility functions of the respondents in this 
figure, the certainly equivalents were normalized by dividing all certainty equivalents by 
each respondents' MLY. 
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АД$ Figure 5. 5a. Aspiration level (AL) of survival in years and 5b. relative aspiration leve 
(RAL) expressed as a proportion of the MLY. 
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Discussion 
In this study most respondents were risk-seeking in the short term, and risk-averse in the 
long term. This is in sharp contrast with expectations on the basis of diminishing marginal 
value for additional years of life, which implies that years nearby in the future are more 
valuable than later years of life. If this would be true, then one would expect the 
respondents to be risk averse in the short term. Discounting of years of life, which is a 
generally accepted procedure in decision analysis, presumes that years later in the future 
are less valuable than years nearby. At first thought, it might therefore appear counterin-
tuive to be risk-seeking in the short term. 
Risk-proneness in the short term is however consistent with prospect theory [2]. Prospect 
theory also provides an explanation for it: if one really wants to achieve the aspiration 
level, one might be willing to take huge risks in order to reach that goal. Although we did 
not register the motivations that our respondents gave for their choices systematically, 
respondents often spontaneously gave explanations for their choices like: "I want to stay 
alive at least until my children are grown up", or, in the case of one respondent, whose 
adult son suffered from an incurable disease: "I want to live so long that I can care for 
my son until his death". In order to achieve at least their aspiration level, respondents are 
more likely to accept risky options. In general, our findings might explain why patients 
opt for treatments that are initially risky, but that promise better chances for longterm 
survival. For example, patients with acute leukemia without a related bone marrow donor 
often consent to transplantation with marrow from a matched unrelated donor, (a risk of 
around 50% to die within the first year [6]), even if their prognosis on the short term is 
better with conservative, less risky treatments [7]. Another wellknown example is the 
treatment of lung cancer: initial surgery carries a higher initial risk, but offers better 
chances with respect to long-term survival [8]. 
An additional observation is that the aspiration level tends to decrease with increasing age, 
which suggests that it is influenced by realistic expectations about life expectancy. If 
aspiration level is expressed as a proportion of the maximal number of life years (MLY) 
in the test, however, no relation between age and aspiration level remains. Since risk 
attitude is determined by aspiration level to a great extent, this suggests that risk attitude is 
not directly influenced by age. The absolute aspiration level tends to be higher for 
younger respondents, thus giving easily the impression of more risk-proneness in younger 
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respondents if gambles with the same numbers of years of life are presented to respon-
dents at different ages. For example, 25 years of survival may be well below the 
aspiration level of a 25-year old respondent, whereas it may be far beyond the aspiration 
level of a 70-year old respondent. Consequently, the younger respondents will tend 
towards risk-proneness, and the older ones will tend towards risk-aversion, if they produce 
certainty equivalents to the same gamble, even without a real difference in risk-attitude 
between younger and older age-groups. 
Although a trend towards a lower aspiration level with increasing age was shown, a large 
interindividual variability remains present. No data were collected that permitted us to 
analyze the causes of this interindividual variability. 
Should our results have consequences for decision analysis? It is easily possible to 
incorporate a logistic utility function for years of life into decision analysis models. These 
models, however, are usually designed with a normative goal: to produce the best 
decision. Thus, the answer to this question depends on whether our findings have 
normative value. As we have already mentioned, we had the impression that most 
respondents had understandable and reasonable arguments for their choices; therefore, we 
believe, that these results might have normative value. However, more systematic 
investigation of the motivations of the respondents and of the robustness of our results in 
patients rather than volunteers is necessary to confirm this impression. 
We conclude that prospect theory provides a good descriptive framework for analysis of 
choices regarding years of life. Further research should be directed towards systematically 
revealing the motivations behind this pattern of choice. If respondents have reasonable and 
sensible arguments for their choices, these results may not only have descriptive but also 
normative value. 
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Appendix 
Inference of aspiration level 
According to Tversky and Kahneman the reference point or aspiration level of the utility 
function is the inflection point of the curve. This point can be found by setting the second 
derivative of the function to zero: 
Ax> — *a 
о 
the first derivative is: 
,<e-l) ƒ(*)= a*c*xv 
(1+фТ**' b 
the second derivative is: 
//(
х
)=£^1£*[(
с
-1)*
ж
('-2)*(1+(£)<)"2-2д:(<г-1)*(1+(-)с)"3*—*χ*-ι>] bc b b bc 
and by setting the second derivative to zero we finally find 
x-. \ c+l 
in which χ denotes the aspiration level. 
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Abstract 
A clinical decision analysis was performed to judge the impact of local recurrences after 
breast conserving treatment (BCT) on the (quality adjusted) life expectancy of breast 
cancer patients. A life-long follow-up of two patient groups, one of which had undergone 
mastectomy and one BCT, was simulated by a Markov model of medical prognosis. Data 
used in the model originated from the literature. Since results in the source papers were 
not split according to stage, we performed two analyses: one with data from all source 
studies (T, and T2) and one with data from source studies, concerning only Ί \ patients. In 
both analyses, the conclusion was that BCT yields better quality adjusted life expectancy 
than mastectomy. Sensitivity analysis, however, identified subgroups of patients who 
should preferably undergo mastectomy. These subgroups are: patients preferring 
mastectomy to BCT, patients with a high risk of local recurrence, young patients and 
patients at high age, if they also have a high local recurrence risk. For these groups, 
patient preferences should play a major role in recommending treatment. 
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Introduction 
Randomized trials which employ modem radiotherapeutic and surgical treatment 
techniques do not show a difference in survival after mastectomy or breast conserving 
treatment (BCT) for early breast cancer[l-ll]. BCT thus seems to be the treatment of 
choice, since it yields the same survival and is less mutilating than mastectomy. However, 
after mastectomy most local recurrences occur within the first three years after initial 
treatment, whereas after BCT the local recurrence risk remains stable during a follow-up 
of 15-20 years [1,13]. Local recurrence rates up to 25 % have been reported after 25 
years of follow-up [14]. 
About 15 % of local recurrences is irresectable and the patient will eventually die from 
the disease [1, 15-23]. The other patients can be treated by a salvage mastectomy and they 
have a good prognosis in comparison to patients who develop a local recurrence after 
mastectomy [24]. Thus, the higher local recurrence rate will not readily affect survival of 
the whole group treated by BCT. Only one study demonstrated impaired survival after 
local recurrence following BCT [25]. 
Apart from survival, it is important to balance the psychological impact of local 
recurrence and salvage mastectomy against the benefit of a preserved breast. We 
performed a clinical decision analysis in order to integrate information from randomized 
trials with data from retrospective series with a longer follow-up. In this way a balanced 
judgment about which therapy is to be preferred can be made. 
Methods 
Definitions 
A local recurrence is localized in the lumpectomy scar or in the ipsilateral breast. No 
distinction is made between a local recurrence and a second primary tumor. A regional 
recurrence is localized in the axilla, supraclavicular or parasternal nodes. 
Literature search 
Literature was obtained from the MEDLINE database, from regularly checking Current 
Contents and from references of papers and books. Inclusion criteria for papers were: 
results of randomized trials of total or radical mastectomy versus some form of 
tumorectomy with axillary dissection, followed by a radiation dose of at least 50 Gy to the 
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Figure 1 
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Figure 1. Representation of the Markov model. 
tumorbed, reported according to the TNM-classification and concerning Τ,^ Νο,,Μο 
patients. In order to estimate the local recurrence risk beyond the follow-up period of the 
trials, we searched for retrospective series, which were included in the analysis if they 
provided an actuarial follow-up of at least 15 years and provided separate local and 
regional recurrence rates. Because no series were available in which all patients had 
undergone axillary dissection, we included papers reporting the results of BCT without 
axillary dissection. The search yielded 234 papers, among which where 15 reports about 4 
randomized trials [2-12, 26-29], and the rest were reviews, comments, and papers on 
retrospective series of breast cancer patients, treated by BCT. If we found more than one 
report about the same patient group, we utilized the report that provided the most detailed 
information. 
One of the four trials [26-29] did not meet our criteria. After selection, references [1, 3, 
4, 7, 13-23, 30] were used. 
Model 
We modeled a Markov process to describe the fate of patients undergoing either BCT or 
mastectomy [31]. The model is represented in figure 1. Five possible health outcomes or 
Markov states were defined. Every year a patient can move from one state to another with 
a certain transition probability. After BCT, a patient will be in the state preserved breast. 
She might develop a local recurrence, which will be treated by a salvage mastectomy 
(Markov state salvage). If the local recurrence is irresectable, the patient moves to the 
state irresectable. From all states, it is possible to move to the final state dead. 
After mastectomy, patients will live in the state mastectomy, until they move to the state 
dead, either from their cancer or from age-specific mortality. Metastatic disease is not 
modeled in a separate Markov-state, since the endpoints of interest are the occurrence of 
local recurrence and death. 
The Markov model calculates the total amount of time that an individual is expected to 
spend in each health state after either treatment. Time spent in each Markov-state is not of 
equal value. Every state is assigned a value between 0.00 and 1.00, a utility. A utility is 
referred to as ustate. The numerical value of a utility depends on its relative value among 
all possible health states. If Markov states are valued in this way, the resulting number is 
the expected number of Quality Adjusted Life Years or QALYs [32]. In order to obtain 
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the unadjusted life expectancy, all Markov states are assigned the value 1, except xidead, 
wich equals 0. 
Table 1 
Study 
Milan [12] 
Gustave-Roussy 
[4] 
NSABP [3] 
Treatment options 
Quadrai tectomy, 
axillary dissection and 
irradiation 
Halsted mastectomy 
Tumorectomy, axillary 
dissection and 
irradiation 
Halsted mastectomy 
Lumpectomy and 
axillary dissection 
Lumpectomy, axillary 
dissection and 
irradiation 
Total mastectomy 
Number of 
patients 
352 
349 
88 
91 
636 
629 
590 
Stage 
Τ,ΝοΜο 
Τ,Ν,ΜΜΟ 
T,.2No.iM0 
(Τ max. 4 
cm) 
Actuarial 
follow-up 
10 years 
10 years 
8 years 
Table 1. Characteristics of the three triah. 
Transition probabilities and utilities 
For every transition probability, a baseline value was computed. From the actuarial 
survival curves published in the reports of the trials (table 1) it is possible to estimate the 
overall mortality risk (OMR) in every particular year of follow-up. The yearly risks from 
three trials were combined to one value by computing mean yearly risks, weighted for the 
number of patients. After subtracting the age- and sex-specific mortality risk (ASR) [33] 
from these weighted mortality risks, the breast cancer specific mortality risk (BCR) 
results. Since the reported follow-up in the NSABP-trial was only 8 years, it was possible 
to compute a mortality risk for only this time. The BCR in the 9th year was assumed to 
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equal to the arithmetic mean of the risks in the preceding years, and to decrease linearly 
in the subsequent years to zero in the 30th year of follow-up. To compute the OMR for 
every plausible age at diagnosis after any period of follow-up, OMR was modeled as 
follows: 
OMR
 m
 = BCR
 (() + ASR ( l t e + „ {1} 
in which t is the time in years from the diagnosis, and age is age at diagnosis. 
The yearly risk of local recurrence was computed by applying formula {2} to the weighted 
average of the 8-year local recurrence rates given in the trial reports. 
yearly risk = l-t(l-R)1"] {2} 
in which R is the cumulative risk at χ years. The yearly risk in the 9th to 20th year of 
follow-up was calculated from the retrospective series by computing a weighted mean of 
the local recurrence risks at 20 years [1,14,15], and transforming this value into a yearly 
risk according to formula {1}. The local recurrence risk at 20 years as calculated by the 
model is lower than the risk reported by the retrospective series, because information of 
the older series with a higher risk was combined with the results of the newer trials, 
which reported a lower risk in the first years. We assumed that the yearly local recurrence 
risk beyond 20 years would linearly decrease to zero in the 25th year of follow-up. 
The baseline values used in the analysis are estimates based on literature research. The 
baseline age at diagnosis is the weighted mean of the mean age at entry as reported in the 
papers. The baseline analysis is performed with these estimates. In order to account for 
the uncertainty of these estimates, the probabilities and utilities are varied between a low 
and a high estimate, the 'plausible range'. Thus the sensitivity of the decision to variations 
over this range can be assessed [34]. The low and high values that constitute the 
boundaries of the plausible ranges are computed by calculating a 95 % confidence interval 
of the values found in the literature. 
The utilities assigned to the health states and their plausible ranges are based on the 
utilities and their standard deviations as measured by De Haes et al, who performed a 
utility measurement among experts in the field of breast cancer [35] (table 2). 
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Table 2 
plausible range 
variable baseline value low high 
age all trials 50.9* 
Τ, only 50.7* 25.0 100.0 
local recurrence risk at 20 years (T, 
only) 0.14 0.06 0.21 
local recurrence risk at 20 years (all 
trials) 0.19 0.11 0.26 
proportion of operable relapses 
0.86 0.60 1.00 
probability to survive 10 years after 
salvage 0.56 0.44 0.68 
probability to survive 5 years after 
inoperable relapse 0.13 0.00 0.26 
duration of breast cancer 
risk 
mortality 
duration of local recurrence risk 
discount rate 
¡¡preserved breast 
umastectomy 
wsalvage 
unresectable 
30 
25 
0.00 
0.96 
0.95 
0.84 
0.61 
25 
20 
0.00 
0.82 
0.77 
0.50 
0.00 
35 
30 
0.10 
1.00 
0.96 
0.95 
0.84 
Table 2. Baseline values with plausible range. 
* Weighted mean for the number of patients. 
In the model, the utilities were incorporated in such a way, that upreserved breast _> 
umastectomy _> »salvage >_ uirresectabJe >_ udead. This was achieved by defining all 
utilities, except udead, which always equals 0, in terms of differences between upreserved 
breast and the actual utility. 
Future life years were not discounted in the baseline analysis. In order to account for time 
preference, we examined the effects of different discount rates d in the sensitivity 
analysis. The utility of future life-years was divided by (1 + d)' , where t is the elapsed 
time in years from the starting age [36, 37]. 
Grouping of studies according to stage 
Because the Gustave-Roussy and the Milan trial consisted of T, patients, contrary to the 
NSABP study, in which nearly half of the patients were T2 patients, we performed two 
separate analyses. One was based on the data from the Gustave-Roussy and the Milan trial 
and one on the data of all three trials. It is thus possible to explore a possible shift in 
effect between T! patients and a mixture of T[ and T2 patients. 
All calculations were performed by the software package DecisionMaker 6.1.01 [38]. 
Results 
Baseline analyses 
According to the baseline analysis, a 50-year old woman with early breast cancer (T, or 
small Tj) has a life-expectancy of 20.92 years after mastectomy and of 21.31 years after 
BCT. In terms of QALYs, the model predicts 19.81 QALYs after mastectomy and 20.23 
QALYs after BCT, a benefit of 0.42 QALYs for BCT. 
If we know that this woman has a T, tumor, we can estimate her prognosis more accurate: 
life-expectancy is 22.63 years after mastectomy and 22.57 years after BCT, a loss of 0.06 
life years or 22 days. In terms of QALYs, however, she can expect 21.43 QALYs after 
mastectomy and 21.50 QALYs after BCT, a gain of 0.07 QALYs. The decision to 
perform BCT in this patient thus requires a tradeoff between quality of life and life 
quantity. 
On the basis of our baseline analysis we predict that the 'average' patient with a small 
breast tumor will prefer BCT to mastectomy. 
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Table 3 
mastectomy 
all trials 
20.92 
Τ, only 
22.63 
low risk 
22.12 
23.47 
breast conserving therapy 
baseline risk high risk 
21.31 20.54 
22.57 21.75 
Table 3. Effect of différera local recurrence risks on life expectancy (years). The results 
are given for all studies (first row) and for T¡ - studies only (second row). 
Sensitivity analyses 
In order to study the effect of different patient characteristics on the stability of the 
conclusions, various sensitivity analyses were performed. 
The effects on life expectancy of different local recurrence risks after BCT are presented 
in table 3. In both analyses, a high local recurrence risk results in a shorter life 
expectancy after BCT than after mastectomy. 
It was not possible to define a simple plausible range for mortality risk, because these 
risks are different each year. Instead, threshold values for mortality risk were computed. 
The threshold value of mortality is the extra yearly risk of mortality that causes the 
preference to switch from BCT to mastectomy. For T, patients, the baseline analysis 
predicts a shorter life expectancy after BCT than after mastectomy. If the 10-year survival 
after BCT is augmented by 0.2%, or the 10-year survival after mastectomy lowered by 
0.2%, the life expectancy after both treatments would be the same. The corresponding 
threshold values for both T, and T2 patients are an extra 10-year survival after mastectomy 
of 1.2% and a diminished 10-year survival after BCT of 1.3%. This 'lability' of 
preference is expected, since the baseline mortality risks are virtually equal, thus a small 
weight on one side of the balance can cause a switch from one side to the other. 
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Table 4 
Variable Value 
age 25 
50 
75 
100 
local recurrence risk at 20 0.11 
years** 0.19* 
0.26 
proportion of operable relapses 0.6 
0.86* 
1.0 
probability to survive 10 years 0.44 
after salvage 0.56* 
0.68 
probability to survive 5 years 0.00 
after inoperable relapse 0.13* 
0.26 
duration of breast cancer 25 
mortality risk 30* 
35 
20 
duration of local recurrence 25* 
risk 30 
discount rate 0.00* 
0.05 
0.10 
Table 4. Sensitivity analysis. 
* Baseline value. 
** First column denotes the risbfor all 
Benefit of BCT in QALYs 
All trials 
-0.47 
0.41 
0.25 
0.02 
1.31 
0.42 
-0.43 
0.02 
0.42 
0.64 
0.12 
0.42 
0.77 
0.39 
0.42 
0.44 
0.25 
0.42 
0.54 
0.54 
0.42 
0.35 
0.42 
0.30 
0.21 
T, only 
-1.13 
0.05 
0.20 
0.02 
1.04 
0.07 
-0.84 
-0.23 
0.07 
0.22 
-0.14 
0.07 
0.31 
0.05 
0.07 
0.08 
-0.03 
0.07 
0.14 
0.15 
0.07 
-0.01 
0.07 
0.17 
0.15 
:, the second column for Τ ¡-patients only. 
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Table 4 (continued) 
Variable 
»preserved breast 
umastectomy 
usalvage 
unresectable 
Value 
0.82 
0.96* 
1.00 
0.77 
0.95* 
0.96 
0.50 
0.84* 
0.95 
0.00 
0.61* 
0.84 
Benefit of BCT in QALYs 
All trials 
0.36 
0.42 
0.44 
3.79 
0.42 
0.17 
-0.17 
0.42 
0.61 
0.39 
0.42 
0.43 
T, only 
0.08 
0.07 
0.06 
3.83 
0.07 
-0.21 
-0.41 
0.07 
0.21 
0.04 
0.07 
0.08 
Table 4. Sensitivity analysis. 
* Baseline value. 
In table 4, the effects of varying different variables over their plausible ranges are 
displayed. Local recurrence risk, age, the proportion of operable relapses and the 
probability to survive 10 years after salvage, the durations of both local recurrence and 
breast cancer specific mortality risk, »preserved breast and usalvage can alter the 
decision. 
Figure 2 illustrates the interaction of age with local recurrence risk, both for T, patients 
only and for all trials. The area above the curve represents ages at which, in combination 
with a certain local recurrence risk, mastectomy is preferred. This figure is based on 
quality adjusted life expectancy. The combination of young age and higher local 
recurrence risk reinforces the preference for mastectomy. The different curves denote 
different values of umastectomy. The lower the utility of mastectomy, the smaller the area 
that represents a preference for mastectomy. It is remarkable, that when umastectomy is 
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Figure 2. Threshold analysis of quality adjusted life expectancy for varying ages at 
diagnosis and local recurrence rates after breast conserving treatment (BCT) in the choice 
between mastecomy (M) and BCT; the lines denote combinations of age and recurrence 
risks for which the quality adjusted life expectancy are equal following BCT or M. Every 
line represents another value of umastectomy. The solid line represents the baseline 
utility. Figure 2a represents the analysis for all trials, figure 2b represents T¡ patients 
only. If a certain point, representing a combination of age and local recurrence risk is 
located below the line, BCT is the preferred treatment, if it is above the Une, M is the 
preferred treatment. 
high, not only at young, but also at old age a threshold is found. Because local recurrence 
risk diminishes in time, the maximal gain from BCT is achieved after some time. The 
probability to move to states with low utility, like salvage or irresectable will have 
become very small, but the difference in utility between umastectomy and upreserved 
breast remains constant. At old age, life expectancy is short, and people will not reach 
this period of maximal gain from BCT. 
In figure 3, the relation between age at diagnosis, local recurrence risk and usalvage is 
displayed. For young age and high local recurrence risk the preference is very sensitive to 
diminishing usalvage. 
Some patients may, contrary to our assumptions, prefer mastectomy to BCT, because they 
feel safer when their breast is completely removed. We performed a threshold analysis 
with umastectomy in which the condition umastectomy <_ upreserved breast did not apply. 
If umastectomy equals 0.97 or more (at a baseline value of upreserved breast of 0.96), 
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Figure 3. Threshold analysis of quality adjusted life expectancy for varying ages at 
diagnosis and local recurrence rates after breast conserving treatment (BCT) in the choice 
between mastecomy βί) and BCT; the lines denote combinations of age and recurrence 
risks for which the quality adjusted life expectancy are equal following BCT or M. Every 
line represents another value of usalvage. The solid line represents the baseline utility. 
Figure 3a represents the analysis for all trials, figure 3b represents T, patients only. If a 
certain point, representing a combination of age and local recurrence risk is located 
below the line, BCT is the preferred treatment, if it is above the line, M is the preferred 
treatment. 
mastectomy is the preferred treatment for all trials. For the T, patients, mastectomy is the 
preferred treatment, when umastectomy equals 0.95 or more. 
Discussion 
Treatment effects in patients with early breast cancer are difficult to evaluate because the 
time frame of the disease is very long. To predict the eventual effect of the primary 
treatment on survival, a life-long follow-up is needed, because of the prolonged risk of 
recurrence. With a Markov-model, it is possible to simulate such a life-long follow-up. 
The value of the Markov-analysis presented here is, that we were able to highlight the 
effect of a factor that has caused concern: the continuous occurrence of local relapses after 
BCT during a long time. 
In order to design a manageable model, we created only separate Markov-states for health 
states, that were directly related to the questions posed. Possible side-effects of 
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radiotherapy or complications of mastectomy were not incorporated in the analysis. Side-
effects of radiotherapy, other than fibrosis of the breast, have become very rare with 
modem radiotherapeutic techniques. The main consequence of breast fibrosis is a poor 
cosmetic result. By assuming a lower utility value for life with preserved breast, it is 
possible to account for this possibility in the sensitivity analysis. 
The occurrence of lymfedema depends on the treatment of the axilla, which is essentially 
independent from the treatment of the breast. Thus, we cannot expect a difference 
between patients treated by mastectomy or by BCT in this respect. 
Complications of mastectomy, such as seroma or complicated wound healing are, in view 
of the time-frame of the analysis, considered negligible. Operative mortality after 
mastectomy is assumed to be equal to operative mortality after lumpectomy and 
irradiation. 
A remarkable observation in the analysis is that conservative therapy is supported more 
strongly, when T2 patients are included. This is entirely due to the study by Fisher et al, 
who observed a (non-significant) gain in survival after BCT, as compared to mastectomy 
[3]. Since the model copies the published survival curves exactly, this gain in life-
expectancy is reproduced, and results in a stabler preference for breast conserving 
therapy. We did not find an explanation for this observation in Fisher's report. It might be 
due to a random variation in treatment outcomes, and the gain in life expectancy of 
lumpectomy and irradiation compared to mastectomy may well vanish when the follow-up 
becomes longer. 
The differences found in the analysis were usually small and the choice between 
mastectomy and BCT can be characterized as a toss-up [39]. Because of its less mutilating 
character, BCT is to be preferred to mastectomy. 
However, we identified some subgroups of patients who are possibly better off with a 
mastectomy. These patients are: 
1. Those who prefer mastectomy to BCT. 
2. Patients with a high local recurrence risk. 
3. Young women. In these patients conservative therapy can eventually result in a 
shorter (quality adjusted) life expectancy because they are at risk for a very long 
time. If a young patient also has a high local recurrence risk, mastectomy 
deserves serious consideration. 
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4. Women of old age with a high local recurrence risk. Their life-expectancy is too 
short to accrue enough extra QALYs from the preserved breast to compensate for 
the shorter life-expectancy and the loss of utility associated with local recurrence. 
We did not specify what constitutes a high local recurrence risk; many prognostic factors 
have been mentioned in the literature of which extensive ductal carcinoma in situ, 
involved resections margins and invasion of lymphatic vessels are the most prominent. 
Young age may also be an indicator of a higher than average local recurrence risk 
[40,41,42]. In interpreting the results of this analysis, the clinician should use his clinical 
judgment of which patient has a low, moderate or high local recurrence risk, taking into 
account the treatment results in his own hospital. 
We believe, that it is an important observation, that even when a life-long follow-up is 
simulated, both treatments yield a virtually equal life expectancy at a baseline local 
recurrence risk of 14 % for Ti patients and 19 % for both T, and T2 patients. This risk is 
partially based on the results of older series and evidence cumulates, that with newer 
treatment techniques and sufficient radiation doses the local recurrence risk will be lower 
for patients treated nowadays [3,4,12]. However, we also showed, that a high local 
recurrence rate is able to affect survival, thus emphasizing the importance of maintaining 
a good local control rate. 
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Abstract 
Background. Recently, much attention has been paid to the prevention of breast cancer, 
especially in women at high risk for the disease. Since the efficacy of tamoxifen in 
preventing breast cancer is still uncertain, the only effective mode of prevention 
currently available is prophylactic mastectomy (PM). The aim of this study was to 
investigate whether women at high risk for breast cancer are better off with a PM than 
with breast cancer screening at regular intervals. 
Methods. A clinical decision analysis was performed, using Markov processes of medical 
prognosis, in which two options, PM and regular screening were compared with respect 
to their effect on life-expectancy and quality of life. The risk to develop breast cancer, 
dependent on the presence or absence of several risk factors was modeled and the effect 
of both options on life-expectancy and quality-adjusted life-expectancy was computed. 
Results. Life-expectancy was always higher after PM than under regular follow-up, 
except for old women in whom the perioperative risk looms larger than the risk to die 
from breast cancer. After PM, the maximal possible gain was 8 years. Quality-adjusted 
life-expectancy, however, was better under follow-up if the relative risk to develop 
breast cancer, under baseline assumptions, was lower than 17.4. The analysis was 
repeated with different assumptions. Major factors that influenced the choice were age, 
the risk to develop breast cancer, and the subjective desirability of life after PM and 
under regular follow-up. 
Conclusions. Although life-expectancy may be years higher after PM than after follow-
up, only very few women would benefit from a PM if quality of life is taken into 
account. 
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Introduction 
Breast cancer is the most common malignant tumor in women in the western world. 
About 1 in 12 women will develop the disease, and about 30% of these will eventually 
die of it, despite optimal surgical, radiotherapeutic and systemic treatment [1]. Therefo-
re, prevention of breast cancer, especially in women with a high risk to develop the 
disease has recently gained attention. 
Known risk factors, however, do not give easy clues to effective modes of prevention. 
The most important risk factor for breast cancer is family history. Women with a 
positive family history for breast cancer carry an enlarged risk to develop the disease. 
The risk is higher if more, particularly first-degree, relatives are involved, if the age at 
onset was low and if one or more cases of bilateral breast cancer are reported. 
Linkage analyses have recently resulted in the linkage of breast cancer susceptibility 
genes to the 17q21 chromosome in 40 % of 23 breast cancer families [2] and Narod et al 
showed, that also in families with both breast- and ovarian cancer considerable linkage 
with this chromosome was present [3]. It is however not yet possible to identify the gene 
carriers within the families. Lynch estimated that around 5 % of all breast cancer cases 
represent manifestations of hereditary breast cancer [4]. 
In many families with more than one case of breast cancer, the pattern of incidence 
merely supports a polygenic tendency to develop breast cancer than a dominant gene. In 
such families, the increased risk is most likely caused by a mix of genetic susceptibility 
and shared risk factors [5]. The presence or absence of certain risk factors, like high 
body-mass index, early menarche, late first pregnancy and particularly benign breast 
disease modify the risk to develop breast cancer to a considerable degree [6,7] and the 
risk may approach that of women from a family of hereditary breast cancer [8]. Neither 
of these risk factors, however, gives an easy clue to prevention. One possible exception 
is the relation between age at menarche and age at menopause and breast cancer. This 
relationship might indicate that long periods of exposition to estrogens is an important 
factor in the development of breast cancer. In line with this hypothesis is the observation 
in clinical trials of tamoxifen as an adjuvant agent in the treatment of breast cancer, that 
the incidence of second primary breast cancer was reduced by approximately one third 
[9,10]. Clinical trials investigating the efficacy of tamoxifen in preventing in high-risk 
groups the disease have been started [11, 12]. It will however take several years before 
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the results of these trials will become available. It is possible that the observed reduction 
in incidence merely reflects a delay in onset than a real risk reduction. 
The necessity of screening in women at high risk for breast cancer is obvious, but yearly 
mammography and regular palpation of the breasts might not detect a tumor in a curable 
stage. Therefore, some authors have suggested bilateral prophylactic mastectomy (PM) in 
these women [13, 14, IS]. Surgery will prolong the life-expectancy of these women, but 
at the cost of a serious mutilation. Moreover, PM does not reduce the breast cancer risk 
to zero [13]. 
Current options for women at high risk for breast cancer are regular follow-up or 
prophylactic bilateral mastectomy. The purpose of this study was to explore the benefits 
(in terms of life-expectancy) and immaterial costs (in terms of subjective desirability) of 
each of these options at different levels of risk for breast cancer. A decision analysis 
model was created, that incorporated the risk of breast cancer, to develop metastases, the 
effectiveness of PM and quality of life. Sensitivity analyses were performed in order to 
develop clinically meaningful diagrams that can be used in the counseling of individual 
women at high risk for breast cancer. 
Methods 
Basic model 
The primary study problem was stated as follows: Should a woman at high risk for 
breast cancer undergo PM? Or is she better off with regular mammograms and clinical 
follow-up in order to detect a tumor as early as possible? In order to explore these 
questions a decision analysis model was developed. Markov processes were implemented 
in the model to calculate the cumulative values in simulated cohorts of women after 
follow-up or after PM [16]. Markov processes have been used in the past to model 
several clinical problems in breast cancer management and screening [17, 18, 19]. A 
cohort of women is sent through the model, moving from one health state to another 
according to transition probabilities. In figure 1, a representation of a Markov process is 
shown. Three Markov processes, which were structurally very similar, but differed in 
the probabilities to develop breast cancer and to die from it, were implemented into the 
model: If follow-up is chosen, a Markov process is started to model the risk to develop 
breast cancer, to develop metastases and to die from the disease or from other causes. 
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Figure 1 
Figure 1. Representation of the Markov model. Health states are denoted by ovals. Each 
year, the women of a simulated cohort of women can move from one health state to 
another or stay in the same health state according to the arrows, with variable pro-
babilities. 
After PM, there is a small probability of perioperative mortality (0.001). The women 
surviving surgery form the starting cohort of two similar Markov processes: in a small 
proportion of women a clinically occult carcinoma will be detected in the mastectomy 
specimen, and the fate of these women is modeled by a separate Markov process. The 
large majority of the cohort starts in a Markov process which models their (reduced) 
probability to develop breast cancer. Markov states are health states that last a finite time 
period and women from a simulated cohort can move from one state to another. Every 
year, the proportions of the cohort in each health state are registered. Markov states in 
our model were: 1. WELL, either after having chosen for follow-up (annual mammo-
graphies and bi-annual palpation) or after PM, 2. BREAST CANCER, either a clinically 
occult carcinoma detected in the mastectomy specimen at PM, or breast cancer following 
a previous PM or breast cancer detected in the follow-up, 3. life with a breast cancer 
RECURRENCE, and 4. DEATH. After choosing follow-up, everybody starts in the state 
'WELL'. After PM everybody also starts in the 'WELL' state, except those who have 
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died from surgery (state 'DEATH') and those who have an occult invasive carcinoma 
(state 'BREAST CANCER*). A woman who is in the WELL state may develop breast 
cancer. If she develops breast cancer, she will undergo mastectomy and she will stay in 
the state 'BREAST CANCER' if she is cured. Else, she will move, after a variable time 
period, to the state 'RECURRENCE'. In order to model the diminishing risk in time to 
develop distant metastases after primary breast cancer, 20 different breast cancer states 
were modeled, which are omitted in figure 1 with in each subsequent state a lower risk 
to develop a recurrence, until the risk has become zero after 20 years. The women with 
a clinically occult breast cancer, discovered at PM, start in the state 'BREAST CAN-
CER'. They may also develop a recurrence and eventually die from the disease, but the 
probability to do so is smaller than in the other groups. From all states, it is possible to 
move to the state 'DEATH*. In the state 'RECURRENCE', death can either be due to 
breast cancer or to mortality from other causes. In all other states the probability to die 
is modeled according to the age-specific mortality rates of the Dutch female population 
[20]. Although the pathways are essentially the same in each Markov process, the risks 
to develop breast cancer or subsequently, to develop a recurrence and to die from it, are 
different. The model was allowed to run until age 80. 
We made some prior assumptions in order to be able to build a clear representation of 
the problem addressed. PM is assumed to concern a total mastectomy and not a 
subcutaneous mastectomy. If a subcutaneous mastectomy is performed, breast tissue can 
remain in place and breast cancer can still develop [13]. This risk is diminished after 
total mastectomy [21]. 
We assumed that there was no enlarged risk to develop any other tumor; if no breast 
cancer developed, the risk of dying from other causes was equal to the risk in the 
general population. We did not model the possibility of a second breast tumor. If breast 
cancer develops, it is assumed that the treatment will be a total mastectomy. 
Modeling the risk to develop breast cancer 
A central issue in this analysis is how to model the risk to develop breast cancer. One 
modeling approach is based on the multiplication of a baseline rate with a relative risk 
(RR). Most studies concerning the breast cancer risk in family members of breast cancer 
patients report RR's or hazard ratios, which are assumed to be constant over time [7,22, 
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Figure 2. The cumulative risk to develop breast cancer as a function of age f or various 
relative risks. The dashed lines denote the risk estimates, based on the publication by 
Gail et al. f8], in which separate relative risks are calculated below and over age 50, 
yielding a lower cumulative risk. The solid lines denote the cumulative risk based on a 
constant relative risk. The relative risks are indicated at the right side of the graph. 
Where two numbers are given, these denote the relative risk before and after age 50. 
23, 24]. In figure 2, the cumulative risk to develop breast cancer for several RR's within 
the range that has been reported by Claus et al. [22] are shown (solid lines). This graph 
illustrates, that the assumption of a constant RR over time yields counterintuitive results. 
On the basis of family history alone, without additional information on other risk factors 
or benign breast disease, the total cumulative risk should not exceed 50 % by far [5, 
23]. Using constant RR's, for example the hazard ratio of 44.2 reported by Claus [22] 
for women with a mother and two or more sisters with early-onset breast cancer (age at 
onset < 30), yields a cumulative risk of more than 90 % by age 80. Very high RR's do 
not increase the cumulative incidence very much, but merely decrease the age of 
incidence; in order to model for example a cumulative risk of 25 % at age 40 a constant 
RR of 35 should be assumed, because the baseline rate in young age groups is very low. 
A RR of 35, however, results in an implausible high cumulative risk at age 80 of nearly 
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Figure 2 
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Table 1 
Risk factor 
Age at menarche (yr) 
> 14 
12-13 
<12 
Number of previous breast biopsies 
Age < 50 year 
0 
1 
¿ 2 
Age >_ 50 yr 
0 
1 
>2 
Outcome of previous breast biopsy 
No biopsy performed 
No atypical hyperplasia 
Atypical hyperplasia 
Age at first live birth Number of first-degree relatives 
with breast cancer 
< 20 0 
1 
>. 2 
20-24 0 
1 
>.2 
25-29 or nulliparous 0 
1 
>. 2 
>.30 0 
1 
>.2 
Table 1. Relative risks associated with the risk factors used 
Associated relative 
risk 
1.000 
1.099 
1.207 
1.000 
1.698 
2.882 
1.000 
1.273 
1.620 
1.000 
0.930 
1.823 
1.000 
2.607 
6.798 
1.244 
2.681 
5.775 
1.548 
2.756 
4.907 
1.927 
2.834 
4.169 
in the model [8]. 
90%. 
A second modeling approach is based on the published RR's of Gail et al.[8]. They 
published a model to project individualized probabilities in women who undergo annual 
screening. Gail et al. calculated separate RR's for age ranges less than 50 years and 50 
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years or more. This model produces plausible cumulative risk estimates of up to 27 % in 
30 years on the basis of family history alone. In this model, RR's based on family 
history are modified by the presence or absence of other risk factors, i.e. the number of 
first-degree relatives with breast cancer, age at menarche, number of previous biopsies, 
outcome of previous biopsies and age at first live birth. Each risk factor yields a RR and 
the combined RR for a patient with a particular risk profile is found by multiplication. 
For example, a woman of age 38 with one first-degree relative with breast cancer, 
without children, one previous breast biopsy with outcome fibroadenoma, and age 13 at 
menarche has an RR of 2.756 χ 1.698 χ 0.93 χ 1.099 = 4.78. Since there is an 
interaction between the number of biopsies and age, this RR drops after age 50 to 2.756 
χ 1.273 χ 0.93 χ 1.099 = 3.59 (see table 1). The reference group on the basis of which 
RR's were calculated, is a group without the mentioned risk factors, published by Gail et 
al [8]. Cumulative risk estimates based on this model are more plausible. The worst 
combination of risk factors in this model still yields a cumulative risk around 80% in 60 
years, but this estimate is based on information about several risk factors and not on the 
basis of family history alone. The advantages of this approach are clear: it is possible to 
combine information about several risk factors to estimate the breast cancer risk, and the 
cumulative risks are more plausible due to the estimation of separate RR's before and 
after age 50. Therefore, we decided to use the model based on the risk estimates of Gail 
et al [8]. in our analysis. 
Summary of the data 
Prognosis of breast cancer 
The most important prognostic factors in breast cancer are tumor size and nodal status 
[25, 26]. Since it is assumed in the model that women at high risk for breast cancer will 
be screened at annual intervals, both clinically and mammographically, it can be 
expected that the proportion of node-negative patients will be higher in our analysis than 
in an unscreened patient population. Baker [27] reported the results of annual clinical 
and mammographie screening in a group of women of all ages, and found that thepro-
portion of node-negative breast cancers was 80 %. No age-specific proportion of node-
negative tumors was reported, although it can be anticipated that in younger women with 
usually denser breast tissue, tumors will be detected at a larger size [28] and thus, that 
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Table 2 
Tumor size 
baseline 
1-2 cm 
2-3 cm 
3-4 cm 
4-5 cm 
> 5 cm 
Prop 
0.80 
0.67 
0.55 
0.48 
0.40 
0.30 
ortion node-negatives 
Table 2. Proportion of node-negatives depending on tumor size [26, 27] 
the proportion of node-positive tumors will be higher. Carter reported the relationship 
between tumor size and proportion node-negative breast cancers [26]. This relation is 
summarized in table 2. 
A generally accepted treatment policy is to offer premenopausal women with node-
positive breast cancer adjuvant chemotherapy, whereas node-positive postmenopausal 
women are offered adjuvant tamoxifen. Women with node-negative breast cancer often 
do not receive adjuvant systemic therapy outside clinical trials. The recurrence rates as 
reported by the Early Breast Cancer Trialists' Group [10, 29] were used to model the 
probability to develop a recurrence after breast cancer. Recurrence rates for patients who 
develop breast cancer before age 50 were calculated as the weighted mean recurrence 
rates of the node-negative control group (weight 0.8) and the recurrence rates of the 
treated arm of the node-positives of the polychemotherapy trials (weight 0.2) [10]. 
Patients, who develop breast cancer after age 50, were subject to similarly weighted 
recurrence rates derived from the node-negative controls and the node-positives treated 
by tamoxifen [29]. The unweighted recurrence rates are listed in table 3. For example, a 
woman who develops breast cancer before age 50, has a recurrence risk according to this 
model of 0.8 * 0.085 + 0.2 * 0.127 = 0.0934 in the third year of follow-up. The 
yearly risk to die from breast cancer after having developed a recurrence was estimated 
0.25 per year, which corresponds to a median survival time of 3 years with metastases 
[30]. 
After PM, there is a probability that an occult invasive cancer or a non-invasive cancer 
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Table 3 
node-negative breast 
cancer 
no adjuvant systemic 
therapy 
years 0-4 
years 5-9 
years 10-20 
adjuvant systemic therapy 
years 0-4 
years 5-9 
years 10-20 
age at diagnosis < 50 
0.0850 
0.0399 
linearly decreasing to 0 
0.0606 
0.0408 
linearly decreasing to 0 
age at diagnosis >_ 50 
0.0522 
0.0404 
linearly decreasing to 0 
0.0362 
0.0407 
linearly decreasing to 0 
node-positive breast 
cancer 
adjuvant systemic therapy 
years 0-4 
years 5-9 
years 10-20 
0.1270 
0.0698 
linearly decreasing to 0 
0.1135 
0.0680 
linearly decreasing to 0 
Table 3. Unweighted yearly probabilities to develop a breast cancer recurrence [10, 29] 
is detected in the mastectomy specimen. Carcinoma in situ is treated sufficiently by a 
total mastectomy, but subclinical invasive carcinoma might be disseminated already at 
the time of the PM. The probability that an occult carcinoma will be detected is equal to 
the sum of the probabilities to develop a clinical detectable cancer in the two subsequent 
years following PM, since breast cancers are present in the breast for about two years 
before they become clinically apparent. Such occult tumors will usually be small. A 
tumor size of 1.0 cm corresponds to a proportion of node-negative patients of 0.8 [26]. 
However, most of these occult cancers will be smaller than 1.0 cm, and the probability 
to develop a recurrence is smaller for patients with a small tumor than for patients with a 
larger tumor, given that they have the same nodal status [25, 26]. Therefore, the 
recurrence rates based on a distribution of 80 % node-negatives and 20 % node-positives 
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as described above, can be viewed as the upper bound of the plausible true recurrence 
rate. The recurrence rates for mammographically or clinically detected cancers were 
therefore multiplied by an arbitrary factor of 0.5 (range 0.1-1). 
Prophylactic mastectomy 
From the literature, it appears that subcutaneous mastectomy has been performed more 
often than total mastectomy. After subcutaneous mastectomy, not all breast tissue can be 
removed and a cumulative incidence of 0.5 % in an average follow-up of 7 years, (a 
yearly incidence of 0.07 %) after subcutaneous mastectomy was described by Pennisi 
[13] in a series of 1244 patients from San Francisco. Under the assumption that the 
population of Pennisi had a relative risk of 2 compared to an unselected population [31], 
it is possible to calculate the risk reduction by prophylactic subcutaneous mastectomy, by 
comparing the incidence per age group in Pennisi's group with the breast cancer 
incidence in per age group in San Francisco Bay area [32] (see appendix). This yields a 
risk reduction by subcutaneous mastectomy with a factor 0.23. Since we want to 
evaluate the effects of prophylactic total mastectomy we chose to reduce this factor by an 
arbitrary 0.5 in the baseline analysis (baseline value= 0.115) and we used the value 
based on Pennisi's series as an upper bound of a plausible range of risk reduction factors 
(range 0.01-0.23). 
Utilities 
Utilities are subjective values assigned to each health state in order to adjust life years 
for the quality of life in each health state. Utilities were measured by the time tradeoff-
test (TTO) and the certainty equivalent method was used to measure attitude towards risk 
(CE) in a group of students in health science (n=14), who performed three test replicati­
ons [33]. 
Utilities were incorporated into the model using the QALY-utility model of Miyamoto 
and Eraker [34]: 
U(Y,Q) lJ*L*Y'*Q' 
Ymax' 
in which U(Y,Q) is the utility of a number of life years Y with health quality Q, and г is 
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Table 4 
Markov state 
Metastasized breast cancer 
Mastectomy for breast cancer 
Prophylactic mastectomy 
Regular follow-up 
Risk parameter r** 
Mean 
0.55 
0.78 
0.79 
0.91 
1.18 
utility* 95% confi 
0.47-0.63 
0.72-0.84 
0.73-0.85 
0.86-0.96 
0.91-1.55 
Table 4. Mean utilies with 95% confidence intervals. 
* Calculated with the results of13 respondents, after the omission of one outlier. 
** The mean and range of r are calculated on the basis of a geometric mean. 
a risk parameter. Q is, by convention, scaled between 0 for the health state death and 1 
for complete health. Ymax is the maximum number of life years that is described by the 
utility function, that is in our model the number of life years until age 80. is a 
Ymax' 
scaling constant, chosen so, that the resulting utilities are within 0 and 100. The 
resulting utility will have the value 100 if the maximum number of life years has been 
spent in complete health, and 0 if immediate death occurs. 
The risk parameter r indicates the willingness of the patient to accept risks with respect 
to years of life. If r > 1, the patient is risk-seeking, if г < 1, the patient is risk-averse, 
and if г = 1, the patient is risk-neutral. For a more extensive explanation of risk attitude 
see for example McNeil et al. or Sox et al. [35, 36] and for detailed derivations of the 
risk parameter r see Miyamoto and Eraker [34]. The mean utility values from the TTO 
and mean risk parameter, derived from the CE are listed in table 4. If no adjustments for 
quality of life are made, the decision model yields the average expected life-expectancy 
after each strategy. 
Software 
All analyses were performed with the decision-analysis program Smltree (Smltree 2.9, 
1989, J.P. Hollenberg). 
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Results 
Baseline analysis 
Life expectancy 
Without a correction for quality of life, the analysis yields the expected number of life 
years after PM and after the follow-up strategy. PM always yields the highest life-
expectancy, even in women without elevated risk. Only in very old women the risk of 
perioperative death outweighs the gain in life expectacy expected after PM. The gain 
after PM is larger, if the risk to develop breast cancer is higher and if the age of the 
patient is lower. The largest possible gain after PM is estimated to be 8 years in young 
women with the most unfavourable constellation of risk factors: age 20, age at menarche 
< 12 years, two or more previous biopsies of which one yielded atypical hyperplasia, 
age at first live birth < 20, and two or more first-degree relatives with breast cancer. In 
figure 3, the relationship between expected gain of PM in terms of life years and age is 
shown for various RR's. This is done separately for women without previous biopsies 
Figure 3 
10 
number of 
life years
 R 
gained 
60 70 
age (years) 
Figure 3. The expected gain in terms of life years after PM for various relative risks 
(indicated by the numbers printed in the graph) and for women aged less than 50 who 
have had either 0, 1 or 2 or more biopsies and for women aged 50 and over. 
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(solid line, no markers), one previous biopsy (open circles) and two or more previous 
biopsies (closed circles), and women aged 50 or older (open squares). These categories 
are denoted separately, because the influence of the number of biopsies on the RR is 
different before and after age 50. In the calculation of the expected gain at any age < 
50, the influence of the number of biopsies on the later RR should be taken into account. 
For example, a woman with one previous biopsy, outcome atypical hyperplasia, one 
first-degree relative with breast cancer, age at first live birth 23, and age 13 at menar-
che, has a RR of 1.698 χ 1.823 χ 1.244 χ 1.099 = 4.23 if she is younger than 50. 
When her age increases to 50 or older, her RR drops to 1.273 χ 1.823 χ 1.244 χ 1.099 
= 3.17. If we want to predict the expected gain over a whole lifetime for women 
younger than 50 with one or more previous breast biopsies, we have to take the 
prospective decrease in RR into account. As can be inferred from table 1, this decrease 
in RR at age 50 occurs only in women who have undergone previous breast biopsies. If 
age >_ 50 there is no change in RR anymore with increasing age, so that it is unnecessa­
ry to make a distinction between women with 0, 1 or 2 previous biopsies. The RR of 
any individual woman can be calculated using table 1 and the expected gain of PM can 
be estimated from figure 3. 
The analysis was performed with every possible combination of risk factors and some 
findings that may be useful in the counseling of an individual patient will be highlighted 
here. The expected gain of a woman without a first-degree family member with breast 
cancer will not exceed 3.25 years after PM. If she has one first-degree relative with 
breast cancer the maximal expected gain is 4.5 years and with two or more first-degree 
family members the maximal expected gain is 8 years. The expected gain decreases 
rapidly with age, especially in the higher risk categories. Thus, if life-expectancy were 
the only basis upon which to decide, PM would be favoured for every healthy woman, 
except those older than 65 years of age. 
Quality-adjusted life expectancy 
If utilities are used to adjust the life-expectancy for quality of life and risk-attitude, quite 
a different picture is emerging. Under baseline assumptions, PM is favoured only for 
women with a very high risk, that is a RR of 17.4 or higher. This implies, that in 
women without a previous biopsy follow-up is always the best option. In figure 4, the 
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two lines denote the demarcation between combinations of age and RR at which PM is 
favoured and combinations were follow-up is favoured. The dashed line denotes the 
demarcation for women with two previous breast biopsies, and the solid line for women 
with one previous breast biopsy. For women without previous breast biopsies PM is 
never preferred. At first glance it may appear odd, that the area where PM is preferred 
is smaller after two previous biopsies than after one. This is caused by the interaction of 
age and RR; the RR is reduced more after age age SO for women with two previous 
biopsies ( from 2.882 to 1.620, a factor 0.56) then for women with one previous biopsy 
(from 1.698 to 1.273, a factor 0.75) The same initial RR thus yields a lower risk after 
two biopsies than after one biopsy. Because the RR after two biopsies is, however, much 
higher, PM will sooner be favoured after two biopsies than after one biopsy. An 
example: a woman aged 35, with age at menarche 13, no previous breast biopsies, two 
relative 
risk 40-
35-
30-
25-
Figure 4 
— one previous biopsy 
•- two previous biopsies 
prophylactic 
mastectomy 
40 45~~ 50 
age (years) 
Figure 4. This graph illustrates for which combinations of RR and age PM is favoured, 
and for which combinations follow-up is favoured at the baseline assumptions, if quality 
of life is taken into account. The solid line denotes the demarcation for women with one 
previous biopsy, and the dashed line for women with two previous biopsies. For women 
without previous biopsies, PM will never be favoured, since their RR cannot increase to 
more than 8.2. Therefore, a line denoting the demarcation for women without previous 
biopsies was omitted. 
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first-degree relatives with breast cancer and without children has a RR of 1.099 χ 
4.907= 5.4 (table 1). The combination age 35 and RR 5 is in the follow-up area; if she 
would have had two previous biopsies with outcome atypical hyperplasia, the RR would 
have been 1.099 χ 2.882 χ 1.823 χ 4.907 = 28.3 which is in the area where PM is 
favoured. 
Sensitivity analyses - What if.....? 
A sensitivity analysis tests the sensitivity of the decision for changes in the probabilities, 
utilities or assumptions, and can most conveniently be described as posing 'what if 
questions. Several questions were addressed. 
What if the patient considers a PM as a burden, that will greatly decrease her quality of 
life? Or what if she views a PM as an unpleasant but quite acceptable solution? 
The choice between PM and follow-up depends strongly on the subjective desirability of 
PM, as is illustrated in figure 5. The two lines, marked with 0.79, which is the 
45 
relative 40 -
risk
 3 5 
Figure 5 
— one biopsy 
two biopsies 
no biopsies 
prophylactic 
mastectomy 
0.73 
45 50 
age (years) 
Figure 5. The influence on the treatment preference of variations in the desirability 
(utility) of PM is illustrated here. If the utility of PM is low (utility =0.73), the area 
where PM is favoured is much smaller; if the utility of propylactic mastectomy is high 
(utility =0.85) the area where PM is favoured is much larger. 
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baseline estimate of the utility of PM, denote the demarcation between the area where 
PM is favoured, and the area where follow-up is favoured for women who have 
undergone one or two biopsies. The upper line in the graph, which denotes the same 
demarcation at a utility of PM of 0.73, shifts to the upper border of the graph. The area 
where PM is favoured is smaller, if the desirability of PM is less than the baseline 
value. For women with one previous biopsy, PM is never favoured within the possible 
range of RR for this group (maximal 25.4) at a utility of 0.73. Similarly, the lines shift 
markedly to the bottom of the graph, if the utility of PM is much greater than the 
baseline value (0.85). If the desirability of PM is 0.85, even women without previous 
biopsies may prefer PM to follow-up. 
What if the breast tissue is so dense that screening mammography becomes unreliable? 
If the breast tissue is very dense, the probability that a tumor will be detected at an early 
stage is smaller, and consequently the risk that a breast tumor will be node-positive is 
higher (table 2). Figure 6 shows the shift in the demarcation line if the proportion node-
relative 
risk 40 -
35-
30 
25 
Figure б 
— · — prop, node negatives 0.8, one biopsy 
--»-- prop, node-negatives 0.8, two biopsies 
—β— prop, node-negatives 0.3, one biopsy 
--о ·• prop, node-negatives 0.3, two biopsies 
prophylactic 
mastectomy 
45 50 
age (years) 
Figure 6. Influence of the proportion of node-negative breast cancers on treatment 
preference. The lines denoted by the closed circles are found under baseline as­
sumptions, the lines denoted by open circles are found under the worst-case assumption 
of a proportion of node-negatives of 0.3 despite screening. 
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negatives is 0.8 (closed circles) and under the worst-case assumption, a proportion node-
negatives of 0.3 (open circles). As is indicated in table 3, if all tumors would be >_ 5 
cm at detection, such a low proportion is expected. However, even under this extreme 
assumption, the influence of this variable on the treatment preferences is not very large, 
although in women with a RR around 20, unreliability of mammography could turn the 
scale in making a decision. 
What if anything possible would be done if breast cancer would develop, i.e. what if 
adjuvant systemic therapy would be given if node-negative breast cancer would occur? 
In the baseline analysis, it was assumed, that women with node-negative breast cancer 
would not receive adjuvant systemic therapy. In order to answer this question, the 
analysis was performed with recurrence rates that were published by the Early Breast 
Cancer Trialists' Group [10, 29] for node-negatives who received adjuvant chemotherapy 
at age < 50, and adjuvant tamoxifen at age _> 50 (table 2). Although follow-up is a 
. . 45 
relative 
risk 40 
Figure 7 
one previous biopsy 
two previous biopsies 
prophylactic 
mastectomy 
follow-up 
~40~ ~~45 50 
age (years) 
Figure 7. Influence of the effectiveness of PM on treatment preference. The upper, 
middle and lower solid lines denote the demarcation lines between a preference for 
prophylactic mastecomy and follow-up at a risk reduction by PM by a factor 0.01, 0.115 
and 0.23 respectively, for women with one previous biopsy. The dashed lines denote the 
corresponding lines for women with two previous biopsies. 
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more attractive option under this assumption, the effect on the treatment preference is 
small, in size about half the effect of the proportion of node-negatives in figure 6 (data 
not shown). Thus, the intention to do everything possible, if breast cancer would occur, 
should not add much weight to the scale. 
What ifPM is much more or much ¡ess effective than estimated in this analysis? 
In our baseline analysis, we assumed, that PM would reduce the risk to develop breast 
by a factor 0.115. If it is assumed, like some authors claim, that PM is much more 
effective than our baseline estimate [37], implying for example a risk reduction by a 
factor 0.01, then PM would more easily be favoured. Others claim, on the basis of 
animal experiments, that PM is far less effective [38] than is usually assumed. Our worst 
case estimate was a risk reduction by a factor 0.23. Under the latter assumption, follow-
up would be favoured more easily. The size of this effect is however small (figure 7). 
What if a patient shows a lot of aversion to take risks with her life, or the opposite, if 
she is quite willing to take a chance? 
This question was investigated by reevaluating the analysis with different risk parame-
ters. A risk-averse (r=0.91) and a risk-prone attitude (r=1.55) only have a minor 
influence on the treatment preference (data not shown). The direction of this small shift 
is towards PM for a risk-averse attitude, and towards follow-up for a risk-seeking 
attitude. 
What if a patient of age 50 or older wishes to be informed about her breast cancer risk 
and the possible benefits of a PM? 
Under baseline assumptions, PM is never favoured for women older than 52. The 
decrease in quality of life caused by PM will then not be compensated anymore by the 
expected gain in life-expectancy. The effect of factors already discussed above in women 
older than 50 is usually small. In figure 8, two factors that had prominent influence on 
treatment preference are illustrated. These were the desirability of PM and the effective-
ness of PM in preventing breast cancer. Factors that had no or minimal influence were 
the expected proportion of node-negative breast cancers and the effect of adjuvant 
systemic therapy in node-negative breast cancer. 
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Figure 8 
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Figure 8. Treatment preferences at age 50 and older. The solid line denotes the 
demarcation between combinations of RR and age that imply a treatment preference for 
either PM or follow-up at baseline assumptions. The coarse-dashed and fine-dashed line 
denote the corresponding demarcation under the assumption of a high effectiveness of 
PM and high utility ofPM, respectively. 
Discussion 
Our analysis not surprisingly shows that PM will virtually always yield a benefit in terms 
of life-expectancy, even in women without increased risk. The only exception is old 
women, in whom the operative nsk outweighs the reduction in breast cancer mortality. 
Any healthy woman below age 65 will increase her life-expectancy by having a PM 
performed. It is clear that in this decision problem life-expectancy is only one of the 
factors that influence the decision. Major factors are the risk to develop breast cancer, 
age, subjective desirability of PM and of life under regular follow-up examinations. 
Minor factors that may play an additional role are the probability to detect the tumor in 
an early stage, the probability to develop a recurrence, and the probability that a breast 
tumor will develop despite a PM. 
In our baseline analysis we found that if the initial RR was lower than 17.4, follow-up 
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was the preferred option. Women who either do not want to live with the uncertainty of 
follow-up, or who do not expect a decrease of quality of life after PM, may opt for a 
PM at a lower RR. Only a small proportion of women with an elevated risk, however, 
have such a high RR. In general, if we take subjective desirability into account, PM is 
not the therapy of choice in women at high risk for breast cancer. 
This is in accordance with most authors [S, 15, 39] who emphasize the importance of a 
careful risk estimation and extensive counseling before deciding on a PM. Women who 
visit their doctor because they are at high risk to develop breast cancer, may easily 
misinterpet information about breast cancer risk [5], and overestimate their expected 
benefit from a PM. A careful estimate of the expected benefit of PM on the basis of 
individual risk factors, may therefore be very helpful for women who are anxious about 
their breast cancer risk. 
This model is entirely based on the study of Gail et al [8]. Although it was a large 
study, and one of the few studies that reported RR's for combinations of risk factors, the 
limitations of this study are reproduced in our model. For example, biopsy as such is 
probably not an independent risk factor, but it is an indication that both physicians and 
women are convinced of an elevated risk, which is the reason that biopsy is performed 
easHy [40]. Thus, the introduction of biopsy as a risk indicator will probably lead to the 
underestimation of the importance of 'true' risk factors because it is an indicator of other 
risk factors rather than an independent risk factor. Our model is therefore most suitable 
for use in the large group of women at a minimally to moderately increased risk, where 
a combination of several risk factors, which separately do not increase the breast cancer 
risk very much, may result in a clinically important elevated risk. 
In women with an extremely high risk, for example women with several first-degree 
relatives with early onset breast cancer, the model may be less appropriate. According to 
this model, if no previous biopsies would be performed the RR cannot exceed 8.2, and 
PM would not be favoured for such women. Some women may have a much higher RR, 
based on family history alone as has been shown by various authors. Claus et al. [22] 
estimated RR's up to 44.2 based on family history alone. 
Our graphs can be used for estimating the benefit, that woman with a RR based on 
family history alone will have from a PM. A 30-year old woman with a RR of 25 will 
gain approximately 5.5 years by having a PM performed, according to our analysis 
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(figure 3). This benefit is an underestimation if the assumption of a constant RR is 
accepted as valid. Our analysis is somewhat more conservative with respect to PM than 
under the assumption of a constant relative risk, i.e. if in the present analysis PM is 
favoured to follow-up, this would certainly have been so under the assumption of a 
constant relative risk. As has been pointed out in the methods section already, very high 
RR's are found if the age at onset is low, because the baseline risk is then very low (see 
also figure 2). It is implausible that such a high relative risk would really be constant 
over time, since the probability to develop breast cancer would approach 100 %. If these 
considerations are borne in mind, our graphs can also be used for women with an 
elevated RR, for example on the basis of family history alone. 
Given these limitations, we think that the present analysis may assist in the counseling 
women towards the difficult decision whether or not to undergo PM. Often, a careful 
estimate of the range within which an individual risk will fall, and an estimate of the 
expected gain in terms of life years after PM may be sufficient in counseling the patient 
towards a decision. A more accurate approach would be to assess the utilities and risk 
attitude of each individual patient, and base the treatment advice on these utilities. This 
is subject to further research in our institution [41]. 
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Appendix 
Prophylactic mastectomy 
From the literature, it appears that subcutaneous mastectomy has been performed more 
often than total mastectomy. After subcutaneous mastectomy, not all breast tissue can be 
removed and a cumulative incidence of 0.5 % in an average follow-up of 7 years, (a 
yearly incidence of 0.07 %) after subcutaneous mastectomy was described by Pennisi 
[13]. In order to find out what is the risk reduction from subcutaneous mastectomy we 
need to know what the risk to develop breast cancer would have been, if PM would not 
have been performed. The risk in the general population with this age distribution over 7 
years can be computed on the basis of the published incidence rates in San Francisco 
Bay Area [32] (table 5): 
Table 5 
Age Number of Age at start 
<. 25 
26-30 
31-35 
36-40 
41-45 
46-50 
51-55 
56+ 
Total 
women 
49 
117 
174 
239 
296 
221 
93 
55 
1244 
of follow-up 
22.5 
27.5 
32.5 
37.5 
42.5 
47.5 
52.5 
57.5 
Cumulative incidence per 100.000 Weight 
in seven years 
1.4*1.5+8.0*5+30.6*0.5 2.26 
8.0*1.5+30.6*5+76.4*0.5 19.11 
30.6*1.5+76.4*5 + 129.5*0.5 68.91 
76.4*1.5 + 129.5*5 + 191.6*0.5 164.82 
129.5*1.5 + 191.6*5+229.9*0.5 301.52 
191.6*1.5+229.9*5+268.9*0.5 279.15 
229.9*1.5+268.9*5+311.5*0.5 137.94 
268.9*1.5+311.5*5+356.7*0.5 94.58 
1068.29 
Table 5. For explanation, see text. 
The weight in the last column is found by multiplying the cumulative incidence per age 
group by the number of women in that age group and dividing the result by the total 
number of women. Thus the expected cumulative rate for a group with this age distribu-
tion in seven years would be 1068.29 per 100.000 women or 1.06829 per 100 women. 
The corresponding cumulative risk is 1.06 % [42]. The group reported by Pennisi is a 
miscellaneous group, with various forms of 'fibrocystic disease' which generally carries 
a relative risk of 2 [40]. It is likely that the real relative risk was not much higher, since 
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the major risk determinant in breast cancer is family history and only 218 (17.5 %) of 
patients had a history of one or more first-degree relatives with breast cancer. Therefore, 
this risk would be doubled, yielding a total risk of 2.12 % over 7 years or a yearly 
incidence of 0.0031 or 0.31%. After subcutaneous mastectomy the yearly risk was 
0.07% yielding a risk reduction with a factor 0.07/0.31=0.23. In the baseline analysis, 
we used a risk reduction by a factor 0.115, since we have considered total mastectomy 
and not subcutaneous mastectomy, and in the sensitivity analyses a range from 0.01 to 
0.23 was used. 
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Chapter 8 
General discussion 

General discussion 
The aim of the research reported in chapters 2, 3, 4, and 5 was to investigate the 
feasibility, test-retest reliability and internal consistency of assessment methods for the 
measurement of utilititíes of life years and health status. Chapter 2 contains a theoretical 
comparison of utility assessment methods, followed by results of applied research in 
chapters 3, 4 and 5. In this thesis, the results of administering three utility tests to three 
groups of respondents are reported: two groups of students, and a group of women 
performed the tests at two or three occasions. 
The sample-sizes were small (n=14, 17 and 30, respectively) which was mainly due to 
practical reasons: the respondents performed test replications at four or five occasions. In 
the group of women the tests were performed in individual interviews, and every 
respondent received an individual test variant. 
All groups were respondents, who did not actually face a treatment decision. The 
intention of the study was to explore and compare utility assessment methods before 
using them in patients. It was anticipated that these tests might upset patients and 
therefore the tests were first offered to volunteers. It is, of course, possible, that the 
results of testing patients will differ from the results found in volunteers. 
The methods under investigation were additive conjoint measurement (ACM), time 
tradeoff test (TTO) and the certainty equivalent method (CE). ACM and TTO are both 
methods designed to assess utilities without introducing uncertainty; these methods yield 
riskless utilities. The CE was used to assess risky utility of healthy life years under 
uncertainty and a risk parameter can be derived from such a risky utility function. Thus, 
TTO and ACM both measure riskless utilities of various health states and the CE 
measures risky utilities, in our application, of healthy life years. Therefore, the CE is a 
different entity that cannot be compared to ACM and TTO. Our findings with respect to 
feasibility, reliability and consistency will subsequently be discussed here, followed by a 
discussion of the two decision analyses reported in chapters 6 and 7. 
Feasibility 
All three tests were acceptable to most respondents. In the two students groups, all 
respondents completed the test procedures, and in the group of volunteers 27 out of 30 
respondents performed the test procedure completely. Three respondents were not able to 
159 
perform the CE because the questions were not meaningful to them. Therefore, we may 
conclude, that although neither of the tests is completely infeasible, the CE was the least 
acceptable test for the respondents. 
The mode of administration, i.e. self-administering, classroom setting or individual inter­
views is also ал important determinant of feasibility. In the student groups, all three tests 
were administered in a classroom setting after an explanation to the group. In the group 
of volunteers, all three tests were administered in individual interviews. In the TTO and 
the CE, every item was asked by a bracketing procedure until the respondent was 
indifferent between the alternatives. This was quite time-consuming: the first interview 
took a median time of 78 minutes, and the second a median time of 45 minutes. The 
time needed for TTO and CE separately was not measured. 
The ACM-test, which in our study consisted of 90 paired comparisons, could, after 
sufficient explanation be performed without the individual assistance of an interviewer, 
although the presence of the investigator was necessary to answer upcoming questions. 
The time needed for the ACM-test was therefore lower than for the TTO and CE, 
despite the larger number of items: in the first, second and third replication the median 
time needed was 40, 25, and 20 minutes, respectively. Thus, ACM was not extremely 
time-consuming as compared to TTO and CE and requires less assistance from the 
interviewer. The latter property is important, since this property prevents undue 
influence of the interviewer on the results. 
Another aspect of feasibility is the flexibility of the test method: can it easily be adapted 
to various clinical problems? For this aspect of feasibility it is important that many 
different health states can be assessed at a time. The possibility to assess many different 
health states depends largely on the extent to which internal consistency is tested; if 
consistency is not checked, one TTO-question is enough to assess the utility of one 
health state. The same is true for the CE: if no consistency checks are performed, one 
(for Maas' lambda [1]) or three (Miyamoto's r [2]) gambles are sufficient to determine 
risk attitude. As we have shown in chapters 3 and 5, however, it is not advisable to 
perform these tests without replications, which makes it much more cumbersome. 
The current design of the ACM (three replications, extensive consistency checks) does 
not permit the assessment of more than four, or maximal five health states at a time. 
This is caused by the large numbers of tradeoffs that are necessary to check the validity 
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of the assumptions underlying ACM. In our research, 90 tradeoffs were made by the 
respondents, which was feasible, but which was also a task that asked all the attention of 
the respondents. This is a major practical limitation of this test method, which has forced 
us to oversimplify the decision problems under study in order to limit the number of 
health states. 
Test-retest reliability 
Test-retest reliability of the TTO was not very satisfactory. In group A, no systematic 
differences between replications were found. In group B, a systematic difference between 
replications 1 and 2, but not between replication 2 and 3 was found, suggesting that 
familiarity with the test improved reliability. In group C, a systematic difference 
between replications was found. Furthermore, the precision of the test, indicated by the 
roots MSE, ranged from 0.109 to 0.144, a relative measurement error of 10-15 %. This 
is high in view of the small difference in utility that may change treatment preference in 
decision analyses (see chapters 6 and 7). 
A striking observation is that the roots of the mean squared errors, which are estimates 
of the precision of the test, in the health state 'metastasized breast cancer' tended to be 
larger than in the other health states. The health state 'metastasized breast cancer' is a 
complex health state, that can manifest itself in various ways. The accents that are placed 
by the respondents may change the perception of this health state to a great extent. It is 
therefore not surprising that there was a great variability in responses. 
It would probably have been better to split this health state into several health states, 
with varying degrees of pain, inability, and levels of social activities. We were however 
limited in the number of health states that could be assessed at a time by the ACM (see 
section feasibility). This was the reason that only one health state 'metastasized breast 
cancer' was assessed. 
Test-retest reliability of the CE was slightly better than in the TTO. The relative 
measurement error ranged from 4 to 9 %. 
Test-retest reliability of the ACM was better than random to the extent of three standard 
deviations in all respondents with the exception of one respondent in the group of 
volunteers. 
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Internal consistency 
In the ITO, internal consistency in the sense of the validity of the proportionality of the 
time tradeoff was not violated. Internal consistency in the sense of robustness of utilities 
across differently framed questions was only tested in the group of volunteers. We found 
that internal consistency was violated. That this is clearly undesirable can be explained 
by the following example: If the measured height of a mountain would vary, depending 
on whether the result were expressed in centimeters rather than in meters, nobody would 
accept this inconsistency. The inconsistencies found in the TTO are analogous. We have 
attributed these inconsistencies to salience of the attribute life-expectancy. Salience 
means, that the attention of the respondents is focused on the attribute with which is 
traded off, or gambled with, which is in the TTO life-expectancy. A possible means of 
avoiding salience is, to offer respondents paired comparisons rather than matching 
questions [3]. Neither of the two attributes is then emphasized a priori. 
Internal consistency of the certainty equivalent method was satisfactory. Since also 
reliability was judged to be satisfactory, this implies that the CE is an acceptable test to 
assess utilities for life years. 
In the ACM, internal consistency was violated in 45% of the respondents in all three 
groups. The most striking observation was the violation of independence in the health 
state metastasized breast cancer. Respondents insisted on these preferences when asked 
whether these were their true preferences. Their motivation was, although not registered 
systematically, quite uniform, as far as the health state 'metastasized breast cancer' was 
concerned: the respondents expected not to be able to endure the health state 'metastasi-
zed breast cancer' any longer than a limited time period. These preferences follow the 
concept of maximal endurable time (MET) [4]. The concept of MET is illustrated in 
figure 1 of chapter 4. 
Violations of cancellation were also seen frequently, although less often than violations 
of independence. In these respondents preference differences vary, dependent on the 
context: in two different comparisons the degree of preference for the same health state 
varies. 
Serious and persistent violations of transitivity were encountered in only two respon-
dents, one in one of the student groups and one in the group of volunteers. 
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Decision models: breast conserving treatment versus mastectomy 
The main conclusion from the decision analysis reported in chapter 6, is that breast 
conserving treatment and mastectomy are medically nearly equivalent. Although breast 
conserving is usually favoured, young women, patients with a high local recurrence risk 
and those who prefer mastectomy to breast conserving treatment are better off with a 
mastectomy. The factor with the largest influence on the choice is the utility of mastecto-
my. However, very small changes in this utility may cause a shiñ in the treatment 
preference, which makes it infeasible to use individual utility assessment make a 
decision. The precision of the assessment methods is insufficient to justify the claim that 
it is possible to make a distinction between a utility of 0.96 and a utility of 0.97 (see for 
example the TTO-utilities in chapter 7, table 4). 
Furthermore, the utility assessment methods that were applied in our research presumed 
a tradeoff between quality and quantity of life. However, even if a high local recurrence 
risk is assumed, the maximal possible gain in terms of life-expectancy was 0.9 years 
after mastectomy in a life-time. In view of the uncertainties that are inevitably part of a 
decision analysis, it must be concluded that breast conserving treatment and mastectomy 
are essentially equivalent in terms of life-expectancy. This implies, that assessment 
methods that imply a tradeoff in quality and quantity of life are superfluous. 
This does not mean however, that the choice between these treatments is always clear: 
there is a real increase in the risk of local recurrence after breast conserving therapy but 
this hardly affects life-expectancy [5]. Thus, the real tradeoff is between the preservation 
of the breast and local recurrence risk. Furthermore, some women may reject the idea of 
irradiation, many women complain of pain in the irradiated breast and cosmesis may not 
always be optimal. Depending on the tumor characteristics and the preferences of the 
patients, either of the two treatment modalities may be preferred. As has been pointed 
out in the general introduction, there is cumulating evidence that in clinical practice the 
choice for either of these treatments is influenced mainly by the subjective values of the 
physician and not by the subjective values of the patient or by the characteristics of the 
tumor. Since it is clearly undesirable that the subjective values of the doctor overrule the 
values of the patient, preference assessment might possibly help. The tradeoff should, 
however, not be made between quality and quantity of life. It is possible to apply ACM 
using other attributes than quality of life and longevity, for example, cosmesis, tempora-
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ry or permanent sequelae of irradiation, or life without breast but, as has been pointed 
out above, the assessment of more attributes will lead to an infeasible number of 
tradeoffs to be made by the respondent. A possible useful alternative might be found in 
the analytic hierarchy process, which allows more attributes to be assessed [6, 7]. 
Furthermore, the patient can select the attributes that she considers important. This 
means that these attributes are not necessarily quality of life and longevity but can also 
be the cosmetic results of the treatment, the short- and long-term side-effects of 
irradiation, or postoperative complications. These aspects are futile when traded off 
against life-expectancy but may still be relevant for a decision, especially if the life-
expectancy after both treatment alternatives is the same. The attributes are subsequently 
translated into tradeoffs, which are made by the patient. The objective values (like 
probability of recurrence) are provided by the physician, so that the objective informati-
on provided by the physician and the subjective tradeoffs of the patient are integrated. 
Decision models: prophylactic mastectomy versus follow-up 
Unlike the choice between breast conserving therapy and mastectomy, there is a real 
tradeoff between life-expectancy and quality of life for women with a high risk to 
develop breast cancer who face the choice between follow-up and prophylactic mastecto-
my. The maximal gain was 8 years for the women with the highest risk under baseline 
assumptions. Nevertheless, in the baseline analysis, prophylactic mastectomy was 
preferred only in women with a relative risk to develop breast cancer higher than 17.4, 
which corresponds to a gain of around 5 life years (chapter 7, figure 3). Therefore, the 
investigated utility tests are suitable for this problem since the essential tradeoff is a 
tradeoff between longevity and quality of life. This is the reason that in currently 
executed research the application of ACM, TTO and CE in this and closely related 
clinical problems (the treatment of women with premalignant breast diseases) are 
investigated. 
Recommendations for improvements and future research 
On the basis of the experience that has been acquired by the research reported here, 
several recommendations to improve the tests can be made. 
The health state that caused problems both in ACM and TTO was 'metastasized breast 
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cancer'. In the ACM, this health state caused frequent and persistent violations of 
independence. These problems could be attributed to two main factors: 1. the health state 
'metastasized breast cancer' is quite complex and dependent on the accents that are 
placed by the respondents, this health state may easily be appreciated in very different 
manners, and 2. it is a mediocre health state, which causes the phenomenon of 'maximal 
endurable time' (a shorter number of life years is preferred to a longer time in this 
health state [4, chapter 4]) to occur in an important proportion of respondents. Possible 
ways to forego these difficulties might be to split up this health state into either several 
dimensions or several health states of variable severity. For example, the health state 
'metastasized breast cancer' could be split up into an initial stage with localized 
complaints and a subsequent health state with generalized disability. An increase of the 
number of (dimensions of) health states is, however, problematic in the current design of 
ACM because of the exponentional rise in the number of paired comparisons that is 
associated with an increase in the number of health states. In chapter 4, a more extensive 
explanation of this idea can be found. Future research, directed towards reducing the 
number of consistency checks in the ACM to an acceptable minimum, so that the 
number of health states that can be assessed at the same time can be increased, would be 
very useful. 
An additional means of improving the utility assessment procedure might be found in the 
improvement of the provision of information. Human capacity to process information is 
limited, and the complexity of a health state like 'metastasized breast cancer' requires a 
lot of effort in this respect, especially for lay people. In the reported research, informati-
on was provided by showing the respondents video films, which took about an hour. In a 
videofilm, the information is provided in a fixed tempo, the respondent cannot easily ask 
additional information or skip parts that are irrelevant to her. Recent developments in 
audiovisual techniques open perspectives in this respect, by the application of an 
interactive videodisc, on which information about relevant aspects of the health states is 
stored. A respondent can, with the help of a computer, call for the information on the 
screen, that he or she wishes to see [8]. It is possible that better provision of information 
about the assessed health state will improve reliability. Indeed, if a respondent initially 
focusses on for example the aspect pain, when valuing the health state metastasized 
breast cancer, and in a subsequent session on the aspect self-care, the resulting utility 
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may differ greatly between replications. Optimization of the provision of information 
might in this way help stabilizing utilities. 
General conclusions 
The application of utility assessment to support treatment choices in breast cancer is 
feasible but, as has been pointed out above, there remain some problems to be solved 
which are focussed on two aspects. The first aspect is the proper definition of the 
attributes to be traded off, the importance of which is shown by the choice between 
breast conserving therapy or mastectomy, which is not a tradeoff between quality of life 
and longevity. 
The second aspect is feasibility: once the proper tradeoffs are defined, a test that is both 
feasible and valid in the sense that consistency is checked should be available. The TTO 
always presumes a tradeoff between quality of life and longevity but consistency checks 
at the individual level are cumbersome. This is possible in the ACM but the current test 
design makes it impossible to test more than 4 or 5 health states at a time. This is 
subject of further research. 
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Summary 
Chapter 1 provides a general background of clinical decision analysis. The research questions 
of this thesis are discussed: Can decision analysis and utility assessment be applied to assist in 
treatment choices in breast cancer? 
In chapter 2, four methods (visual analog scaling (VAS), time tradeoff test (TTO), standard 
gamble (SG) and additive conjoint measurement (ACM)) are reviewed. These methods are 
compared with respect to their feasibility, reliability, and validity and with respect to their 
ability to distinguish between valid and invalid responses of the individuals tested. Violations 
of basic assumptions underlying utility assessment are often encountered, but only additive 
conjoint measurement is designed to recognize violations, when they occur. We conclude that 
the TTO, adjusted for risk attitude, ACM, adjusted for risk attitude, and the SG can be applied 
for the purpose of assessing risky utilities, but that ACM is best suited for systematic 
investigation of the extent and nature of violations of basic assumptions of utility assessment. 
The need to further investigate the reasons why and the extent to which people violate these 
basic assumptions is emphasized. 
Chapter 3 reports the test-retest reliability and internal consistency of the TTO and the certainty 
equivalent method, which is a specific form of the SG (CE). The clinical problems addressed 
were 1. the choice between breast conserving therapy and mastectomy and 2. the decision 
whether or not to perform prophylactic mastectomy in women who are descendants from a 
family in which hereditary breast cancer is segregating. The TTO was applied to elicit riskless 
utilities for health states and the CE to measure risk attitude for life years. These methods were 
applied in three groups of volunteers: two groups of students in health science (groups A and 
B, n=14 and n=17, respectively) and a group of women (group C, n=30). The respondents 
performed two (groups A and C) or three (group B) replications of the TTO and CE. Highly 
significant systematic differences were found in groups В and С between replication 1 and 2. 
This difference was not found between replication 2 and 3 in group B, suggesting that utilities 
stabilize after two replications. The standard error of measurement varied between 0.109 and 
0.144. Furthermore, the TTO was inconsistent (group C). Reliability and internal consistency 
of the CE were to be satisfactory. We conclude that the responses to the TTO are neither 
reliable nor consistent, and that the use of the TTO in utility assessment is questionable. 
In chapter 4, we studied the reliability and internal consistency of ACM. The method of paired 
comparisons was used to simultaneously measure utilities and to test the underlying assumptions. 
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The clinical problems addressed were the same as in chapter 3, as were the groups participating 
in the study. The respondents performed three replications of ACM. In about 45% of the 
respondents in all three groups violations of internal consistency, particularly of independence 
in the health state "metastasized breast cancer", were seen. Reliability was sufficient in all but 
one respondent in additive conjoint measurement. The observed pattern of violations of 
independence supports the concept of "maximal endurable time", that is, more than a certain 
amount of time in the health state "metastasized breast cancer" is undesirable. We conclude that 
applicability of utility assessment is seriously hampered by the demonstrated violations of 
independence, especially in health states with a considerable degree of disability. 
Chapter 5 elaborates on the notion of risk attitude. According to prospect theory, risk attitude 
changes depending on whether a prospect is perceived as a gain or a loss relative to a reference 
or aspiration level. In order to investigate risk attitude with respect to years of life, we elicited 
utilities at two occasions by the certainty equivalent method in 30 women from the general 
population. The respondents gave certainty equivalents to gambles with years of life. The 
gambles were two-outcome gambles with equal probabilities to experience each outcome. A 
shift from a risk-seeking towards a risk-averse attitude was observed with increasing expected 
value of the gambles. For each individual, the averaged responses over two replications were 
fitted with an s-shaped logistic curve which showed an excellent fit (r2 _> 0.97) in all respon­
dents). The aspiration level (AL) of survival can be derived from this function and was 
negatively correlated with age (r= -0.43, ρ < 0.025). Our data are consistent with prospect 
theory and may explain why patients opt for risky treatments since most respondents are risk-
seeking in the short term. 
Chapters 6 and 7 report two decision analysis models. In chapter 6, the question which 
treatment is preferred for patients with early breast cancer, is addressed: breast conserving 
treatment (BCT) or mastectomy. The impact of both treatments on the (quality adjusted) life 
expectancy of breast cancer patients is analyzed. A life-long follow-up of two patient groups, 
one of which had undergone mastectomy and one BCT, was simulated by a Markov model of 
medical prognosis. Data used in the model originated from the literature. Since results in the 
source papers were not split according to stage, we performed two analyses: one with data from 
all source studies (T, and T2) and one with data from source studies concerning only T, patients. 
In both analyses, the conclusion was that BCT yields better quality adjusted life expectancy than 
mastectomy. Sensitivity analysis, however, identified subgroups of patients who should 
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preferably undergo mastectomy. These subgroups are: patients preferring mastectomy to BCT, 
patients with a high risk of local recurrence, young patients, and patients at high age with a high 
risk of local recurrence. For these groups, patient preferences should play a major role in 
recommending treatment. 
Chapter 7 addresses the question which women at high risk for breast cancer are better off with 
a prophylactic mastectomy than with screening at regular intervals. A clinical decision analysis 
was performed, using Markov processes of medical prognosis, in which two options, 
prophylactic mastectomy and regular screening, were compared with respect to their effect on 
life-expectancy and quality of life. The combined effect of several risk factors on the total risk 
to develop breast cancer and on (quality-adjusted) life-expectancy was modeled and the (quality-
adjusted) life-expectancy after each option computed. 
Life-expectancy was always higher after prophylactic mastectomy than under regular follow-up, 
except for old women in whom the perioperative risk looms larger than the risk to die from 
breast cancer. The maximal possible gain was 8 years after prophylactic mastectomy if surgery 
was performed at age 20 and the woman was subject to the maximal breast cancer risk. Quality-
adjusted life-expecancy, however, was better under follow-up if the relative risk was lower than 
17.4 under baseline assumptions. The analysis was repeated with various assumptions, for 
example high and low effectiveness of prophylactic mastectomy, high and low probability to 
detect breast cancer in an early stage, and high and low desirability of prophylactic mastectomy. 
Major factors that influenced the choice were age, the risk to develop breast cancer, and the 
subjective desirability of life after prophylactic mastectomy and under regular follow-up. 
Although life-expectancy is virtually always longer after prophylactic mastectomy than after 
follow-up, if quality of life is taken into account there are only very few women who would 
benefit from a prophylactic mastectomy. 
Chapter 8 contains a general discussion and recommandations for improvements and future 
research. 
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Samenvatting 
In hoofdstuk één wordt een algemene achtergrond van de klinische besliskunde gegeven. 
Verder wordt de onderzoeksvraagstelling van dit proefschrift besproken: Kunnen 
besliskunde en utiliteitsmeting worden toegepast bij het maken van keuzes tussen 
behandelingen bij borstkanker? 
In hoofdstuk twee worden vier methoden om nutsfuncties te meten besproken: visueel 
analoge schalen (VAS), time tradeoff test (TTO), standard gamble (SG) en additief 
conjunct meten (ACM). Deze methoden worden vergeleken met betrekking tot hun 
haalbaarheid, betrouwbaarheid en validiteit en met betrekking tot hun vermogen om 
onderscheid te maken tussen valide en niet-valide antwoorden van de respondenten. Het 
komt vaak voor dat basale veronderstellingen, die ten grondslag liggen aan 
utiliteitsmeting, worden geschonden, maar dit is op individueel niveau alleen goed te 
onderkennen met ACM. Geconcludeerd wordt dat zowel de TTO als ACM, gecorrigeerd 
voor risico-attitude ofwel the de S G kunnen worden aangewend voor het meten van 
utiliteiten voor riskante keuzen. ACM is echter het best geschikt om op systematische 
wijze te onderzoeken in welke mate en in welk opzicht de onderliggende 
veronderstellingen geschonden worden. Het belang van dergelijk onderzoek wordt 
benadrukt. 
In hoofdstuk 3 worden de resultaten van onderzoek naar de test-hertest betrouwbaarheid 
en de interne consistentie van de TTO en de certainty equivalent method (dit is een 
specifieke vorm van de SG (CE)) beschreven. De klinische problemen die voorgelegd 
werden aan de respondenten waren 1. de keuze tussen borstsparende behandeling en 
mastectomie en 2. de keuze om al dan niet een profylactische mastectomie te ondergaan 
voor vrouwen met een sterk met borstkanker belaste familie-anamnese. De TTO werd 
toegepast om nutsfuncties te meten en de CE om risico-attitude met betrekking tot 
levensjaren te meten. Deze methoden werden toegepast bij drie groepen vrijwilligers: twee 
groepen studenten in de gezondheidswetenschappen (groep A en B, resp. n=14 en η=17) 
en een groep vrouwen (groep C, η=30). De deelnemers voerden de TTO en de CE twee 
(groep A en C) - of driemaal (groep B) uit. Statistisch significante systematische 
verschillen tussen de eerste en tweede replicatie werden gevonden in de groepen В en С 
Dit verschil werd niet gevonden tussen de tweede en derde replicatie in groep B, wat 
suggereert dat utiliteiten niet meer veranderen na de tweede replicatie. De standaardfout 
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varieerde tussen 0.109 en 0.144. De resultaten van de TTO waren bovendien inconsistent 
(groep C). De test-hertest betrouwbaarheid van de CE was voldoende, evenals de interne 
consistentie. Geconcludeerd wordt, dat de resultaten van de ITO noch betrouwbaar, noch 
consistent waren, en dat het gebruik van de ITO in utiliteitsmeting twijfelachtig is. 
In hoofdstuk 4 wordt het onderzoek naar de betrouwbaarheid en de interne consistentie 
van ACM beschreven. In ons onderzoek wordt ACM toegepast met behulp van gepaarde 
vergelijkingen, wat het mogelijk maakt om tegelijkertijd nutsfuncties te meten en te 
toetsen of door de individuele respondent voldaan wordt aan de onderliggende 
veronderstellingen. De keuzeproblemen waren dezelfde als in hoofdstuk 3, evenals de 
groepen respondenten. De deelnemers voerden de ACM-test driemaal uit. Ongeveer 45% 
van de deelnemers in alle drie de groepen toonden schendingen van interne consistentie. 
Met name in de keuzes met de gezondheidstoestand 'uitgezaaide borstkanker' werden 
schendingen van onafhankelijkheid gezien. De test-hertest betrouwbaarheid was slechts bij 
één respondent onvoldoende. De veelvuldige schending van onafhankelijkheid past in het 
concept van 'maximaal draaglijke tijd', hetgeen wil zeggen dat meer dan een bepaalde 
tijdsduur in de gezondheidstoestand uitgezaaide borstkanker' als onwenselijk wordt gezien. 
Geconcludeerd wordt dat het meten van nutsfuncties ernstig kan worden bemoeilijkt door 
deze schending, met name in gezondheidstoestanden waarbij de kwaliteit van leven ernstig 
te lijden heeft. 
In hoofstuk 5 wordt ingegaan op risico-attitude met betrekking tot levensjaren. Prospect 
theory, beschreven door Kahneman en Tversky, stelt dat risico-attitude verandert als er 
winst of verlies te behalen valt. Verlies of winst wordt gedefinieerd afhankelijk van de 
status quo of van een aspiratie niveau. Met het doel om risico-attitude met betrekking tot 
levensjaren te onderzoeken, werden van 30 vrijwilligers de nutsfuncties voor levensjaren 
met de CE geconstrueerd. De deelnemers voerden de test tweemaal uit. De deelnemers 
kregen tien loterijen met twee mogelijke uitkomsten in termen van gezonde levensjaren 
voorgelegd en gaven een zekerheidsequivalent voor iedere loterij. Een verschuiving van 
een risicozoekende naar een risicomijdende attitude werd gezien met oplopende verwachte 
waarde van de loterij. De gemiddelde antwoorden van twee replicaties werden gebruikt 
om voor ieder individu een s-vormige curve te passen. De passing van de curves was 
uitstekend (r2 >_ 0.97 voor alle deelnemers). Het aspiratieniveau (AN) met betrekking tot 
levensduur kan uit deze curves worden afgeleid. Het AN was negatief gecorreleerd met 
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leeftijd (г= - 0.43, ρ< 0.025). Onze resultaten komen overeen met wat zou worden 
verwacht op basis van prospect theory en kunnen mogelijk verklaren waarom patiënten 
onder bepaalde omstandigheden kiezen voor riskante behandelingen, omdat de meeste 
deelnemers risicozoekend waren op de korte termijn. 
In de hoofdstukken 6 en 7 worden twee besliskundige modellen beschreven. In hoofdstuk 
wordt een besliskundig model beschreven, dat beoogt de vraag te beantwoorden of het 
hogere locaal recidiefrisico na een borstsparende behandeling in vergelijking met een 
mastectomie invloed heeft op de keuze van behandeling bij borstkankerpatiënten. Met 
behulp van een Markov-model werd een levenslange follow-up van twee groepen patiënten 
gesimuleerd. Eén groep had mastectomie ondergaan, de andere groep een borstsparende 
behandeling. De gegevens waarop het model gebaseerd is, komen uit de literatuur. Omdat 
veel resultaten uit de literatuur niet waren uitgesplitst naar tumorstadium, werden twee 
analyses uitgevoerd: één op basis van de gegevens uit alle geselecteerde onderzoeken (T, 
en Tz) en één op basis van gegevens uit onderzoeken, die alleen patiënten met Ti-tumoren 
in het onderzoek betrokken hadden. Uit beide analyses bleek, dat na borstsparende 
therapie een betere voor kwaliteit van leven gecorrigeerde levensverwachting volgde dan 
na mastectomie. Uit gevoeligheidsanalyses bleek, dat er echter subgroepen van patiënten 
zijn bij wie mastectomie de voorkeur verdient. Dat geldt met name voor patiënten die 
mastectomie prefereren boven borstsparende therapie, patiënten met een hoog locaal 
recidief risico en jonge patiënten. Afhankelijk van de exacte utiliteiten, ligt de 
leeftijdsgrens ongeveer bij 40 jaar. Bij deze patiënten hangt het sterk van de voorkeur van 
de patiënt af welke behandeling de voorkeur verdient. 
Hoofdstuk 7 beschrijft een besliskundig model, dat de keuze tussen profylactische 
mastectomie of regelmatige screening bij vrouwen met een hoog risico op borstkanker 
analyseert. Evenals in hoofdstuk 6 werd een Markov-model gebruikt om de mogelijke 
gebeurtenissen na profylactische mastectomie en bij regelmatige screening te beschrijven. 
Als parameters werden de verwachte levensduur en de voor kwaliteit van leven 
gecorrigeerde levensduur gebruikt. Het gecombineerde effect van verschillende 
risicofactoren op het risico op borstkanker te ontwikkelen werd gemodelleerd aan de hand 
van een gepubliceerd risicomodel. De levensverwachting en de voor kwaliteit 
gecorrigeerde levensduur na profylactische mastectomie en onder screening werden 
berekend. 
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De levensverwachting was altijd hoger na profylactische mastectomie, behalve bij oude 
vrouwen, bij wie het peri-operatieve risico zwaarder woog dan de kans om te overlijden 
aan borstkanker. De maximaal mogelijke winst na profylactische mastectomie was 8 jaar, 
als de operatie werd uitgevoerd op 20-jarige leeftijd en de vrouw een maximaal risico op 
borstkanker heeft. 
De voor kwaliteit gecorrigeerde levensverwachting was echter hoger bij screening, mits 
het relatieve risico om borstkanker te ontwikkelen kleiner is dan 17.4, gegeven een aantal 
basisveronderstellingen. De analyse werd herhaald met verschillende 
basisveronderstellingen, bijvoorbeeld een hoge en lage effectiviteit van profylactische 
mastectomie in het voorkomen van borstkanker, een hoge en lage waarschijnlijkheid om 
borstkanker in een vroeg stadium te ontdekken en een hogere en lagere utiliteit van het 
leven na profylactische mastectomie. Belangrijke factoren die de keuze kunnen 
beïnvloeden zijn leeftijd, het individuele risico borstkanker te ontwikkelen, en de utiliteit 
van profylactische mastectomie. Hoewel de levensverwachting dus bijna altijd langer is na 
profylactische mastectomie dan bij screening, is profylactische mastectomie vrijwel nooit 
geïndiceerd op basis van de voor kwaliteit van leven gecorrigeerde levensverwachting. 
Hoofdstuk 8 is een afsluitend hoofdstuk, waarin de resultaten uit de voorgaande 
hoofdstukken worden bediscussieerd en suggesties worden gegeven voor verder 
onderzoek. 
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1. Utiliteiten bestaan niet. 
2. A clear picture of a fuzzy scene would be an inaccurate picture. 
F. Wittgenstein. In Raehlin H. Judgment, decision and choice: Λ cognitive/behavioral synthesis. 
New York, ¡989. 
3. Het is onvermijdelijk, dat de subjectieve waarde-oordelen van de dokter een 
doorslaggevende rol zullen spelen bij de keuze van behandelingen indien de 
waarde-oordelen ал de patiënt niet op een onafhankelijke wijze in de beslissing 
betrokken worden. 
Dit proefschrift 
4. De time-tradeoff test is een onbetrouwbare methode om utiliteiten te meten. 
Dit proefschrift 
5. De uitspraak van Coombs & Avrunin: 'Good things satiate and bad things 
escalate' is ook van toepassing op het goede van een lang leven en het slechte van 
een slechte gezondheidstoestand. 
Dit proefschrift 
6. Het is onjuist om er in besliskundige analyses vanuit te gaan dat mensen risico-
neutraal zijn. 
Dit proefschrift 
7. De keuze van de primaire therapie bij vrouwen met een vroeg stadium van 
borstkanker, borstamputatie of borstsparende therapie, beïnvloedt de levensduur 
niet. 
Dit proefschrift 
8. De beslissing om al dan niet een dubbelzijdige borstamputatie te ondergaan ter 
preventie van borstkanker, dient in grotere mate afhankelijk te zijn van de waarde 
die de vrouw aan het behoud van haar borsten hecht, dan van haar kans op 
borstkanker. 
Dit proefschrift 
9. Gezien de afnemende toegevoegde waarde van levensjaren die ver in de toekomst 
gelegen zijn, valt het niet te verwachten dat mensen zullen stoppen met roken 
teneinde een ver in die toekomst gelegen ziekte te voorkomen. 
10. The most common pitfall in decision analysis is to produce a sophisticated solution 
to the wrong problem. 
Von Winlerfeldl D. Edwards E. Decision analysis and behavioral research. Cambridge: Cambridge 
University Press;¡986:29. 
11. People are often inconsistent, but priorities must be assigned and things done 
despite inconsistency. 
Saary 7t. Pie analytic hierarchy process. New York. 1980: pp. 9. 
12. Zolang er geen verplicht zwangerschaps- en ouderschapsverlof voor mannen 
bestaat, is het niet realistisch te verwachten dat werkgevers bij gelijke geschiktheid 
de voorkeur zullen geven aan een vrouw. 
13. De kwaliteit van een beslissing kan niet worden afgemeten aan de uitkomst ervan. 
14. De beste beslissing is die beslissing, die een gevoel van tevreden opluchting 
teweegbrengt. 



